STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 127078

TO: Terra Gibbs
Location: REM-2D10/2C18
Art Unit: 1635
Tuesday, July 13, 2004
Case Serial Number: 10/000213

From: Paul Schulwitz
Location: Biotech-Chem Library
REM-1A65
Phone: (571)272-2527

paul.schulwitz@uspto.gov

Search Notes

Examiner Gibbs,

See attached results.

If you have any questions about this search feel free to contact me at any time.

Thank you for using STIC search services!

Paul Schulwitz
Technical Information Specialist
STIC Biotech/Chem Library
(571)272-2527

7/1 03H

Schulwitz, Paul

From: Gibbs, Terra
Sent: Thursday, July 01, 2004 1:53 PM
To: Schulwitz, Paul
Subject: Sequence search request...

Hi David,
I have another request for a score over length search:
I need a length limited nucleotide sequence search of nucleobases 1710 through 1757 of SEQ ID NO:3 in USSN 10/000,213, where the returns are rank ordered based on the score over length/ratio as we've discussed. I need the lengths limited to hits between 8 and 80 nucleotides, and I'll take as many hits as you can import into excel (64,000?), and alignments for anything above .75 on the above ratio. Hope this is clear, please call me if it's not. I also need the interference databases searched.

Terra Cotta Gibbs, Ph.D.
Art Unit 1635
Remsen Building 2D10
571-272-0758

This Page Blank (uspto)

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: July 13, 2004, 11:01:34 ; Search time 0.001 Seconds
(without alignments)
59.424 Million cell updates/sec

Title: us-10-000-213-3
Perfect score: 48
Sequence: 1 ggctgctgactgatgttgag.....caggagaaatgcatccattc 48

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 46 seqs, 619 residues

Total number of hits satisfying chosen parameters: 92

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 50 summaries

Database : rgedb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
c	1	14.8	30.8	18	1	AR075067	ACCESSION:AR075067
c	2	14.8	30.8	18	1	AR141885	ACCESSION:AR141885
c	3	14.4	30.0	18	1	AR336915	ACCESSION:AR336915
	4	13.4	27.9	16	1	AR328438	ACCESSION:AR328438
c	5	12.8	26.7	16	1	A45190	ACCESSION:A45190
c	6	12.8	26.7	16	1	A88951	ACCESSION:A88951
c	7	12.8	26.7	16	1	AR202833	ACCESSION:AR202833
	8	12.8	26.7	16	1	AR328439	ACCESSION:AR328439
c	9	12.8	26.7	16	1	BD066464	ACCESSION:BD066464
c	10	12.8	26.7	17	1	AX673162	ACCESSION:AX673162
	11	12.8	26.7	17	1	AX733659	ACCESSION:AX733659
c	12	12.8	26.7	17	1	AX737062	ACCESSION:AX737062
	13	11.8	24.6	15	1	AR009449	ACCESSION:AR009449
c	14	11.8	24.6	15	1	AR055874	ACCESSION:AR055874
c	15	11.8	24.6	15	1	AR113632	ACCESSION:AR113632
c	16	11.8	24.6	15	1	AX632925	ACCESSION:AX632925
c	17	11.8	24.6	15	1	BD208780	ACCESSION:BD208780
c	18	11.4	23.7	15	1	AR180533	ACCESSION:AR180533
	19	10.4	21.7	12	1	AR013953	ACCESSION:AR013953
	20	10.4	21.7	12	1	I79681	ACCESSION:I79681
	21	10	20.8	11	1	AX624126	ACCESSION:AX624126
c	22	10	20.8	11	1	AX625561	ACCESSION:AX625561
c	23	10	20.8	11	1	AX628640	ACCESSION:AX628640
	24	10	20.8	11	1	AX631547	ACCESSION:AX631547
	25	10	20.8	13	1	A25126	ACCESSION:A25126
c	26	10	20.8	13	1	AR030055	ACCESSION:AR030055
	27	9.8	20.4	13	1	I21833	ACCESSION:I21833
c	28	9.8	20.4	13	1	I21840	ACCESSION:I21840
c	29	9.8	20.4	13	1	AR310639	ACCESSION:AR310639
	30	9.8	20.4	13	1	AX711140	ACCESSION:AX711140
	31	9.4	19.6	11	1	AX470508	ACCESSION:AX470508
c	32	9.4	19.6	11	1	AX623937	ACCESSION:AX623937
	33	9.4	19.6	11	1	AX625659	ACCESSION:AX625659
	34	9.4	19.6	11	1	AX625973	ACCESSION:AX625973
	35	9.4	19.6	11	1	AX626369	ACCESSION:AX626369
	36	9.4	19.6	11	1	AX627679	ACCESSION:AX627679
	37	9.4	19.6	11	1	AX628604	ACCESSION:AX628604
c	38	9.4	19.6	11	1	AX629528	ACCESSION:AX629528
	39	9.4	19.6	11	1	AX630375	ACCESSION:AX630375
c	40	9.4	19.6	11	1	AX631358	ACCESSION:AX631358
c	41	9.4	19.6	12	1	A36017	ACCESSION:A36017
	42	9.4	19.6	12	1	BD248202	ACCESSION:BD248202
	43	9.4	19.6	12	1	E07501	ACCESSION:E07501
c	44	9.4	19.6	12	1	E07516	ACCESSION:E07516
c	45	9.4	19.6	12	1	I24583	ACCESSION:I24583
	46	9.4	19.6	12	1	BD064791	ACCESSION:BD064791
c	47	8.8	18.3	17	1	AX733659	ACCESSION:AX733659
	48	7.8	16.3	11	1	AX625561	ACCESSION:AX625561
	49	7.4	15.4	15	1	AR180533	ACCESSION:AR180533
c	50	7.2	15.0	13	1	A25126	ACCESSION:A25126

ALIGNMENTS

RESULT 1
AR075067/c
LOCUS AR075067 18 bp DNA linear PAT 28-AUG-2000
DEFINITION Sequence 27 from patent US 5955306.
ACCESSION AR075067
VERSION AR075067.1 GI:10001819
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Gimeno,C.J. and Errada,P.R.
TITLE Genes encoding proteins that interact with the tub protein
JOURNAL Patent: US 5955306-A 27 21-SEP-1999;
FEATURES Location/Qualifiers
source 1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 30.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.2;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1714 GCTGACTGATGTTGAGGG 1731
              ||||||||| | ||||||
Db         18 GCTGACTGACGCTGAGGG 1
```

RESULT 2
AR141885/c
LOCUS AR141885 18 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 27 from patent US 6147192.
ACCESSION AR141885
VERSION AR141885.1 GI:15101401
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Gimeno,C.J. and Errada,P.R.
TITLE Tub interactor (TI) polypeptides and uses therefor
JOURNAL Patent: US 6147192-A 27 14-NOV-2000;
FEATURES Location/Qualifiers
source 1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 30.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.2;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1714 GCTGACTGATGTTGAGGG 1731
              ||||||||| | ||||||
Db         18 GCTGACTGACGCTGAGGG 1
```

RESULT 3
AR336915/c
LOCUS AR336915 18 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 23 from patent US 6566131.
ACCESSION AR336915
VERSION AR336915.1 GI:33722769
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cowsert,L.M.
TITLE Antisense modulation of Smad6 expression
JOURNAL Patent: US 6566131-A 23 20-MAY-2003;
FEATURES Location/Qualifiers
source 1. .18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 30.0%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 3.8;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1723 TGTTGAGGGAACAGAC 1738
              |||||||||||| |||
Db         18 TGTTGAGGGAACGGAC 3
```

RESULT 4
AR328438
LOCUS AR328438 16 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 5840 from patent US 6566127.
ACCESSION AR328438
VERSION AR328438.1 GI:33714246
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 5840 20-MAY-2003;
FEATURES Location/Qualifiers
source 1. .16
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 27.9%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 5.4;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1715 CTGACTGATGTTGAG 1729
              |||| ||||||||||
Db          2 CTGAGTGATGTTGAG 16
```

RESULT 5
A45190/c
LOCUS A45190 16 bp DNA linear PAT 07-MAR-1997
DEFINITION Sequence 67 from Patent WO9517507.
ACCESSION A45190
VERSION A45190.1 GI:2299685
KEYWORDS .
SOURCE unidentified
ORGANISM unidentified
unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Brysch,W., Schlingensiepen,K., Schlingensiepen,R. and Schlingensiepen,G.
TITLE ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB PLAYS A ROLE
JOURNAL Patent: WO 9517507-A 67 29-JUN-1995;
BIOGNOSTIK GES (DE)
COMMENT Other publication AU 1313095 950710.
FEATURES Location/Qualifiers
source 1. .16
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 26.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 6.9;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1723 TGTTGAGGGAACAGAC 1738
              |||||||||||| | ||
Db         16 TGTTGAGGGAAAACAC 1
```

RESULT 6
A88951/c
LOCUS A88951 16 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 1099 from Patent WO9833904.
ACCESSION A88951
VERSION A88951.1 GI:6737521
KEYWORDS .
SOURCE unidentified
ORGANISM unidentified
unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Brysch,W. and Schlingensiepen,K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 1099 06-AUG-1998;
BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES Location/Qualifiers
source 1. .16
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 26.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 6.9;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1723 TGTTGAGGGAACAGAC 1738
              |||||||||||| | ||
Db         16 TGTTGAGGGAAAACAC 1
```

RESULT 7
AR202833/c
LOCUS AR202833 16 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 67 from patent US 6365345.
ACCESSION AR202833
VERSION AR202833.1 GI:21499063
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Brysch,W., Schlingensiepen,K.-H., Schlingensiepen,R. and Schlingensiepen,G.-F.
TITLE Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbB plays a role
JOURNAL Patent: US 6365345-A 67 02-APR-2002;
FEATURES Location/Qualifiers
source 1. .16
/organism="unknown"
/mol_type="unassigned DNA"

```
  Query Match            26.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 6.9;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1723 TGTTGAGGGAACAGAC 1738
              ||||||||||| | ||
Db         16 TGTTGAGGGAAAACAC 1


RESULT 8
AR328439
LOCUS       AR328439                  16 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 5841 from patent US 6566127.
ACCESSION   AR328439
VERSION     AR328439.1  GI:33714247
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 5841 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match            26.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 6.9;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1717 GACTGATGTTGAGGGA 1732
              || |||||||||||  |
Db          1 GAGTGATGTTGAGGAA 16


RESULT 9
BD066464/c
LOCUS       BD066464                  16 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD066464
VERSION     BD066464.1  GI:22612067
KEYWORDS    JP 2001511000-A/1099.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 1099 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/1099
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                 Location/Qualifiers
            FT   source          1. .16
            FT                   /organism='Unknown'.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match            26.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 6.9;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1723 TGTTGAGGGAACAGAC 1738
              ||||||||||| | ||
Db         16 TGTTGAGGGAAAACAC 1


RESULT 10
AX673162/c
LOCUS       AX673162                  17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 1607 from Patent WO03004526.
ACCESSION   AX673162
VERSION     AX673162.1  GI:29331510
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
  JOURNAL   Patent: WO 03004526-A 1607 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match            26.7%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 7.1;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1737 ACAGGAGAAATGCATC 1752
              |||||||||| | |||
Db         16 ACAGGAGAAAGGGATC 1


RESULT 11
AX733659
LOCUS       AX733659                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 5293 from Patent WO03025175.
ACCESSION   AX733659
VERSION     AX733659.1  GI:30513002
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 5293 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match            26.7%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 7.1;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1731 GAACAGACAGGAGAAA 1746
              || ||| |||||||||
Db          1 GATCAGGCAGGAGAAA 16


RESULT 12
```

```
AX737062/c
LOCUS       AX737062                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2652 from Patent WO03025177.
ACCESSION   AX737062
VERSION     AX737062.1  GI:30516350
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 2652 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             26.7%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 7.1;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1737 ACAGGAGAAATGCATC 1752
              | ||||||||||| |||
Db         16 ATAGGAGAAATGGATC 1


RESULT 13
AR009449
LOCUS       AR009449                  15 bp    DNA     linear   PAT 04-DEC-1998
DEFINITION  Sequence 5 from patent US 5756294.
ACCESSION   AR009449
VERSION     AR009449.1  GI:3968254
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   White,M.B. and Sadzewicz,L.K.
  TITLE     Susceptibility mutation for breast and ovarian cancer
  JOURNAL   Patent: US 5756294-A 5 26-MAY-1998;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             24.6%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 10;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1731 GAACAGACAGGAGAA 1745
              ||||| | |||||||
Db          1 GAACACAGAGGAGAA 15


RESULT 14
AR055874/c
LOCUS       AR055874                  15 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 78 from patent US 5837542.
ACCESSION   AR055874
VERSION     AR055874.1  GI:5981451
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Intercellular adhesion molecule-1 (ICAM-1) ribozymes
  JOURNAL   Patent: US 5837542-A 78 17-NOV-1998;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             24.6%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 10;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1724 GTTGAGGGAACAGAC 1738
              ||  ||||||||||||
Db         15 GTCCAGGGAACAGAC 1


RESULT 15
AR113632/c
LOCUS       AR113632                  15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 78 from patent US 6132967.
ACCESSION   AR113632
VERSION     AR113632.1  GI:14093954
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Ribozyme treatment of diseases or conditions related to levels of
            intercellular adhesion molecule-1 (ICAM-1)
  JOURNAL   Patent: US 6132967-A 78 17-OCT-2000;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             24.6%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 10;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1724 GTTGAGGGAACAGAC 1738
              ||  ||||||||||||
Db         15 GTCCAGGGAACAGAC 1


RESULT 16
AX632925/c
LOCUS       AX632925                  15 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 64 from Patent EP1260586.
ACCESSION   AX632925
VERSION     AX632925.1  GI:28468539
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 64 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32644"

  Query Match             24.6%;  Score 11.8;  DB 1;  Length 15;
```

```
  Best Local Similarity   86.7%;  Pred. No. 10;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1724 GTTGAGGGAACAGAC 1738
              ||  ||||||||||||
Db         15 GTCCAGGGAACAGAC 1


RESULT 17
BD208780/c
LOCUS       BD208780                 15 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Enzymatic nucleic acid treatment of diseases or conditions related
            to hepatitis C virus infection.
ACCESSION   BD208780
VERSION     BD208780.1  GI:33018550
KEYWORDS    JP 2002512791-A/2370.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Blatt,L., Mcswiggen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
  TITLE     Enzymatic nucleic acid treatment of diseases or conditions related
            to hepatitis C virus infection
  JOURNAL   Patent: JP 2002512791-A 2370 08-MAY-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Hepatitis virus (hepatitis C virus)
            PN   JP 2002512791-A/2370
            PD   08-MAY-2002
            PF   26-APR-1999 JP 2000545991
            PR   27-APR-1998 US    60/083217,18-SEP-1998 US    60/100842 PR
            25-FEB-1999 US    09/257608,23-MAR-1999 US    09/274553 PI
            LAWRENCE BLATT,JAMES A MCSWIGGEN,ELISABETH ROBERTS,PAMELA A  PI
            PAVCO,
            PI   DENNIS MACEJAK
            PC   C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
            PC   A61K37/66,
            PC   C12N15/00
            CC   Enzymatic nucleic acid treatment of diseases or conditions  CC
                 related to
            CC   hepatitis C virus infection.
            FH   Key             Location/Qualifiers
            FT   source          1. .15
            FT                   /organism='Hepatitis virus (hepatitis C  FT
                              virus)'.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:32644"

  Query Match             24.6%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 10;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1714 GCTGACTGATGTTGA 1728
              ||||| ||||| |||
Db         15 GCTGAGTGATGGTGA 1


RESULT 18
AR180533/c
LOCUS       AR180533                 15 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 601 from patent US 6333152.
ACCESSION   AR180533
VERSION     AR180533.1  GI:20222566
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
  TITLE     Gene expression profiles in normal and cancer cells
  JOURNAL   Patent: US 6333152-A 601 25-DEC-2001;

FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             23.7%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 12;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1739 AGGAGAAATGCAT 1751
              ||||| |||||||
Db         14 AGGAGGAATGCAT 2


RESULT 19
AR013953
LOCUS       AR013953                 12 bp    DNA     linear   PAT 05-DEC-1998
DEFINITION  Sequence 8 from patent US 5773226.
ACCESSION   AR013953
VERSION     AR013953.1  GI:3971407
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 12)
  AUTHORS   Millan,J.L.
  TITLE     Recombinant calf intestinal alkaline phosphatase
  JOURNAL   Patent: US 5773226-A 8 30-JUN-1998;
FEATURES             Location/Qualifiers
     source          1. .12
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 16;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1733 ACAGACAGGAGA 1744
              ||||| ||||||
Db          1 ACAGAGAGGAGA 12


RESULT 20
I79681
LOCUS       I79681                   12 bp    DNA     linear   PAT 10-JUN-1998
DEFINITION  Sequence 8 from patent US 5707853.
ACCESSION   I79681
VERSION     I79681.1  GI:3207971
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 12)
  AUTHORS   Millan,J.L.
  TITLE     Nucleic acid encoding calf intestinal alkaline phosphatase
  JOURNAL   Patent: US 5707853-A 8 13-JAN-1998;
FEATURES             Location/Qualifiers
     source          1. .12
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 16;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1733 ACAGACAGGAGA 1744
              ||||| ||||||
Db          1 ACAGAGAGGAGA 12


RESULT 21
AX624126
LOCUS       AX624126                 11 bp    DNA     linear   PAT 21-FEB-2003
```

```
DEFINITION  Sequence 1167 from Patent WO02053774.
ACCESSION   AX624126
VERSION     AX624126.1  GI:28452067
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 1167 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             20.8%;  Score 10;  DB 1;  Length 11;
  Best Local Similarity   100.0%;  Pred. No. 18;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1715 CTGACTGATG 1724
              ||||||||||
Db          1 CTGACTGATG 10


RESULT 22
AX625561/c
LOCUS       AX625561                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 2602 from Patent WO02053774.
ACCESSION   AX625561
VERSION     AX625561.1  GI:28453502
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 2602 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             20.8%;  Score 10;  DB 1;  Length 11;
  Best Local Similarity   100.0%;  Pred. No. 18;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1747 TGCATCCATT 1756
              ||||||||||
Db         11 TGCATCCATT 2


RESULT 23
AX628640/c
LOCUS       AX628640                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 5681 from Patent WO02053774.
ACCESSION   AX628640
VERSION     AX628640.1  GI:28456678
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 5681 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             20.8%;  Score 10;  DB 1;  Length 11;
  Best Local Similarity   100.0%;  Pred. No. 18;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1731 GAACAGACAG 1740
              ||||||||||
Db         10 GAACAGACAG 1


RESULT 24
AX631547
LOCUS       AX631547                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 8589 from Patent WO02053774.
ACCESSION   AX631547
VERSION     AX631547.1  GI:28459613
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 8589 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             20.8%;  Score 10;  DB 1;  Length 11;
  Best Local Similarity   100.0%;  Pred. No. 18;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1715 CTGACTGATG 1724
              ||||||||||
Db          1 CTGACTGATG 10


RESULT 25
A25126
LOCUS       A25126                    13 bp    DNA     linear   PAT 21-SEP-1995
DEFINITION  Synthetic EcoRI adaptor.
ACCESSION   A25126
VERSION     A25126.1  GI:1247054
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 13)
  AUTHORS   .
  JOURNAL   Patent: DE 3925748-A 5 11-APR-1991;
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             20.8%;  Score 10;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 19;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1746 ATGCATCCAT 1755
              ||||||||||
```

```
Db          3 ATGCATCCAT 12


RESULT 26
AR030055/c
LOCUS       AR030055                  13 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 244 from patent US 5861244.
ACCESSION   AR030055
VERSION     AR030055.1  GI:5943269
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 13)
  AUTHORS   Wang,C.-G. and Hepburn,A.G.
  TITLE     Genetic sequence assay using DNA triple strand formation
  JOURNAL   Patent: US 5861244-A 244 19-JAN-1999;
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             20.8%;  Score 10;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 19;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1727 GAGGGAACAG 1736
             ||||||||||
Db         12 GAGGGAACAG 3


RESULT 27
I21833
LOCUS       I21833                    13 bp    DNA     linear   PAT 07-OCT-1996
DEFINITION  Sequence 10 from patent US 5525468.
ACCESSION   I21833
VERSION     I21833.1  GI:1602187
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 13)
  AUTHORS   McSwiggen,J.A.
  TITLE     Assay for Ribozyme target site
  JOURNAL   Patent: US 5525468-A 10 11-JUN-1996;
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 21;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1737 ACAGGAGAAATGC 1749
              || ||||||| ||
Db          1 ACTGGAGAAAGGC 13


RESULT 28
I21840/c
LOCUS       I21840                    13 bp    DNA     linear   PAT 07-OCT-1996
DEFINITION  Sequence 17 from patent US 5525468.
ACCESSION   I21840
VERSION     I21840.1  GI:1602194
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 13)
  AUTHORS   McSwiggen,J.A.
  TITLE     Assay for Ribozyme target site
  JOURNAL   Patent: US 5525468-A 17 11-JUN-1996;
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 21;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1737 ACAGGAGAAATGC 1749
              || ||||||| ||
Db         13 ACTGGAGAAAGGC 1


RESULT 29
AR310639/c
LOCUS       AR310639                  13 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 3 from patent US 6559125.
ACCESSION   AR310639
VERSION     AR310639.1  GI:31703742
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 13)
  AUTHORS   Dervan,P.B., Wurtz,N. and Chang,A.
  TITLE     Polyamide-alkylator conjugates and related products and method
  JOURNAL   Patent: US 6559125-A 3 06-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 21;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1741 GAGAAATGCATCC 1753
              ||||  |||||||
Db         13 GAGAGCTGCATCC 1


RESULT 30
AX711140
LOCUS       AX711140                  13 bp    DNA     linear   PAT 11-APR-2003
DEFINITION  Sequence 440 from Patent EP1288296.
ACCESSION   AX711140
VERSION     AX711140.1  GI:29787521
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Draper,K.G., Mcswiggen,J.A., Holecek,J.J., Dudycz,L.W.,
            Macejak,D.G. and Mamone,J.A.
  TITLE     Method and reagent for inhibiting HBV viral replication
  JOURNAL   Patent: EP 1288296-A 440 05-MAR-2003;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 21;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1737 ACAGGAGAAATGC 1749
              || ||||||| ||
Db          1 ACTGGAGAAAGGC 13
```

```
RESULT 31
AX470508
LOCUS       AX470508                  11 bp    DNA     linear   PAT 09-AUG-2002
DEFINITION  Sequence 85 from Patent WO02053773.
ACCESSION   AX470508
VERSION     AX470508.1  GI:22205633
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Hofmann,K., Conradt,M. and Petersohn,D.
  TITLE     Method for determining skin stress or skin ageing in vitro
  JOURNAL   Patent: WO 02053773-A 85 11-JUL-2002;
            HENKEL KGAA (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             19.6%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 23;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1712 CTGCTGACTGA 1722
             ||||||| |||
Db          1 CTGCTGAGTGA 11


RESULT 32
AX623937/c
LOCUS       AX623937                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 978 from Patent WO02053774.
ACCESSION   AX623937
VERSION     AX623937.1  GI:28451878
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 978 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             19.6%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 23;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1747 TGCATCCATTC 1757
             ||||| |||||
Db         11 TGCATTCATTC 1


RESULT 33
AX625659
LOCUS       AX625659                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 2700 from Patent WO02053774.
ACCESSION   AX625659
VERSION     AX625659.1  GI:28453600
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 2700 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             19.6%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 23;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1743 GAAATGCATCC 1753
             ||||||| ||
Db          1 GAAATGCAGCC 11


RESULT 34
AX625973
LOCUS       AX625973                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 3014 from Patent WO02053774.
ACCESSION   AX625973
VERSION     AX625973.1  GI:28454011
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 3014 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             19.6%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 23;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1718 ACTGATGTTGA 1728
             |||||| ||||
Db          1 ACTGATCTTGA 11


RESULT 35
AX626369
LOCUS       AX626369                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 3410 from Patent WO02053774.
ACCESSION   AX626369
VERSION     AX626369.1  GI:28454407
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 3410 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
```

```
  Query Match             19.6%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 23;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1720 TGATGTTGAGG 1730
              || ||||||||
Db          1 TGGTGTTGAGG 11


RESULT 36
AX627679
LOCUS       AX627679                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 4720 from Patent WO02053774.
ACCESSION   AX627679
VERSION     AX627679.1  GI:28455717
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 4720 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             19.6%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 23;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1738 CAGGAGAAATG 1748
              |||||||| ||
Db          1 CAGGAGAACTG 11


RESULT 37
AX628604
LOCUS       AX628604                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 5645 from Patent WO02053774.
ACCESSION   AX628604
VERSION     AX628604.1  GI:28456642
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 5645 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             19.6%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 23;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1712 CTGCTGACTGA 1722
              ||||||| |||
Db          1 CTGCTGAGTGA 11


RESULT 38
AX629528/c
LOCUS       AX629528                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 6569 from Patent WO02053774.
ACCESSION   AX629528
VERSION     AX629528.1  GI:28457566
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 6569 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             19.6%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 23;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1745 AATGCATCCAT 1755
              | |||||||||
Db         11 AGTGCATCCAT 1


RESULT 39
AX630375
LOCUS       AX630375                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 7416 from Patent WO02053774.
ACCESSION   AX630375
VERSION     AX630375.1  GI:28458413
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 7416 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             19.6%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 23;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1730 GGAACAGACAG 1740
              |||||| ||||
Db          1 GGAACAAACAG 11


RESULT 40
AX631358/c
LOCUS       AX631358                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 8400 from Patent WO02053774.
ACCESSION   AX631358
VERSION     AX631358.1  GI:28459404
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
```

```
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 8400 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             19.6%;  Score 9.4;  DB 1;  Length 11;
  Best Local Similarity   90.9%;  Pred. No. 23;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1747 TGCATCCATTC 1757
              ||||| |||||
Db         11 TGCATTCATTC 1


RESULT 41
A36017/c
LOCUS       A36017                    12 bp    DNA     linear   PAT 04-MAR-1997
DEFINITION  Sequence 16 from Patent EP0564801.
ACCESSION   A36017
VERSION     A36017.1  GI:2293645
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 12)
  AUTHORS   Sommergruber,W.D., Auer,H., Blaas,D.D., Frasel,L., Hartmuth,K.D.,
            Kuechler,E.P., Kowalski,H., Liebig,H.D., Skern,T.D. and
            Ziegler,G.S.
  TITLE     Analysis of host cell shut-off
  JOURNAL   Patent: EP 0564801-A 16 13-OCT-1993;
            BOEHRINGER INGELHEIM INT (DE)
COMMENT     Other publication DE 4206769 930909
            Other publication JP 6197799 940719
            Other publication CA 2090834 930905
            Other publication DE 4217929 931202.
FEATURES             Location/Qualifiers
     source          1. .12
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             19.6%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   90.9%;  Pred. No. 23;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1747 TGCATCCATTC 1757
              | |||||||||
Db         11 TTCATCCATTC 1


RESULT 42
BD248202
LOCUS       BD248202                  12 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Short-chain oligonucleotide for inhibiting VEGF expression.
ACCESSION   BD248202
VERSION     BD248202.1  GI:33057972
KEYWORDS    JP 2002524038-A/21.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 12)
  AUTHORS   Uhlmann,E., Peyman,A., Bitonti,A. and Woessner,R.
  TITLE     Short-chain oligonucleotide for inhibiting VEGF expression
  JOURNAL   Patent: JP 2002524038-A 21 06-AUG-2002;
            AVENTIS PHARMA DEUTSCHLAND GMBH
COMMENT     OS   Artificial Sequence
            PN   JP 2002524038-A/21
            PD   06-AUG-2002
            PF   29-JUL-1999 JP 2000563768
            PR   07-AUG-1998 EP   98114853.9
            PI   EUGEN UHLMANN,ANUSCHIRWAN PEYMAN,ALAN BITONTI,RICHARD WOESSNER
            PC   C12N15/09,A61K31/711,A61K31/7115,A61K31/712,A61K31/7125 PC
            ,A61K48/00,A61P9/00,
            PC   A61P13/12,A61P17/16,A61P27/02,A61P29/00,A61P35/00,A61P43/00,
            PC   C12N15/00
            CC   Description of Artificial Sequence: Antisense FH   Key
                Location/Qualifiers
            FT   source          1. .12
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .12
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             19.6%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   90.9%;  Pred. No. 23;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1736 GACAGGAGAAA 1746
              ||||| |||||
Db          1 GACAGCAGAAA 11


RESULT 43
E07501
LOCUS       E07501                    12 bp    DNA     linear   PAT 29-SEP-1997
DEFINITION  Synthetic DNA for probe.
ACCESSION   E07501
VERSION     E07501.1  GI:2175639
KEYWORDS    JP 1994133799-A/10.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 12)
  AUTHORS   Yamanishi,K., Yamamoto,T. and Mori,H.
  TITLE     ANALYSIS OF HUMAN HERPES VIRUS 6 TYPE @(3754/24)HHV-6) DNA AND
            DISCRIMINATION OF SUB-TYPE
  JOURNAL   Patent: JP 1994133799-A 10 17-MAY-1994;
            INTERNATL REAGENTS CORP
COMMENT     OS   None
            OC   Artificial sequences.
            PN   JP 1994133799-A/10
            PD   17-MAY-1994
            PF   27-OCT-1992 JP 1992311416
            PI   YAMANISHI KOICHI, YAMAMOTO TAKESHI, MORI HIROYUKI PC
            C12Q1/68,C12Q1/68,C12N15/11,C12N15/38;
            CC   strandedness: Single;
            CC   topology: Linear;
            CC   hypothetical: No;
            CC   anti-sense: No;
            FH   Key             Location/Qualifiers
            FH
            FT   source          1. .12
            FT                   /organism='Artificial sequences'.
FEATURES             Location/Qualifiers
     source          1. .12
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             19.6%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   90.9%;  Pred. No. 23;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1744 AAATGCATCCA 1754
              ||||| |||||
Db          2 AAATGTATCCA 12


RESULT 44
```

```
E07516/c
LOCUS       E07516                    12 bp    DNA     linear   PAT 29-SEP-1997
DEFINITION  Synthetic DNA for probe.
ACCESSION   E07516
VERSION     E07516.1  GI:2175653
KEYWORDS    JP 1994133799-A/25.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 12)
  AUTHORS   Yamanishi,K., Yamamoto,T. and Mori,H.
  TITLE     ANALYSIS OF HUMAN HERPES VIRUS 6 TYPE @(3754/24)HHV-6) DNA AND
            DISCRIMINATION OF SUB-TYPE
  JOURNAL   Patent: JP 1994133799-A 25 17-MAY-1994;
            INTERNATL REAGENTS CORP
COMMENT     OS   None
            OC   Artificial sequences.
            PN   JP 1994133799-A/25
            PD   17-MAY-1994
            PF   27-OCT-1992 JP 1992311416
            PI   YAMANISHI KOICHI, YAMAMOTO TAKESHI, MORI HIROYUKI PC
            C12Q1/68,C12Q1/68,C12N15/11,C12N15/38;
            CC   strandedness: Single;
            CC   topology: Linear;
            CC   hypothetical: No;
            CC   anti-sense: Yes;
            FH   Key             Location/Qualifiers
            FH
            FT   source          1. .12
            FT                   /organism='Artificial sequences'.
FEATURES             Location/Qualifiers
     source          1. .12
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match           19.6%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   90.9%;  Pred. No. 23;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1744 AAATGCATCCA 1754
             ||||| |||||
Db         11 AAATGTATCCA 1


RESULT 45
I24583/c
LOCUS       I24583                    12 bp    DNA     linear   PAT 07-OCT-1996
DEFINITION  Sequence 11 from patent US 5545526.
ACCESSION   I24583
VERSION     I24583.1  GI:1604453
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 12)
  AUTHORS   Baxter-Lowe,L.Ann.
  TITLE     Method for HLA Typing
  JOURNAL   Patent: US 5545526-A 11 13-AUG-1996;
FEATURES             Location/Qualifiers
     source          1. .12
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match           19.6%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   90.9%;  Pred. No. 23;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1730 GGAACAGACAG 1740
             ||||||| |||
Db         12 GGAACAGCCAG 2


RESULT 46
BD064791
LOCUS       BD064791                  12 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Method for detecting the extent of binding of transcriptional
            regulatory protein to oligoDNA.
ACCESSION   BD064791
VERSION     BD064791.1  GI:22610394
KEYWORDS    JP 2001275678-A/3.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 12)
  AUTHORS   Kishimoto,T., Niwa,S., Mori,Y., Sachiyo, Mimaki, Fukushima,R. and
            Nishikawa,K.
  TITLE     Method for detecting the extent of binding of transcriptional
            regulatory protein to oligoDNA
  JOURNAL   Patent: JP 2001275678-A 3 09-OCT-2001;
            SUMITOMO ELECTRIC INDUSTRIES LTD
COMMENT     OS   Artificial Sequence
            PN   JP 2001275678-A/3
            PD   09-OCT-2001
            PF   31-MAR-2000 JP 2000096306
            PI   TOSHIHIKO KISHIMOTO,SHINICHIRO NIWA,YUKO MORI,SACHIYO PI
            MIMAKI,REI FUKUSHIMA,
            PI   KAZUKO NISHIKAWA
            PC   C12N15/09,C12N5/10,C12Q1/00,C12Q1/68,C12N15/00,C12N5/00 CC
            Synthetic DNA
            FH   Key             Location/Qualifiers
            FT   source          1. .12
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .12
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match           19.6%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   90.9%;  Pred. No. 23;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1726 TGAGGGAACAG 1736
             || ||||||||
Db         2 TGTGGGAACAG 12


RESULT 47
AX733659/c
LOCUS       AX733659                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 5293 from Patent WO03025175.
ACCESSION   AX733659
VERSION     AX733659.1  GI:30513002
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 5293 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match           18.3%;  Score 8.8;  DB 1;  Length 17;
  Best Local Similarity   83.3%;  Pred. No. 31;
  Matches   10;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       1712 CTGCTGACTGAT 1723
                || ||| |||||
Db         13 CTCCTGCCTGAT 2


RESULT 48
AX625561
LOCUS       AX625561                  11 bp    DNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 2602 from Patent WO02053774.
ACCESSION   AX625561
VERSION     AX625561.1  GI:28453502
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE     Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 2602 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES             Location/Qualifiers
     source          1. .11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             16.3%;  Score 7.8;  DB 1;  Length 11;
  Best Local Similarity   81.8%;  Pred. No. 40;
  Matches    9;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1744 AAATGCATCCA 1754
                ||||| || ||
Db          1 AAATGGATGCA 11


RESULT 49
AR180533
LOCUS       AR180533                  15 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 601 from patent US 6333152.
ACCESSION   AR180533
VERSION     AR180533.1  GI:20222566
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
  TITLE     Gene expression profiles in normal and cancer cells
  JOURNAL   Patent: US 6333152-A 601 25-DEC-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             15.4%;  Score 7.4;  DB 1;  Length 15;
  Best Local Similarity   88.9%;  Pred. No. 47;
  Matches    8;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1749 CATCCATTC 1757
                ||| |||||
Db          1 CATGCATTC 9


RESULT 50
A25126/c
LOCUS       A25126                    13 bp    DNA     linear   PAT 21-SEP-1995
DEFINITION  Synthetic EcoRI adaptor.
ACCESSION   A25126
VERSION     A25126.1  GI:1247054
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 13)
  AUTHORS   .
  JOURNAL   Patent: DE 3925748-A 5 11-APR-1991;
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             15.0%;  Score 7.2;  DB 1;  Length 13;
  Best Local Similarity   75.0%;  Pred. No. 49;
  Matches    9;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1746 ATGCATCCATTC 1757
                ||| || ||| |
Db         12 ATGGATGCATGC 1


Search completed: July 13, 2004, 11:01:34
Job time : 0.001 secs
```

OM nucleic - nucleic search, using sw model

Run on: July 13, 2004, 11:03:42 ; Search time 0.001 Seconds
(without alignments)
218.208 Million cell updates/sec

Title: us-10-000-213-3
Perfect score: 48
Sequence: 1 ggctgctgactgatgttgag.....caggagaaatgcatccattc 48

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 169 seqs, 2273 residues

Total number of hits satisfying chosen parameters: 338

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 170 summaries

Database : rngdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
c	1	20	41.7	20	1	ADB99915	Vitamin D nuclear
c	2	20	41.7	20	1	ADB99916	Vitamin D nuclear
c	3	20	41.7	20	1	ADB99914	Vitamin D nuclear
c	4	20	41.7	20	1	ADB99917	Vitamin D nuclear
c	5	14.8	30.8	18	1	AAV11884	Homo sapiens Tub I
c	6	14.4	30.0	18	1	AAD36184	Human Smad6 antise
	7	13.8	28.7	17	1	ACD62830	HCV minus strand D
c	8	13	27.1	17	1	ABN08350	Human GDMLP-1 17-m
c	9	13	27.1	17	1	ABN08352	Human GDMLP-1 17-m
c	10	13	27.1	17	1	ABN08351	Human GDMLP-1 17-m
c	11	13	27.1	17	1	ABN08349	Human GDMLP-1 17-m
c	12	13	27.1	17	1	ABN08353	Human GDMLP-1 17-m
c	13	12.8	26.7	16	1	AAQ92724	c-erbB-2 antisense
c	14	12.8	26.7	17	1	ACC52840	Human tumour suppr
	15	12.8	26.7	17	1	ABT39656	Tumour suppression
c	16	12.8	26.7	17	1	ACD59839	HCV DNAzyme substr
	17	12	25.0	13	1	ABF92692	Oligonucleotide SE
c	18	12	25.0	13	1	ABF92693	Oligonucleotide SE
c	19	11.8	24.6	15	1	AAT51864	Human ICAM hammerh
c	20	11.8	24.6	15	1	AAZ64202	Substrate for hamm
	21	11.8	24.6	15	1	AAF46891	IGFBP3 oligonucleo
	22	11.8	24.6	15	1	AAF46892	IGFBP3 oligonucleo
c	23	11.8	24.6	15	1	ABN81214	ASO probe #7 for d
c	24	11.8	24.6	15	1	ABX01255	Hepatitis C virus
c	25	11.6	24.2	15	1	AAL48035	Human CSF3 gene al
c	26	11.4	23.7	13	1	ABC12425	Oligonucleotide SE
	27	11.4	23.7	13	1	ABC12424	Oligonucleotide SE
c	28	11.4	23.7	15	1	AAX31546	Tag sequence of a
	29	11.4	23.7	15	1	AAF46889	IGFBP3 oligonucleo
	30	11.4	23.7	15	1	AAF46890	IGFBP3 oligonucleo
c	31	11.4	23.7	15	1	AAS98675	Colony stimulating
	32	11.4	23.7	15	1	ABK96525	Human PLAU gene, a
c	33	11.4	23.7	15	1	ABK32500	Human pancreatic c
	34	11	22.9	12	1	ABI55463	Oligonucleotide pr
c	35	11	22.9	13	1	ABF42717	Oligonucleotide SE
c	36	11	22.9	13	1	ABH51281	Oligonucleotide SE
c	37	11	22.9	13	1	ABC88045	Oligonucleotide SE
c	38	11	22.9	13	1	ABF28165	Oligonucleotide SE
	39	11	22.9	13	1	ABH51280	Oligonucleotide SE
c	40	11	22.9	13	1	ABH52406	Oligonucleotide SE
	41	11	22.9	13	1	ABC88044	Oligonucleotide SE
	42	11	22.9	13	1	ABF28164	Oligonucleotide SE
	43	11	22.9	13	1	ABF42716	Oligonucleotide SE
	44	11	22.9	13	1	ABH52407	Oligonucleotide SE
c	45	10.8	22.5	14	1	AAA26214	Oestrogen receptor
	46	10.6	22.1	13	1	ABC68262	Oligonucleotide SE
c	47	10.6	22.1	13	1	ABC68263	Oligonucleotide SE
	48	10.4	21.7	12	1	ABH85801	Oligonucleotide pr
	49	10.4	21.7	12	1	ABI41640	Oligonucleotide pr
c	50	10.4	21.7	12	1	ABI49018	Oligonucleotide pr
c	51	10.4	21.7	12	1	ABI62513	Oligonucleotide pr
c	52	10.4	21.7	12	1	ABH69285	Oligonucleotide pr
c	53	10.4	21.7	13	1	ABC94621	Oligonucleotide SE
	54	10.4	21.7	13	1	ABC36414	Oligonucleotide SE
c	55	10.4	21.7	13	1	ABF18905	Oligonucleotide SE
c	56	10.4	21.7	13	1	ABC36415	Oligonucleotide SE
	57	10.4	21.7	13	1	ABF92694	Oligonucleotide SE
	58	10.4	21.7	13	1	ABF18904	Oligonucleotide SE
	59	10.4	21.7	13	1	ABH43430	Oligonucleotide SE
c	60	10.4	21.7	13	1	ABH14879	Oligonucleotide SE
c	61	10.4	21.7	13	1	ABH58053	Oligonucleotide SE
	62	10.4	21.7	13	1	ABF11938	Oligonucleotide SE
c	63	10.4	21.7	13	1	ABC78923	Oligonucleotide SE
c	64	10.4	21.7	13	1	ABF92695	Oligonucleotide SE
c	65	10.4	21.7	13	1	ABF92697	Oligonucleotide SE
c	66	10.4	21.7	13	1	ABF56731	Oligonucleotide SE
	67	10.4	21.7	13	1	ABC94620	Oligonucleotide SE
	68	10.4	21.7	13	1	ABF18906	Oligonucleotide SE
c	69	10.4	21.7	13	1	ABH43431	Oligonucleotide SE
c	70	10.4	21.7	13	1	ABF11939	Oligonucleotide SE
	71	10.4	21.7	13	1	ABF92696	Oligonucleotide SE
	72	10.4	21.7	13	1	ABH14878	Oligonucleotide SE
	73	10.4	21.7	13	1	ABC78922	Oligonucleotide SE
	74	10.4	21.7	13	1	ABF56730	Oligonucleotide SE
c	75	10.4	21.7	13	1	ABF18907	Oligonucleotide SE
	76	10.4	21.7	13	1	ABH58052	Oligonucleotide SE
c	77	10	20.8	10	1	AAF42671	Yeast NORF gene SA
	78	10	20.8	10	1	AAD25438	Human GNRH2 gene p
	79	10	20.8	10	1	AAD53533	Human GNRH2 gene p
	80	10	20.8	11	1	ABV63381	Human skin EST 116
	81	10	20.8	11	1	ABV70802	Human skin EST 858
c	82	10	20.8	11	1	ABV67895	Human skin EST 568
c	83	10	20.8	11	1	ABV64816	Human skin EST 260
	84	10	20.8	12	1	ABI79664	Oligonucleotide pr
	85	10	20.8	12	1	ABH71192	Oligonucleotide pr
c	86	10	20.8	12	1	ABH80366	Oligonucleotide pr
	87	10	20.8	12	1	ABH87503	Oligonucleotide pr
	88	10	20.8	12	1	ABI01362	Oligonucleotide pr
c	89	10	20.8	13	1	AAX14857	Triple helix third
	90	10	20.8	13	1	ABF28166	Oligonucleotide SE
c	91	10	20.8	13	1	ABH24633	Oligonucleotide SE
c	92	10	20.8	13	1	ABF87825	Oligonucleotide SE
	93	10	20.8	13	1	ABC95357	Oligonucleotide SE
	94	10	20.8	13	1	ABF87824	Oligonucleotide SE
c	95	10	20.8	13	1	ABH06507	Oligonucleotide SE
	96	10	20.8	13	1	ABH06506	Oligonucleotide SE
	97	10	20.8	13	1	ABF97342	Oligonucleotide SE
c	98	10	20.8	13	1	ABH54593	Oligonucleotide SE
c	99	10	20.8	13	1	ABF97343	Oligonucleotide SE
	100	10	20.8	13	1	ABH54592	Oligonucleotide SE
c	101	10	20.8	13	1	ABF28167	Oligonucleotide SE
	102	10	20.8	13	1	ABH24632	Oligonucleotide SE
c	103	10	20.8	13	1	ABC95356	Oligonucleotide SE
	104	9.8	20.4	13	1	AAA92487	DNA replication me
c	105	9.8	20.4	13	1	ABC22259	Oligonucleotide SE
c	106	9.8	20.4	13	1	ABH34097	Oligonucleotide SE

c 107	9.8	20.4	13	1	ABC20825	Oligonucleotide SE
108	9.8	20.4	13	1	ABC07406	Oligonucleotide SE
109	9.8	20.4	13	1	ABF07048	Oligonucleotide SE
110	9.8	20.4	13	1	ABC87934	Oligonucleotide SE
111	9.8	20.4	13	1	ABF21698	Oligonucleotide SE
112	9.8	20.4	13	1	ABH20206	Oligonucleotide SE
113	9.8	20.4	13	1	ABH34096	Oligonucleotide SE
114	9.8	20.4	13	1	ABH42048	Oligonucleotide SE
115	9.8	20.4	13	1	ABC48762	Oligonucleotide SE
c 116	9.8	20.4	13	1	ABC12427	Oligonucleotide SE
c 117	9.8	20.4	13	1	ABC87935	Oligonucleotide SE
c 118	9.8	20.4	13	1	ABC41627	Oligonucleotide SE
c 119	9.8	20.4	13	1	ABH24244	Oligonucleotide SE
120	9.8	20.4	13	1	ABF86806	Oligonucleotide SE
c 121	9.8	20.4	13	1	ABC83525	Oligonucleotide SE
122	9.8	20.4	13	1	ABH24245	Oligonucleotide SE
c 123	9.8	20.4	13	1	ABH42049	Oligonucleotide SE
124	9.8	20.4	13	1	ABH50272	Oligonucleotide SE
125	9.8	20.4	13	1	ABC74874	Oligonucleotide SE
126	9.8	20.4	13	1	ABC10734	Oligonucleotide SE
c 127	9.8	20.4	13	1	ABH20207	Oligonucleotide SE
128	9.8	20.4	13	1	ABH10408	Oligonucleotide SE
c 129	9.8	20.4	13	1	ABF86807	Oligonucleotide SE
c 130	9.8	20.4	13	1	ABF88831	Oligonucleotide SE
c 131	9.8	20.4	13	1	ABF88833	Oligonucleotide SE
c 132	9.8	20.4	13	1	ABH64891	Oligonucleotide SE
133	9.8	20.4	13	1	ABC20824	Oligonucleotide SE
c 134	9.8	20.4	13	1	ABC97855	Oligonucleotide SE
c 135	9.8	20.4	13	1	ABC48763	Oligonucleotide SE
c 136	9.8	20.4	13	1	ABC07407	Oligonucleotide SE
137	9.8	20.4	13	1	ABF18398	Oligonucleotide SE
c 138	9.8	20.4	13	1	ABF21699	Oligonucleotide SE
139	9.8	20.4	13	1	ABF46516	Oligonucleotide SE
140	9.8	20.4	13	1	ABF51962	Oligonucleotide SE
c 141	9.8	20.4	13	1	ABF51963	Oligonucleotide SE
142	9.8	20.4	13	1	ABF02354	Oligonucleotide SE
143	9.8	20.4	13	1	ABC41626	Oligonucleotide SE
144	9.8	20.4	13	1	ABC97854	Oligonucleotide SE
c 145	9.8	20.4	13	1	ABF14030	Oligonucleotide SE
146	9.8	20.4	13	1	ABF88830	Oligonucleotide SE
147	9.8	20.4	13	1	ABH44534	Oligonucleotide SE
148	9.8	20.4	13	1	ABC53910	Oligonucleotide SE
c 149	9.8	20.4	13	1	ABF07049	Oligonucleotide SE
c 150	9.8	20.4	13	1	ABF18399	Oligonucleotide SE
151	9.8	20.4	13	1	ABF88832	Oligonucleotide SE
152	9.8	20.4	13	1	ABH64890	Oligonucleotide SE
153	9.8	20.4	13	1	ABC22258	Oligonucleotide SE
c 154	9.8	20.4	13	1	ABC53911	Oligonucleotide SE
155	9.8	20.4	13	1	ABC83524	Oligonucleotide SE
c 156	9.8	20.4	13	1	ABF11986	Oligonucleotide SE
157	9.8	20.4	13	1	ABF11987	Oligonucleotide SE
c 158	9.8	20.4	13	1	ABH10409	Oligonucleotide SE
c 159	9.8	20.4	13	1	ABH44535	Oligonucleotide SE
c 160	9.8	20.4	13	1	ABH50273	Oligonucleotide SE
161	9.8	20.4	13	1	ABC72954	Oligonucleotide SE
c 162	9.8	20.4	13	1	ABC72955	Oligonucleotide SE
c 163	9.8	20.4	13	1	ABC74875	Oligonucleotide SE
c 164	9.8	20.4	13	1	ABC10735	Oligonucleotide SE
165	9.8	20.4	13	1	ABC12426	Oligonucleotide SE
c 166	9.8	20.4	13	1	ABF02355	Oligonucleotide SE
167	9.8	20.4	13	1	ABF14031	Oligonucleotide SE
c 168	9.8	20.4	13	1	ABF46517	Oligonucleotide SE
c 169	9.8	20.4	13	1	ADD15389	Plasmid pHIV-LTR E
c 170	8.8	18.3	17	1	ABT39656	Tumour suppression

ALIGNMENTS

RESULT 1
ADB99915/c
ID ADB99915 standard; DNA; 20 BP.
XX
AC ADB99915;
XX
DT 04-DEC-2003 (first entry)
XX
DE Vitamin D nuclear receptor antisense oligonucleotide, SEQ ID 54.
XX
KW Cytostatic; gene therapy; antisense oligonucleotide; human;
KW vitamin D nuclear receptor; cancer; developmental disorder;
KW phosphorothioate; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1. .20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "This oligonucleotide has a phosphorothioate
FT backbone and 2-'methyoxyethyl (2'-MOE) wings at the 5'
FT and 3' ends, which are 5 nucleotides in length. Also all
FT cytidine residues are 5-methylcytidines"
XX
PN WO2003041657-A2.
XX
PD 22-MAY-2003.
XX
PF 13-NOV-2002; 2002WO-US036692.
XX
PR 14-NOV-2001; 2001US-00000213.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Baker BF, Dobie K, Roach MP;
XX
DR WPI; 2003-468578/44.
XX
PT New antisense oligonucleotides for modulating vitamin D nuclear receptor
PT gene expression, particularly useful for treating or preventing cancer or
PT developmental disorder, or as diagnostics or research reagents.
XX
PS Claim 3; SEQ ID NO 54; 122pp; English.
XX
CC The present invention relates to novel antisense oligonucleotides
CC (ADB99875-ADB99952) which are targeted to a human vitamin D nuclear
CC receptor coding sequence (ADB99864), and specifically hybridizes with and
CC inhibits the expression of vitamin D nuclear receptor. The antisense
CC oligonucleotides are useful for treating an animal having a disease or
CC condition associated with vitamin D nuclear receptor, e.g. cancer or
CC developmental disorder.
XX
SQ Sequence 20 BP; 3 A; 8 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 41.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.2;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1722 ATGTTGAGGGAACAGACAGG 1741
||||||||||||||||||||
Db 20 ATGTTGAGGGAACAGACAGG 1

RESULT 2
ADB99916/c
ID ADB99916 standard; DNA; 20 BP.
XX
AC ADB99916;
XX
DT 04-DEC-2003 (first entry)
XX
DE Vitamin D nuclear receptor antisense oligonucleotide, SEQ ID 55.
XX
KW Cytostatic; gene therapy; antisense oligonucleotide; human;
KW vitamin D nuclear receptor; cancer; developmental disorder;
KW phosphorothioate; ss.

```
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "This oligonucleotide has a phosphorothioate
FT                   backbone and 2-'methyoxyethyl (2'-MOE) wings at the 5'
FT                   and 3' ends, which are 5 nucleotides in length. Also all
FT                   cytidine residues are 5-methylcytidines"
XX
PN   WO2003041657-A2.
XX
PD   22-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036692.
XX
PR   14-NOV-2001; 2001US-00000213.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Baker BF,  Dobie K,  Roach MP;
XX
DR   WPI; 2003-468578/44.
XX
PT   New antisense oligonucleotides for modulating vitamin D nuclear receptor
PT   gene expression, particularly useful for treating or preventing cancer or
PT   developmental disorder, or as diagnostics or research reagents.
XX
PS   Claim 3; SEQ ID NO 55; 122pp; English.
XX
CC   The present invention relates to novel antisense oligonucleotides
CC   (ADB99875-ADB99952) which are targeted to a human vitamin D nuclear
CC   receptor coding sequence (ADB99864), and specifically hybridizes with and
CC   inhibits the expression of vitamin D nuclear receptor. The antisense
CC   oligonucleotides are useful for treating an animal having a disease or
CC   condition associated with vitamin D nuclear receptor, e.g. cancer or
CC   developmental disorder.
XX
SQ   Sequence 20 BP; 1 A; 7 C; 3 G; 9 T; 0 U; 0 Other;

  Query Match             41.7%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.2;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1730 GGAACAGACAGGAGAAATGC 1749
              ||||||||||||||||||||
Db         20 GGAACAGACAGGAGAAATGC 1


RESULT 3
ADB99914/c
ID   ADB99914 standard; DNA; 20 BP.
XX
AC   ADB99914;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Vitamin D nuclear receptor antisense oligonucleotide, SEQ ID 53.
XX
KW   Cytostatic; gene therapy; antisense oligonucleotide; human;
KW   vitamin D nuclear receptor; cancer; developmental disorder;
KW   phosphorothioate; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "This oligonucleotide has a phosphorothioate
FT                   backbone and 2-'methyoxyethyl (2'-MOE) wings at the 5'
FT                   and 3' ends, which are 5 nucleotides in length. Also all
FT                   cytidine residues are 5-methylcytidines"
XX
PN   WO2003041657-A2.
XX
PD   22-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036692.
XX
PR   14-NOV-2001; 2001US-00000213.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Baker BF,  Dobie K,  Roach MP;
XX
DR   WPI; 2003-468578/44.
XX
PT   New antisense oligonucleotides for modulating vitamin D nuclear receptor
PT   gene expression, particularly useful for treating or preventing cancer or
PT   developmental disorder, or as diagnostics or research reagents.
XX
PS   Claim 3; SEQ ID NO 53; 122pp; English.
XX
CC   The present invention relates to novel antisense oligonucleotides
CC   (ADB99875-ADB99952) which are targeted to a human vitamin D nuclear
CC   receptor coding sequence (ADB99864), and specifically hybridizes with and
CC   inhibits the expression of vitamin D nuclear receptor. The antisense
CC   oligonucleotides are useful for treating an animal having a disease or
CC   condition associated with vitamin D nuclear receptor, e.g. cancer or
CC   developmental disorder.
XX
SQ   Sequence 20 BP; 6 A; 8 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             41.7%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.2;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1710 GGCTGCTGACTGATGTTGAG 1729
              ||||||||||||||||||||
Db         20 GGCTGCTGACTGATGTTGAG 1


RESULT 4
ADB99917/c
ID   ADB99917 standard; DNA; 20 BP.
XX
AC   ADB99917;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Vitamin D nuclear receptor antisense oligonucleotide, SEQ ID 56.
XX
KW   Cytostatic; gene therapy; antisense oligonucleotide; human;
KW   vitamin D nuclear receptor; cancer; developmental disorder;
KW   phosphorothioate; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "This oligonucleotide has a phosphorothioate
FT                   backbone and 2-'methyoxyethyl (2'-MOE) wings at the 5'
FT                   and 3' ends, which are 5 nucleotides in length. Also all
FT                   cytidine residues are 5-methylcytidines"
XX
PN   WO2003041657-A2.
XX
PD   22-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036692.
XX
```

```
PR   14-NOV-2001; 2001US-00000213.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Baker BF,  Dobie K,  Roach MP;
XX
DR   WPI; 2003-468578/44.
XX
PT   New antisense oligonucleotides for modulating vitamin D nuclear receptor
PT   gene expression, particularly useful for treating or preventing cancer or
PT   developmental disorder, or as diagnostics or research reagents.
XX
PS   Claim 3; SEQ ID NO 56; 122pp; English.
XX
CC   The present invention relates to novel antisense oligonucleotides
CC   (ADB99875-ADB99952) which are targeted to a human vitamin D nuclear
CC   receptor coding sequence (ADB99864), and specifically hybridizes with and
CC   inhibits the expression of vitamin D nuclear receptor. The antisense
CC   oligonucleotides are useful for treating an animal having a disease or
CC   condition associated with vitamin D nuclear receptor, e.g. cancer or
CC   developmental disorder.
XX
SQ   Sequence 20 BP; 4 A; 4 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             41.7%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.2;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1738 CAGGAGAAATGCATCCATTC 1757
             ||||||||||||||||||||
Db         20 CAGGAGAAATGCATCCATTC 1


RESULT 5
AAV11884/c
ID   AAV11884 standard; cDNA; 18 BP.
XX
AC   AAV11884;
XX
DT   11-SEP-1998  (first entry)
XX
DE   Homo sapiens Tub Interactor gene antisense sequence.
XX
KW   antisense; tub interactor; treatment; obesity; cachexia;
KW   anorexia nervosa; diabetes; cell cycle progression; apoptosis;
KW   neurodegenerative disease; Alzheimer's disease; drug screening;
KW   Parkinson's disease; Huntington's chorea; detection; diagnosis;
KW   amylotrophic lateral sclerosis; spinocerebellar degeneration; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9812302-A1.
XX
PD   26-MAR-1998.
XX
PF   05-SEP-1997;   97WO-US015627.
XX
PR   17-SEP-1996;   96US-00715032.
PR   21-JUL-1997;   97US-00897340.
XX
PA   (MILL-) MILLENNIUM PHARM INC.
XX
PI   Gimeno CJ,  Errada PR;
XX
DR   WPI; 1998-217246/19.
XX
PT   Tub interactor genes - used to develop products for the treatment of
PT   obesity, cachexia, anorexia nervosa or related disorders e.g. diabetes.
XX
PS   Disclosure; Page 85; 120pp; English.
XX
CC   The sequence is that of a Tub Interactor (TI) gene antisense sequence
XX
SQ   Sequence 18 BP; 3 A; 8 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             30.8%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 23;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1714 GCTGACTGATGTTGAGGG 1731
              ||||||||| | ||||||
Db         18 GCTGACTGACGCTGAGGG 1


RESULT 6
AAD36184/c
ID   AAD36184 standard; DNA; 18 BP.
XX
AC   AAD36184;
XX
DT   09-AUG-2002  (first entry)
XX
DE   Human Smad6 antisense oligonucleotide, ISIS #28552.
XX
KW   Human; Smad6 protein; antisense; cardiovascular disease; infection;
KW   inflammation; cancer; therapy; phosphorothioate backbone; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .18
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "OTHER = Phosphorothioate backbone"
FT   modified_base    1. .4
FT                    /*tag=  b
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    5. .6
FT                    /*tag=  d
FT                    /mod_base= m5c
FT   modified_base    10. .12
FT                    /*tag=  e
FT                    /mod_base= m5c
FT   modified_base    14
FT                    /*tag=  f
FT                    /mod_base= m5c
FT   modified_base    15. .18
FT                    /*tag=  c
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    17
FT                    /*tag=  g
FT                    /mod_base= m5c
XX
PN   WO200228878-A1.
XX
PD   11-APR-2002.
XX
PF   01-OCT-2001; 2001WO-US030645.
XX
PR   04-OCT-2000; 2000US-00679298.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Cowsert LM;
XX
DR   WPI; 2002-394345/42.
XX
PT   Oligonucleotides, useful for the modulation of Smad6 expression in the
PT   treatment or prophylaxis of e.g. cardiovascular disease, are targeted to
PT   nucleic acid molecule encoding Smad6.
XX
PS   Example 16; Page 90; 110pp; English.
XX
CC   The invention relates to an antisense oligonucleotide targetted to a
```

```
CC   nucleic acid molecule encoding human Smad6 protein, which specifically
CC   hybridises with the nucleic acid and inhibits its expression. Antisense
CC   compounds of the invention are used for inhibiting the expression of
CC   Smad6 in cells and tissues in the treatment of a disease or condition
CC   associated with Smad6 such as cardiovascular disease, cancer, infection
CC   and inflammation. They are also useful in the diagnostics, as research
CC   reagents, in kits and in antisense therapy. The present sequence is an
CC   antisense oligonucleotide targetted to human Smad6
XX
SQ   Sequence 18 BP; 3 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             30.0%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 26;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1723 TGTTGAGGGAACAGAC 1738
              ||||||||||||  |||
Db         18 TGTTGAGGGAACGGAC 3


RESULT 7
ACD62830
ID   ACD62830 standard; RNA; 17 BP.
XX
AC   ACD62830;
XX
DT   24-SEP-2003  (first entry)
XX
DE   HCV minus strand DNAzyme substrate sequence #749.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis C virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Claim 1; Page 288; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HCV
CC   DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC   invention
XX
SQ   Sequence 17 BP; 3 A; 1 C; 9 G; 0 T; 4 U; 0 Other;

  Query Match             28.7%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 30;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1714 GCTGACTGATGTTGAGG 1730
              ||:|| :||:| :||||
Db          1 GCUGAGUGAUGGUGAGG 17


RESULT 8
ABN08350/c
ID   ABN08350 standard; DNA; 17 BP.
XX
AC   ABN08350;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8342.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
```

```
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 8342; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 8 A; 4 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match             27.1%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 39;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1713 TGCTGACTGATGT 1725
              |||||||||||||
Db         16 TGCTGACTGATGT 4


RESULT 9
ABN08352/c
ID   ABN08352 standard; DNA; 17 BP.
XX
AC   ABN08352;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8344.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 8344; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 6 A; 4 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             27.1%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 39;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1713 TGCTGACTGATGT 1725
              |||||||||||||
Db         14 TGCTGACTGATGT 2


RESULT 10
ABN08351/c
ID   ABN08351 standard; DNA; 17 BP.
XX
AC   ABN08351;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8343.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
```

```
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 8343; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             27.1%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 39;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1713 TGCTGACTGATGT 1725
              |||||||||||||
Db         15 TGCTGACTGATGT 3


RESULT 11
ABN08349/c
ID   ABN08349 standard; DNA; 17 BP.
XX
AC   ABN08349;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8341.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 8341; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 7 A; 5 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match             27.1%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 39;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1713 TGCTGACTGATGT 1725
              |||||||||||||
Db         17 TGCTGACTGATGT 5
```

```
RESULT 12
ABN08353/c
ID   ABN08353 standard; DNA; 17 BP.
XX
AC   ABN08353;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8345.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 8345; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             27.1%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 39;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1713 TGCTGACTGATGT 1725
              |||||||||||||
Db         13 TGCTGACTGATGT 1


RESULT 13
AAQ92724/c
ID   AAQ92724 standard; DNA; 16 BP.
XX
AC   AAQ92724;
XX
DT   13-FEB-1996  (first entry)
XX
DE   c-erbB-2 antisense nucleic acid #67.
XX
KW   Antisense nucleic acid; c-erbB-2; inhibition; fibroblast; neoplasm;
KW   p185-erbB-2 protein tyrosine kinase; tumour; breast cancer; detection;
KW   immune disease; angiogenesis; ss.
XX
OS   Synthetic.
XX
PN   WO9517507-A1.
XX
PD   29-JUN-1995.
XX
PF   09-DEC-1994;   94WO-EP004094.
XX
PR   23-DEC-1993;   93EP-00120710.
XX
PA   (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX
PI   Brysch W,  Schlingensiepen K,  Schlingensiepen R,  Schlingensiepen G;
XX
DR   WPI; 1995-240669/31.
XX
PT   New anti:sense nucleic acid against C-erbB-2 - for treating or preventing
PT   neoplasms, immune disease and angiogenesis, also for diagnosis.
XX
PS   Claim 1; Page 35; 55pp; English.
XX
CC   The sequences given in AAQ92658-762 are antisense nucleic acids which
CC   hybridise with part of the mRNA and/or DNA encoding c-erbB-2. These
CC   antisense nucleic acids are able to inhibit the expression of the p185-
CC   erbB-2 protein tyrosine kinase activity and cell growth in a number of
CC   tumour cells including breast cancer cells. Untransformed normal
CC   fibroblasts are not growth inhibited by anti-c-erbB-2 antisense compounds
CC   suggesting that p185-erbB-2 plays a pathogenic role in the growth of the
CC   above mentioned tumours. These antisense oligonucleotides may be used in
CC   the prevention and treatment of neoplasms, immune diseases and/or
CC   diseases involving pathological angiogenesis when associated with c-erbB-
CC   2 expression. They may also be used to detect expression of the relevant
CC   genes
XX
SQ   Sequence 16 BP; 3 A; 5 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             26.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 40;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1723 TGTTGAGGGAACAGAC 1738
              |||||||||| | ||
Db         16 TGTTGAGGGAAAACAC 1


RESULT 14
```

ACC52840/c
ID ACC52840 standard; DNA; 17 BP.
XX
AC ACC52840;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human tumour suppressor sequence #1607.
XX
KW ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW tumour regression; apoptosis; virus resistance; diagnosis;
KW cellular degeneration.
XX
OS Homo sapiens.
XX
PN FR2826373-A1.
XX
PD 27-DEC-2002.
XX
PF 20-JUN-2001; 2001FR-00008139.
XX
PR 20-JUN-2001; 2001FR-00008139.
XX
PA (MOLE-) MOLECULAR ENGINES LAB SA.
XX
PI Tuijnder M, Telerman A, Amson R;
XX
DR WPI; 2003-250498/25.
XX
PT New nucleic acid sequences associated with tumor suppression, regression,
PT apoptosis or virus resistance are useful to diagnose and treat viral
PT disease, development of tumor cells and cell degeneration.
XX
PS Claim 1; Page 411; 798pp; French.
XX
CC This sequence represents an isolated nucleic acid sequence associated
CC with tumour suppression or regression, apoptosis or virus resistance. The
CC invention relates to these sequences or sequences having at least 80%
CC identity to them, and polypeptides encoded by the sequences or
CC polypeptides having 80% identity to the polypeptide sequences. The
CC invention is used to diagnose or treat viral disease or disease
CC characterized by development of tumour cells or cellular degeneration
XX
SQ Sequence 17 BP; 1 A; 6 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 26.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 42;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1737 ACAGGAGAAATGCATC 1752
              |||||||||| | |||
Db         16 ACAGGAGAAAGGGATC 1
```

RESULT 15
ABT39656
ID ABT39656 standard; DNA; 17 BP.
XX
AC ABT39656;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 5293.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 652; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 8 A; 2 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 26.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 42;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1731 GAACAGACAGGAGAAA 1746
              || ||| |||||||||
Db          1 GATCAGGCAGGAGAAA 16
```

RESULT 16
ACD59839/c
ID ACD59839 standard; RNA; 17 BP.
XX
AC ACD59839;
XX
DT 24-SEP-2003 (first entry)
XX
DE HCV DNAzyme substrate sequence #1529.
XX
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.
XX
OS Hepatitis C virus.
XX

PN WO200281494-A1.
XX
PD 17-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-US009187.
XX
PR 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEEP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
DR WPI; 2003-229207/22.
XX
PT Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
PS Claim 1; Page 261; 387pp; English.
XX
CC The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC invention
XX
SQ Sequence 17 BP; 4 A; 8 C; 2 G; 0 T; 3 U; 0 Other;

Query Match 26.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 42;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1715 CTGACTGATGTTGAGG 1730
              |||| ||||| |||||
Db         17 CTGAGTGATGGTGAGG 2
```

RESULT 17
ABF92692
ID ABF92692 standard; DNA; 13 BP.
XX
AC ABF92692;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 192689 for detecting SNP TSC0047415.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 192689; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 6 G; 4 T; 0 U; 1 Other;

Query Match 25.0%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1720 TGATGTTGAGGG 1731
              ||||||||||||
Db          1 TGATGTTGAGGG 12
```

RESULT 18
ABF92693/c
ID ABF92693 standard; DNA; 13 BP.
XX
AC ABF92693;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 192690 for detecting SNP TSC0047415.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.

XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 192690; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 6 C; 0 G; 2 T; 0 U; 1 Other;

Query Match 25.0%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1720 TGATGTTGAGGG 1731
              ||||||||||||
Db         13 TGATGTTGAGGG 2
```

RESULT 19
AAT51864/c
ID AAT51864 standard; RNA; 15 BP.
XX
AC AAT51864;
XX
DT 25-MAR-2003 (revised)
DT 09-MAR-1997 (first entry)
XX
DE Human ICAM hammerhead ribozyme target sequence (nt. position 770).
XX
KW Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
KW intercellular adhesion molecule; rel A; tumour necrosis factor;
KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KW translocation; chronic myelogenous leukaemia; CML; cancer;
KW Philadelphia chromosome; inflammation; autoimmune disease;
KW atherosclerosis; myocardial infarction; stroke; restenosis;
KW transplant rejection; rheumatoid arthritis; psoriasis;
KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;
KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
KW ss.
XX
OS Homo sapiens.
XX
PN WO9523225-A2.
XX
PD 31-AUG-1995.
XX
PF 23-FEB-1995; 95WO-IB000156.
XX
PR 23-FEB-1994; 94US-00201109.
PR 29-MAR-1994; 94US-00218934.
PR 04-APR-1994; 94US-00222795.
PR 07-APR-1994; 94US-00224483.
PR 15-APR-1994; 94US-00227958.
PR 15-APR-1994; 94US-00228041.
PR 18-MAY-1994; 94US-00245736.
PR 06-JUL-1994; 94US-00271280.
PR 15-AUG-1994; 94US-00291932.
PR 16-AUG-1994; 94US-00291433.
PR 17-AUG-1994; 94US-00292620.
PR 19-AUG-1994; 94US-00293520.
PR 02-SEP-1994; 94US-00300000.
PR 08-SEP-1994; 94US-00303039.
PR 23-SEP-1994; 94US-00311486.
PR 23-SEP-1994; 94US-00311749.
PR 28-SEP-1994; 94US-00314397.
PR 03-OCT-1994; 94US-00316771.
PR 07-OCT-1994; 94US-00319492.
PR 11-OCT-1994; 94US-00321993.
PR 04-NOV-1994; 94US-00334847.
PR 10-NOV-1994; 94US-00337608.
PR 28-NOV-1994; 94US-00345516.
PR 16-DEC-1994; 94US-00357577.
PR 23-DEC-1994; 94US-00363233.
PR 30-JAN-1995; 95US-00380734.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Chowrira B, Direnzo A, Draper KG, Dudycz LW;
PI Grimm S, Karpeisky A, Kisich K, Matulic-Adamic J, Mcswiggen JA;
PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D, Thompson JD;
PI Tracz D, Usman N, Wincott FE, Woolf T;
XX
DR WPI; 1995-351090/45.
XX
PT Ribozymes having modified bases and methods for producing them - for use
PT in inhibiting disease related genes.
XX
PS Claim 2; Page 172; 407pp; English.
XX
CC The present sequence represents a preferred target sequence for an
CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA.
CC Regions of the mRNA that do not form secondary folding structures and
CC that contain potential hammerhead and hairpin ribozyme cleavage sites
CC were identified by computer analysis. Ribozymes directed against these
CC mRNA sequences were designed and synthesised with modifications that
CC improve their nuclease resistance. The ribozymes cleave the ICAM-1 target
CC sequences and thereby inhibit ICAM-1 expression, making them useful for
CC reducing transplant rejection and alleviating symptoms in patients with
CC rheumatoid arthritis, asthma and other inflammatory disorders. (Updated
CC on 25-MAR-2003 to correct PI field.)
XX
SQ Sequence 15 BP; 1 A; 5 C; 4 G; 0 T; 5 U; 0 Other;

Query Match 24.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 53;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1724 GTTGAGGGAACAGAC 1738
              ||  ||||||||||
Db         15 GTCCAGGGAACAGAC 1
```

RESULT 20
AAZ64202/c
ID AAZ64202 standard; RNA; 15 BP.
XX
AC AAZ64202;
XX
DT 28-MAR-2000 (first entry)
XX
DE Substrate for hammerhead ribozyme which cleaves HCV RNA at nt. 6200.
XX
KW Enzymatic nucleic acid; hammerhead ribozyme; virus replication; cleavage;
KW cirrhosis; liver failure; hepatocellular carcinoma; interferon; cancer;
KW autoimmune disease; ss.
XX

OS Hepatitis C virus.
XX
PN WO9955847-A2.
XX
PD 04-NOV-1999.
XX
PF 26-APR-1999; 99WO-US009027.
XX
PR 27-APR-1998; 98US-0083217P.
PR 18-SEP-1998; 98US-0100842P.
PR 25-FEB-1999; 99US-00257608.
PR 23-MAR-1999; 99US-00274553.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Mcswiggen JA, Roberts E, Pavco PA, Macejak D;
XX
DR WPI; 2000-062023/05.
XX
PT Novel ribozymes for the treatment of diseases and conditions related to
PT hepatitis C infection.
XX
PS Claim 1; Page 84; 123pp; English.
XX
CC The present sequence represents the preferred target sequence of an
CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC the Hepatitis C virus (HCV) RNA sequence at the base position given in
CC the descriptor line. The HCV sequence was screened for optimal ribozyme
CC target sites using a computer folding algorithm and regions of the mRNA
CC which did not form secondary folding structures and contained potential
CC ribozyme cleavage sites were identified. Ribozymes were synthesised to
CC target these sites and their activities optimised by either varying the
CC length of the binding arms or by modification to prevent degradation by
CC nucleases. The ribozymes of the invention inhibit gene expression and/or
CC viral replication, and are used to treat diseases associated with
CC Hepatitis C virus (HCV) infection, e.g. cirrhosis, liver failure and
CC hepatocellular carcinoma. The ribozymes may be used in combination with
CC interferon to treat HCV infection, other infectious diseases, autoimmune
CC diseases, and cancer
XX
SQ Sequence 15 BP; 4 A; 7 C; 1 G; 0 T; 3 U; 0 Other;

Query Match 24.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 53;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1714 GCTGACTGATGTTGA 1728
              ||||| ||||| |||
Db         15 GCTGAGTGATGGTGA 1
```

RESULT 21
AAF46891
ID AAF46891 standard; DNA; 15 BP.
XX
AC AAF46891;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP3 oligonucleotide #311.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 7; Page 46; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 1 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 24.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 53;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1710 GGCTGCTGACTGATG 1724
              ||||||| |||| |
Db          1 GGCTGCTGCCTGACG 15
```

RESULT 22
AAF46892
ID AAF46892 standard; DNA; 15 BP.
XX
AC AAF46892;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP3 oligonucleotide #312.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.

XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 7; Page 46; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 1 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 24.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 53;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1711 GCTGCTGACTGATGT 1725
||||||| |||| ||
Db 1 GCTGCTGCCTGACGT 15

RESULT 23
ABN81214/c
ID ABN81214 standard; DNA; 15 BP.
XX
AC ABN81214;
XX
DT 16-AUG-2002 (first entry)
XX
DE ASO probe #7 for detecting CYP1B1 gene polymorphisms.
XX
KW Cytochrome P450; dioxin-inducible; glaucoma 3; CYP1B1; cytostatic;
KW ophthalmological; gene therapy; polymorphism; breast cancer; ASO;
KW primary congenital glaucoma; allele-specific oligonucleotide; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200230951-A2.
XX
PD 18-APR-2002.
XX
PF 15-OCT-2001; 2001WO-US042726.
XX
PR 13-OCT-2000; 2000US-0240211P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Han J, Kliem SE, Sanchis A;
XX
DR WPI; 2002-426265/45.
XX
PT New genetic variants of cytochrome P450, subfamily I dioxin-inducible,
PT polypeptide 1, glaucoma 3, primary infantile gene, CYP1B1 for treatment
PT and expressing CYP1B1 protein for use in identifying drugs to breast
PT cancer.
XX
PS Claim 15; Page 15; 96pp; English.
XX
CC The present invention relates to a novel isolated polynucleotide
CC comprising a nucleotide sequence which is a polymorphic variant of a
CC reference sequence for cytochrome P450, subfamily I (dioxin-inducible),
CC polypeptide 1 (glaucoma 3, primary infantile), (CYP1B1) gene or its
CC fragment, or a polymorphic variant of a reference sequence for a CYP1B1
CC cDNA or its fragment. The polypeptide of the invention has cytostatic and
CC ophthalmological activity. The polynucleotide may have a use in gene
CC therapy, and antisense gene therapy. The polymorphism and haplotype data
CC of the invention are useful for validating whether CYP1B1 is a suitable
CC target for drugs to treat breast cancer and primary congenital glaucoma,
CC screening for such drugs and reducing bias in clinical trials of such
CC drugs. The sequence represents an allele-specific oligonucleotide (ASO)
CC probe, used in the invention to detect polymorphisms in the CYP1B1 gene
XX
SQ Sequence 15 BP; 0 A; 6 C; 1 G; 7 T; 0 U; 1 Other;

Query Match 24.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 53;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1731 GAACAGACAGGAGAA 1745
| ||||| |||||||
Db 15 GGACAGARAGGAGAA 1

RESULT 24
ABX01255/c
ID ABX01255 standard; RNA; 15 BP.
XX
AC ABX01255;
XX
DT 23-DEC-2002 (first entry)
XX
DE Hepatitis C virus substrate #1037 for HCV hammerhead ribozyme #1037.
XX
KW Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;
KW HCV ribozyme; HCV expression; HCV replication; cirrhosis; virucide;
KW liver failure; hepatocellular carcinoma; HCV infection; drug therapy;
KW type I interferon; interferon alpha; interferon beta; cytostatic;
KW interferon gamma; consensus interferon; hepatotropic; antiinflammatory;
KW substrate; hammerhead ribozyme; HH ribozyme; ss.
XX
OS Hepatitis C virus.
XX
PN US2002082225-A1.
XX
PD 27-JUN-2002.
XX
PF 23-MAR-1999; 99US-00274553.
XX
PR 23-MAR-1999; 99US-00274553.
XX
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
PA (ROBE/) ROBERTS B.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
PI Blatt L, Mcswiggen JA, Roberts B, Pavco PA, Macejack D;
XX
DR WPI; 2002-617759/66.
XX
PT New ribozymes targeting RNA derived from hepatitis C virus inhibit viral
PT replication and are useful to treat hepatitis C virus infections and
PT cirrhosis, liver failure or hepatocellular carcinoma.
XX

```
PS   Claim 1; Page 51; 80pp; English.
XX
CC   The present invention relates to enzymatic nucleic acids which
CC   specifically cleave RNA derived from Hepatitis C virus (HCV). The
CC   enzymatic nucleic acid or ribozyme is in a hammerhead (HH) or hairpin
CC   (HP) motif where the binding arms comprise sequences complementary to one
CC   of the substrate sequences defined in the specification. The HCV
CC   ribozymes are useful for modulating the expression and/or replication of
CC   HCV. They can be used to treat cirrhosis, liver failure and/or
CC   hepatocellular carcinoma. The HCV ribozymes are also useful for treating
CC   a condition associated with HCV infection in conjunction with one or more
CC   other drug therapies, particularly type I interferon, especially
CC   interferon alpha, beta or gamma or consensus interferon. The present
CC   sequence represents a substrate for a HCV hammerhead (HH) ribozyme. Note:
CC   Some of the sequence data for this patent did not form part of the
CC   printed specification. The complete sequence data for this patent was
CC   obtained in electronic format directly from the USPTO web site at
CC   seqdata.uspto.gov/psipsDIDEntry.html
XX
SQ   Sequence 15 BP; 4 A; 7 C; 1 G; 0 T; 3 U; 0 Other;

  Query Match             24.6%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 53;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1714 GCTGACTGATGTTGA 1728
              ||||| ||||| |||
Db         15 GCTGAGTGATGGTGA 1


RESULT 25
AAL48035/c
ID   AAL48035 standard; DNA; 15 BP.
XX
AC   AAL48035;
XX
DT   27-SEP-2002  (first entry)
XX
DE   Human CSF3 gene allele specific probe SEQ ID NO: 13.
XX
KW   Human; colony stimulating factor 3(granulocyte); CSF3; SNP; isogene;
KW   chromosome 17q11-12; single nucleotide polymorphism; immunostimulant;
KW   neutropenia; promyelocytic leukaemia; haematological disorder;
KW   gene therapy; probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO200194364-A2.
XX
PD   13-DEC-2001.
XX
PF   11-JUN-2001; 2001WO-US018813.
XX
PR   09-JUN-2000; 2000US-0210380P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Duda A,  Kazemi A,  Messer C,  Sausker EA;
XX
DR   WPI; 2002-566435/60.
XX
PT   New variants of colony stimulating factor 3 (CSF3) isogenes, useful for
PT   improving efficiency and reliability in the development of drugs for
PT   treating diseases associated with CSF3 activity e.g. neutropenia.
XX
PS   Claim 17; Page 13; 68pp; English.
XX
CC   The present invention provides the protein, gene and cDNA sequences of
CC   human colony stimulating factor 3(granulocyte) CSF3. Also described are
CC   single nucleotide polymorphisms (SNPs) identified within these sequences.
CC   The sequences can be used in the treatment of neutropenia, promyelocytic
CC   leukaemia and haematological disorders. The present sequence is an allele
CC   specific probe used to isolate the coding sequences of the invention
XX
SQ   Sequence 15 BP; 1 A; 5 C; 3 G; 5 T; 0 U; 1 Other;

  Query Match             24.2%;  Score 11.6;  DB 1;  Length 15;
  Best Local Similarity   91.7%;  Pred. No. 56;
  Matches   11;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1733 ACAGACAGGAGA 1744
              ||||:|||||||
Db         12 ACAGRCAGGAGA 1


RESULT 26
ABC12425/c
ID   ABC12425 standard; DNA; 13 BP.
XX
AC   ABC12425;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 12432 for detecting SNP TSC0002943.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 12432; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 U; 0 Other;

  Query Match             23.7%;  Score 11.4;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 55;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGAA 1733
              |||||||| ||||
Db         13 GATGTTGATGGAA 1


RESULT 27
```

```
ABC12424
ID   ABC12424 standard; DNA; 13 BP.
XX
AC   ABC12424;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 12431 for detecting SNP TSC0002943.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 12431; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             23.7%;  Score 11.4;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 55;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGAA 1733
              ||||||||  ||||
Db          1 GATGTTGATGGAA 13


RESULT 28
AAX31546/c
ID   AAX31546 standard; DNA; 15 BP.
XX
AC   AAX31546;
XX
DT   21-MAY-1999  (first entry)
XX
DE   Tag sequence of a transcript increased in pancreatic cancer.
XX
KW   Tag sequence; colorectal cancer; pancreatic cancer; colon cancer;
KW   diagnosis; prognosis; treatment; ss.
XX
OS   Homo sapiens.
XX
PN   WO9853319-A2.
XX
PD   26-NOV-1998.
XX
PF   20-MAY-1998;   98WO-US010277.
XX
PR   21-MAY-1997;   97US-0047352P.
XX
PA   (UYJO ) UNIV JOHNS HOPKINS.
XX
PI   Vogelstein B,  Kinzler KW;
XX
DR   WPI; 1999-070161/06.
XX
PT   Use of isolated gene transcripts - useful for developing products for the
PT   diagnosis, prognosis and treatment of cancers, particularly colon and
PT   pancreatic cancer.
XX
PS   Claim 13; Page 60; 120pp; English.
XX
CC   AAX30947-31815 represent tag sequences of transcripts that are
CC   differentially expressed in colorectal cancer, in pancreatic cancer, or
CC   in both. The tag sequences can be used to identify genes by matching the
CC   tag to a gen data base member, or by using the tag sequences as probes to
CC   isolate unidentified genes from cDNA libraries. The tag sequences can
CC   also be used in a method for diagnosing colon or pancreatic cancer in a
CC   sample suspected of being neoplastic. The method comprises comparing the
CC   level of at least one transcript in a first sample of a tissue to a
CC   second sample, where the first sample is a colonic tissue suspected of
CC   being neoplastic and the second sample is a normal human colonic tissue.
CC   The transcript is identified by a tag selected from AAX30947-31815. The
CC   methods of the invention can be used in the diagnosis, prognosis and
CC   treatment of cancer
XX
SQ   Sequence 15 BP; 2 A; 6 C; 1 G; 6 T; 0 U; 0 Other;

  Query Match             23.7%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 60;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1739 AGGAGAAATGCAT 1751
              ||||| |||||||
Db         14 AGGAGGAATGCAT 2


RESULT 29
AAF46889
ID   AAF46889 standard; DNA; 15 BP.
XX
AC   AAF46889;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP3 oligonucleotide #309.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
```

PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 7; Page 46; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 1 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 23.7%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 60;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1710 GGCTGCTGACTGA 1722
||||||||| ||||
Db 3 GGCTGCTGCCTGA 15

RESULT 30
AAF46890
ID AAF46890 standard; DNA; 15 BP.
XX
AC AAF46890;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP3 oligonucleotide #310.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 7; Page 46; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 1 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 23.7%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 60;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1710 GGCTGCTGACTGA 1722
||||||||| ||||
Db 2 GGCTGCTGCCTGA 14

RESULT 31
AAS98675/c
ID AAS98675 standard; DNA; 15 BP.
XX
AC AAS98675;
XX
DT 26-MAR-2002 (first entry)
XX
DE Colony stimulating factor 1 receptor (CSF1R) oligonucleotide #41.
XX
KW Colony stimulating factor 1 receptor; CSF1R; polymorphic variant;
KW cytostatic; gene therapy; malignant histiocytosis; isogene;
KW myeloid malignancy; inflammatory disorder; transgenic animal; haplotype;
KW genotype; human; allele specific oligonucleotide; ASO; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200179225-A2.
XX
PD 25-OCT-2001.
XX
PF 12-APR-2001; 2001WO-US012044.
XX
PR 12-APR-2000; 2000US-0196411P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Chew A, Choi JY, Koshy B;
XX
DR WPI; 2002-075058/10.
XX
PT Novel polymorphic variants of colony stimulating factor 1 receptor useful
PT in studying expression and function of the protein, useful for screening
PT candidate drugs to treat diseases e.g. inflammatory disorders.
XX

PS Claim 15; Page 15; 164pp; English.
XX
CC The invention describes a novel isolated polynucleotide (I) comprising a
CC sequence which is a polymorphic variant (PV) of a reference sequence for
CC colony stimulating factor 1 receptor (CSF1R) gene, found on The
CC polypeptide are useful for improving the discovery and development of
CC drugs for treating diseases associated with CSF1R activity, e.g.,
CC malignant histiocytosis, myeloid malignancies, and inflammatory disorders
CC and the haplotypes can be used to validate CSF1R as a candidate target
CC for treating a specific condition or disease predicted to be associated
CC with CSF1R activity. Genotyping the CSF1R gene of an individual can also
CC be used in developing diagnostic tests and therapeutic treatments. (I) is
CC useful in studying the expression and function of CSF1R, and in
CC expressing CSF1R protein for use in screening for candidate drugs to
CC treat diseases related to CSF1R activity and in studying the effect of
CC the variation on the biological activity of CSF1R as well as on the
CC binding affinity of candidate drugs targeting CSF1R. Antibodies are
CC useful in a variety of diagnostic and prognostic formats and therapeutic
CC methods. A transgenic animal is useful in studying expression of the
CC CSF1R isogenes in vivo, for in vivo screening and testing of drugs
CC targeted against CSF1R protein, and for testing the efficacy of
CC therapeutic agents and compounds. Allele specific oligonucleotides (ASO)
CC are useful as probes and primers, and for assaying a polymorphism in the
CC target region. Without requiring any a priori knowledge of the phenotypic
CC effect of any particular CSF1R or haplotype the invention provides a
CC method for identifying lead compounds that are more likely to show
CC efficacy in clinical trials. This sequence is an allele specific
CC oligonucleotide probe used for detecting CSF1R gene polymorphisms,
CC described in the method of the invention
XX
SQ Sequence 15 BP; 4 A; 4 C; 4 G; 2 T; 0 U; 1 Other;

Query Match 23.7%; Score 11.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 60;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1711 GCTGCTGACTGATGT 1725
              || |||||:|| ||||
Db         15 GCAGCTGRCTCATGT 1
```

RESULT 32
ABK96525
ID ABK96525 standard; DNA; 15 BP.
XX
AC ABK96525;
XX
DT 24-SEP-2002 (first entry)
XX
DE Human PLAU gene, allele specific primer #34.
XX
KW Human; ss; primer; Plasminogen activator; urokinase; PLAU; cancer;
KW cytostatic; serine protease; thrombolytic disorder; isogene; PCR;
KW pulmonary embolism; chromosome 10q24-qter; haplotype; genotype; SNP;
KW single nucleotide polymorphism; thrombolytic; gene therapy.
XX
OS Homo sapiens.
XX
PN WO200240503-A2.
XX
PD 23-MAY-2002.
XX
PF 14-NOV-2001; 2001WO-US044001.
XX
PR 17-NOV-2000; 2000US-0249703P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Anastasio AE, Bentivegna SC, Koshy B;
XX
DR WPI; 2002-519370/55.
XX
PT Genetic variants of Plasminogen activator, Urokinase (PLAU) isogenes,
PT useful for improving efficiency and reliability in drug development for
PT treating thrombolytic disorders and cancer.
XX
PS Claim 14; Page 14; 92pp; English.
XX
CC The invention relates to a polynucleotide comprising a first nucleotide
CC sequence (NS1) comprising a PLAU (plasminogen activator, urokinase, a
CC serine protease) isogene selected from isogenes 1-9 and 11-20 given in
CC the specification, where each isogene comprises the regions of the PLAU
CC gene or cDNA and is further defined by the corresponding sequence of
CC polymorphisms (defining single nucleotide polymorphisms, SNP). Also
CC included are methods of haplotyping/genotyping (and predicting the
CC haplotype/genotype of the PLAU gene of an individual, identifying an
CC association between a trait and at least one haplotype or haplotype pair
CC of the PLAU gene, an isolated oligonucleotide for detecting a
CC polymorphism in the PLAU gene, a recombinant non-human organism
CC transformed or transfected with the gene or cDNA, fragments of the
CC polynucleotides of at least 10 base pairs encompassing a polymorphic
CC site, an isolated polymorphic variant PLAU protein or fragment, an
CC isolated monoclonal antibody specific for PLAU, a computer system for
CC storing and analysing polymorphism data for the PLAU gene and a genome
CC anthology for the PLAU gene. PLAU is useful in screening for drugs
CC targeting PLAU that are useful for treating thrombolytic disorders and
CC cancers. The methods are useful for improving the efficiency and
CC reliability of the discovery and development of drugs for treating
CC diseases associated with PLAU activity, in validating PLAU as a drug
CC target and in the design of clinical trials for treating a specific
CC condition of disease associated with PLAU activity. The antibody is
CC useful in diagnostic, prognostic and therapeutic methods. PLAU
CC polynucleotides are useful in studying the expression and function of
CC PLAU, and in expressing PLAU protein for use in screening for candidate
CC drugs to treat diseases related to PLAU activity. The gene for PLAU is
CC located on chromosome 10q24-qter. The present sequence is an allele
CC specific primer used to amplify PLAU polynucleotides with a specific
CC polymorphism
XX
SQ Sequence 15 BP; 5 A; 2 C; 7 G; 0 T; 0 U; 1 Other;

Query Match 23.7%; Score 11.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 60;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1729 GGGAACAGACAGGAG 1743
              ||||||||||  |:|
Db          1 GGGAACAGACGAGRG 15
```

RESULT 33
ABK32500/c
ID ABK32500 standard; DNA; 15 BP.
XX
AC ABK32500;
XX
DT 23-APR-2002 (first entry)
XX
DE Human pancreatic cancer SAGE tag #52.
XX
KW Human; colon cancer; colorectal cancer; pancreatic cancer; SAGE tag;
KW serial analysis of gene expression; diagnostic; prognostic; probe;
KW cancer marker; ss.
XX
OS Homo sapiens.
XX
PN US6333152-B1.
XX
PD 25-DEC-2001.
XX
PF 20-MAY-1998; 98US-00081646.
XX
PR 20-MAY-1998; 98US-00081646.
XX
PA (UYJO) UNIV JOHNS HOPKINS.
XX

```
PI   Vogelstein B,  Kinzler KW,  Zhang L,  Zhou W;
XX
DR   WPI; 2002-153821/20.
XX
PT   New human nucleic acid containing specific SAGE tags, useful as
PT   diagnostic markers for cancer, also derived probes.
XX
PS   Disclosure; Col 69; 161pp; English.
XX
CC   The invention relates to an isolated, purified human nucleic acid (I)
CC   that has the same sequence as a mRNA found in humans and is a SAGE
CC   (serial analysis of gene expression) tag comprising a single stranded
CC   probe containing at least 10 consecutive nucleotides. SAGE tags, are
CC   diagnostic and prognostic markers of cancer, especially of the colon and
CC   pancreas. ABK31900-ABK32770 represent human colon and pancreatic cancer
CC   SAGE tags of the invention
XX
SQ   Sequence 15 BP; 2 A; 6 C; 1 G; 6 T; 0 U; 0 Other;

  Query Match             23.7%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 60;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1739 AGGAGAAATGCAT 1751
              ||||| |||||||
Db         14 AGGAGGAATGCAT 2


RESULT 34
ABI55463
ID   ABI55463 standard; DNA; 12 BP.
XX
AC   ABI55463;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 355436 for detecting SNP TSC0010480.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 355436; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 3 A; 0 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             22.9%;  Score 11;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 59;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1722 ATGTTGAGGGA 1732
              ||||||||||| 
Db          1 ATGTTGAGGGA 11


RESULT 35
ABF42717/c
ID   ABF42717 standard; DNA; 13 BP.
XX
AC   ABF42717;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 142714 for detecting SNP TSC0035797.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 142714; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 7 C; 0 G; 2 T; 0 U; 1 Other;

  Query Match             22.9%;  Score 11;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 62;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGG 1731
              ||||||||||| 
Db         12 GATGTTGAGGG 2
```

```
RESULT 36
ABH51281/c
ID   ABH51281 standard; DNA; 13 BP.
XX
AC   ABH51281;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 251258 for detecting SNP TSC0061330.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 251258; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;

  Query Match             22.9%;  Score 11;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 62;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1723 TGTTGAGGGAA 1733
             ||||||||||||
Db         12 TGTTGAGGGAA 2


RESULT 37
ABC88045/c
ID   ABC88045 standard; DNA; 13 BP.
XX
AC   ABC88045;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 88062 for detecting SNP TSC0022137.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 88062; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;

  Query Match             22.9%;  Score 11;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 62;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1720 TGATGTTGAGG 1730
             ||||||||||||
Db         11 TGATGTTGAGG 1


RESULT 38
ABF28165/c
ID   ABF28165 standard; DNA; 13 BP.
XX
AC   ABF28165;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 128162 for detecting SNP TSC0032096.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
```

```
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 128162; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;

  Query Match             22.9%;  Score 11;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 62;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1720 TGATGTTGAGG 1730
             ||||||||||| |
Db         13 TGATGTTGAGG 3


RESULT 39
ABH51280
ID   ABH51280 standard; DNA; 13 BP.
XX
AC   ABH51280;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 251257 for detecting SNP TSC0061330.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 251257; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             22.9%;  Score 11;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 62;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1723 TGTTGAGGGAA 1733
             ||||||||||| |
Db          2 TGTTGAGGGAA 12


RESULT 40
ABH52406/c
ID   ABH52406 standard; DNA; 13 BP.
XX
AC   ABH52406;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 252383 for detecting SNP TSC0061567.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 252383; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 0 C; 4 G; 5 T; 0 U; 1 Other;
```

```
  Query Match             22.9%;  Score 11;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 62;
  Matches   11;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1743 GAAATGCATCCAT 1755
              :|||| |||||||
Db         13 RAAATCCATCCAT 1


RESULT 41
ABC88044
ID   ABC88044 standard; DNA; 13 BP.
XX
AC   ABC88044;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 88061 for detecting SNP TSC0022137.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 88061; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             22.9%;  Score 11;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 62;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1720 TGATGTTGAGG 1730
              ||||||||||||
Db          3 TGATGTTGAGG 13


RESULT 42
ABF28164
ID   ABF28164 standard; DNA; 13 BP.
XX
AC   ABF28164;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 128161 for detecting SNP TSC0032096.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 128161; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             22.9%;  Score 11;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 62;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1720 TGATGTTGAGG 1730
              ||||||||||||
Db          1 TGATGTTGAGG 11


RESULT 43
ABF42716
ID   ABF42716 standard; DNA; 13 BP.
XX
AC   ABF42716;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 142713 for detecting SNP TSC0035797.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
```

PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 142713; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 7 G; 3 T; 0 U; 1 Other;

Query Match 22.9%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 62;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1721 GATGTTGAGGG 1731
                ||||||||||| 
Db          2 GATGTTGAGGG 12
```

RESULT 44
ABH52407
ID ABH52407 standard; DNA; 13 BP.
XX
AC ABH52407;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 252384 for detecting SNP TSC0061567.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 252384; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 4 C; 0 G; 3 T; 0 U; 1 Other;

Query Match 22.9%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 62;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1743 GAAATGCATCCAT 1755
                :|||| |||||||
Db          1 RAAATCCATCCAT 13
```

RESULT 45
AAA26214/c
ID AAA26214 standard; DNA; 14 BP.
XX
AC AAA26214;
XX
DT 19-JUL-2000 (first entry)
XX
DE Oestrogen receptor hairpin ribozyme target sequence SEQ ID NO:2712.
XX
KW Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
KW gene expression modification; cancer; phosphorothioate; endonuclease;
KW anticancer; breast cancer; endometrium cancer; ss.
XX
OS Homo sapiens.
XX
PN WO9954459-A2.
XX
PD 28-OCT-1999.
XX
PF 19-APR-1999; 99WO-US008547.
XX
PR 20-APR-1998; 98US-0082404P.
PR 23-JUN-1998; 98US-00103636.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haeberli P;
PI Matulic-Adamic J;
XX
DR WPI; 2000-013248/01.
XX
PT New nucleic acids that interact, and optionally cleave, target sequences,
PT used to treat cancer.
XX
PS Claim 79; Page 103; 148pp; English.
XX
CC The present invention describes nucleic acids (A) that interact stably
CC with a target sequence and contain at least one phosphoro(di)thioate
CC link, having endonuclease activity. (A), and more generally any catalytic

CC nucleic acid (A') that modulates expression of the oestrogen receptor
CC gene, are used to treat cancer (particularly of breast or endometrium),
CC in vivo or by transforming cells ex vivo and implanting treated cells, or
CC for other conditions associated with levels of oestrogen receptor.
CC Because of the high selectivity for targeted RNA, (A) can also be used to
CC correlate inhibition of gene expression with alterations in phenotype,
CC particularly for identification of therapeutic targets, and as research
CC reagents (for RNA, in the same way that restriction endonucleases are
CC used with DNA). The combination of modifications in (A) improves
CC resistance to nucleases, binding affinity and/or activity. AAA23503 to
CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and
CC AAA24748 to AAA25992 represent their corresponding target sequences.
CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme
CC sequences, and AAA26107 to AAA26218 represent their corresponding target
CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and
CC antisense oligonucleotides used in the exemplification of the present
CC invention
XX
SQ Sequence 14 BP; 1 A; 4 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 22.5%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 69;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1726 TGAGGGAACAGACA 1739
|||| ||||||| |
Db 14 TGAGAGAACAGAAA 1

RESULT 46
ABC68262
ID ABC68262 standard; DNA; 13 BP.
XX
AC ABC68262;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 68279 for detecting SNP TSC0017813.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 68279; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 0 C; 5 G; 2 T; 0 U; 1 Other;

Query Match 22.1%; Score 10.6; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 70;
Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1739 AGGAGAAATGC 1749
||||||||||:
Db 3 AGGAGAAATGY 13

RESULT 47
ABC68263/c
ID ABC68263 standard; DNA; 13 BP.
XX
AC ABC68263;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 68280 for detecting SNP TSC0017813.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 68280; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 5 C; 0 G; 5 T; 0 U; 1 Other;

Query Match 22.1%; Score 10.6; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 70;
Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1739 AGGAGAAATGC 1749
||||||||||:

```
Db         11 AGGAGAAATGY 1


RESULT 48
ABH85801
ID   ABH85801 standard; DNA; 12 BP.
XX
AC   ABH85801;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 285794 for detecting SNP TSC0012441.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 285794; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 7 A; 0 C; 4 G; 1 T; 0 U; 0 Other;

  Query Match            21.7%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity  91.7%;  Pred. No. 71;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1737 ACAGGAGAAATG 1748
              | ||||||||||
Db          1 AAAGGAGAAATG 12


RESULT 49
ABI41640
ID   ABI41640 standard; DNA; 12 BP.
XX
AC   ABI41640;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 341613 for detecting SNP TSC0042137.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 341613; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 5 A; 0 C; 6 G; 1 T; 0 U; 0 Other;

  Query Match            21.7%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity  91.7%;  Pred. No. 71;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1726 TGAGGGAACAGA 1737
              |||||||| |||
Db          1 TGAGGGAAGAGA 12


RESULT 50
ABI49018/c
ID   ABI49018 standard; DNA; 12 BP.
XX
AC   ABI49018;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 348991 for detecting SNP TSC0045849.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
```

```
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 348991; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 4 A; 5 C; 0 G; 3 T; 0 U; 0 Other;

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 71;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGA 1732
                ||||||  |||||
Db         12 GATGTTTAGGGA 1


RESULT 51
ABI62513/c
ID   ABI62513 standard; DNA; 12 BP.
XX
AC   ABI62513;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 362486 for detecting SNP TSC0053258.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 362486; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 1 A; 6 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 71;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1726 TGAGGGAACAGA 1737
                ||||||||  |||
Db         12 TGAGGGAAGAGA 1


RESULT 52
ABH69285/c
ID   ABH69285 standard; DNA; 12 BP.
XX
AC   ABH69285;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 269262 for detecting SNP TSC0001682.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 269262; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
```

```
SQ   Sequence 12 BP; 4 A; 4 C; 1 G; 3 T; 0 U; 0 Other;

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 71;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1723 TGTTGAGGGAAC 1734
              ||||||||  |||
Db         12 TGTTGAGGTAAC 1


RESULT 53
ABC94621/c
ID   ABC94621 standard; DNA; 13 BP.
XX
AC   ABC94621;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 94638 for detecting SNP TSC0023588.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 94638; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 U; 0 Other;

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 75;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGA 1732
              |||  ||||||||
Db         12 GATTTTGAGGGA 1


RESULT 54
ABC36414
ID   ABC36414 standard; DNA; 13 BP.
XX
AC   ABC36414;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 36431 for detecting SNP TSC0011440.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 36431; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 0 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 75;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1722 ATGTTGAGGGAA 1733
              |||  ||||||||
Db          2 ATGATGAGGGAA 13


RESULT 55
ABF18905/c
ID   ABF18905 standard; DNA; 13 BP.
XX
AC   ABF18905;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 118902 for detecting SNP TSC0029684.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
```

XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 118902; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 7 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 21.7%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 75;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1721 GATGTTGAGGGA 1732
              ||||| ||||||
Db         12 GATGTGGAGGGA 1
```

RESULT 56
ABC36415/c
ID ABC36415 standard; DNA; 13 BP.
XX
AC ABC36415;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 36432 for detecting SNP TSC0011440.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 36432; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 5 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 21.7%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 75;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1722 ATGTTGAGGGAA 1733
              ||| ||||||||
Db         12 ATGATGAGGGAA 1
```

RESULT 57
ABF92694
ID ABF92694 standard; DNA; 13 BP.
XX
AC ABF92694;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 192691 for detecting SNP TSC0047415.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 192691; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,

```
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 1 C; 6 G; 3 T; 0 U; 1 Other;

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 75;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1720 TGATGTTGAGGG 1731
              ||| ||||||||
Db          1 TGACGTTGAGGG 12


RESULT 58
ABF18904
ID   ABF18904 standard; DNA; 13 BP.
XX
AC   ABF18904;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 118901 for detecting SNP TSC0029684.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 118901; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 0 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 75;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGA 1732
              ||||| ||||||
Db          2 GATGTGGAGGGA 13


RESULT 59
ABH43430
ID   ABH43430 standard; DNA; 13 BP.
XX
AC   ABH43430;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 243407 for detecting SNP TSC0010229.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 243407; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 75;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1718 ACTGATGTTGAG 1729
              | ||||||||||
Db          2 AGTGATGTTGAG 13


RESULT 60
ABH14879/c
ID   ABH14879 standard; DNA; 13 BP.
XX
AC   ABH14879;
XX
DT   22-FEB-2002  (first entry)
```

XX
DE Oligonucleotide SEQ ID NO 214856 for detecting SNP TSC0052286.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 214856; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 5 C; 0 G; 5 T; 0 U; 1 Other;

Query Match 21.7%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 75;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1725 TTGAGGGAACAG 1736
|||||||||.||
Db 13 TTGAGGGAAAAG 2

RESULT 61
ABH58053/c
ID ABH58053 standard; DNA; 13 BP.
XX
AC ABH58053;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 258030 for detecting SNP TSC0062747.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 258030; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 21.7%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 75;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1720 TGATGTTGAGGG 1731
|.||||||||||
Db 12 TTATGTTGAGGG 1

RESULT 62
ABF11938
ID ABF11938 standard; DNA; 13 BP.
XX
AC ABF11938;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 111935 for detecting SNP TSC0027936.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

```
XX
PS   Claim 1; SEQ ID NO 111935; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 75;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGA 1732
                ||||||||||  |
Db          2 GATGTTGAGGTA 13


RESULT 63
ABC78923/c
ID   ABC78923 standard; DNA; 13 BP.
XX
AC   ABC78923;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 78940 for detecting SNP TSC0020091.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 78940; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 1 A; 4 C; 0 G; 8 T; 0 U; 0 Other;

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 75;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1736 GACAGGAGAAAT 1747
                ||  |||||||||
Db         13 GAAAGGAGAAAT 2


RESULT 64
ABF92695/c
ID   ABF92695 standard; DNA; 13 BP.
XX
AC   ABF92695;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 192692 for detecting SNP TSC0047415.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 192692; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 6 C; 1 G; 2 T; 0 U; 1 Other;

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 75;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1720 TGATGTTGAGGG 1731
                |||  ||||||||
Db         13 TGACGTTGAGGG 2
```

```
RESULT 65
ABF92697/c
ID   ABF92697 standard; DNA; 13 BP.
XX
AC   ABF92697;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 192694 for detecting SNP TSC0047415.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 192694; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 6 C; 1 G; 2 T; 0 U; 1 Other;

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 75;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1720 TGATGTTGAGGG 1731
                ||||||  |||||
Db         13 TGATGTCGAGGG 2


RESULT 66
ABF56731/c
ID   ABF56731 standard; DNA; 13 BP.
XX
AC   ABF56731;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 156728 for detecting SNP TSC0039520.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 156728; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 1 A; 5 C; 0 G; 6 T; 0 U; 1 Other;

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 75;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1736 GACAGGAGAAAT 1747
                || |||||||||
Db         13 GAGAGGAGAAAT 2


RESULT 67
ABC94620
ID   ABC94620 standard; DNA; 13 BP.
XX
AC   ABC94620;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 94637 for detecting SNP TSC0023588.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
```

```
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 94637; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 75;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGA 1732
              ||| ||||||||
Db          2 GATTTTGAGGGA 13


RESULT 68
ABF18906
ID   ABF18906 standard; DNA; 13 BP.
XX
AC   ABF18906;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 118903 for detecting SNP TSC0029684.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 118903; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 0 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 75;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGA 1732
              ||||| ||||||
Db          2 GATGTAGAGGGA 13


RESULT 69
ABH43431/c
ID   ABH43431 standard; DNA; 13 BP.
XX
AC   ABH43431;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 243408 for detecting SNP TSC0010229.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 243408; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
```

```
  Query Match           21.7%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity  91.7%;  Pred. No. 75;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1718 ACTGATGTTGAG 1729
              | ||||||||||
Db         12 AGTGATGTTGAG 1


RESULT 70
ABF11939/c
ID   ABF11939 standard; DNA; 13 BP.
XX
AC   ABF11939;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 111936 for detecting SNP TSC0027936.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 111936; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;

  Query Match           21.7%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity  91.7%;  Pred. No. 75;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGA 1732
              |||||||||| |
Db         12 GATGTTGAGGTA 1


RESULT 71
ABF92696
ID   ABF92696 standard; DNA; 13 BP.
XX
AC   ABF92696;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 192693 for detecting SNP TSC0047415.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 192693; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 1 C; 6 G; 3 T; 0 U; 1 Other;

  Query Match           21.7%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity  91.7%;  Pred. No. 75;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1720 TGATGTTGAGGG 1731
              |||||| |||||
Db          1 TGATGTCGAGGG 12


RESULT 72
ABH14878
ID   ABH14878 standard; DNA; 13 BP.
XX
AC   ABH14878;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 214855 for detecting SNP TSC0052286.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
```

```
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 214855; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 0 C; 5 G; 2 T; 0 U; 1 Other;

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 75;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1725 TTGAGGGAACAG 1736
                ||||||||| ||
Db          1 TTGAGGGAAAAG 12


RESULT 73
ABC78922
ID   ABC78922 standard; DNA; 13 BP.
XX
AC   ABC78922;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 78939 for detecting SNP TSC0020091.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 78939; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 8 A; 0 C; 4 G; 1 T; 0 U; 0 Other;

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 75;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1736 GACAGGAGAAAT 1747
                || |||||||||
Db          1 GAAAGGAGAAAT 12


RESULT 74
ABF56730
ID   ABF56730 standard; DNA; 13 BP.
XX
AC   ABF56730;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 156727 for detecting SNP TSC0039520.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 156727; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
```

```
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 0 C; 5 G; 1 T; 0 U; 1 Other;

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 75;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1736 GACAGGAGAAAT 1747
                || |||||||||
Db          1 GAGAGGAGAAAT 12


RESULT 75
ABF18907/c
ID   ABF18907 standard; DNA; 13 BP.
XX
AC   ABF18907;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 118904 for detecting SNP TSC0029684.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 118904; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 6 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 75;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGA 1732
                ||||| ||||||
Db         12 GATGTAGAGGGA 1

RESULT 76
ABH58052
ID   ABH58052 standard; DNA; 13 BP.
XX
AC   ABH58052;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 258029 for detecting SNP TSC0062747.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 258029; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 75;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1720 TGATGTTGAGGG 1731
                | ||||||||||
Db          2 TTATGTTGAGGG 13


RESULT 77
AAF42671/c
ID   AAF42671 standard; DNA; 10 BP.
XX
AC   AAF42671;
XX
DT   23-MAR-2001  (first entry)
XX
DE   Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:10810.
```

XX
KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
KW serial analysis of gene expression; antifungal; tag; identification;
KW linker; PCR primer; ds.
XX
OS Saccharomyces cerevisiae.
XX
PN WO200077214-A2.
XX
PD 21-DEC-2000.
XX
PF 14-JUN-2000; 2000WO-US016223.
XX
PR 16-JUN-1999; 99US-00335032.
XX
PA (UYJO) UNIV JOHNS HOPKINS.
XX
PI Velculescu V, Vogelstein B, Kinzler K;
XX
DR WPI; 2001-061874/07.
XX
PT Yeast gene coding sequences comprising NORF genes with serial analysis of
PT gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle.
XX
PS Example; Page 336; 419pp; English.
XX
CC The present invention describes an isolated DNA molecule comprising a
CC coding sequence of a yeast gene selected from a group of 745 NORF (not
CC previously assigned open reading frame; or nonannotated ORF) genes
CC comprising a SAGE (serial analysis of gene expression) tag. Also
CC described are: (1) a method (M1) of using NORF genes to affect the cell
CC cycle comprising administering a NORF gene whose expression varies by at
CC least 10% between any two phases of the cell cycle selected from log
CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC antifungal drugs comprising: (a) contacting a test substance with a yeast
CC cell; and (b) monitoring expression of a NORF gene whose expression
CC varies as in M1, where a test substance which modifies the expression of
CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
CC identifying human genes which are involved in cell cycle progression
CC comprising contacting human DNA with a probe which comprises at least 10
CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
CC and (4) a method (M4) for identifying a candidate drug as a member of a
CC class of drugs having a characteristic effect on gene expression in a
CC yeast cell comprising contacting a yeast cell with a candidate drug and
CC monitoring expression in the yeast cell of at least 1 NORF gene whose
CC expression is affected by the class of drugs. The NORF genes may be used
CC to study, monitor and affect phases of the cell cycle, the differentially
CC expressed genes may be used as markers of phases of the cell cycle. The
CC methods may be used to identify candidate drugs which affect the cell
CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
CC represent SAGE tags used in the exemplification of the present invention.
CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
CC method, in the exemplification of the present invention
XX
SQ Sequence 10 BP; 4 A; 3 C; 1 G; 2 T; 0 U; 0 Other;

Query Match 20.8%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1719 CTGATGTTGA 1728
||||||||||
Db 10 CTGATGTTGA 1

RESULT 78
AAD25438
ID AAD25438 standard; DNA; 10 BP.
XX
AC AAD25438;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human GNRH2 gene polymorphism detecting primer #9.
XX
KW Human; gonadotropin-releasing hormone 2; GNRH2 gene; haplotyping;
KW genotyping; gene therapy; reproductive disorder; polymorphism; primer;
KW ss.
XX
OS Homo sapiens.
XX
PN WO200187910-A2.
XX
PD 22-NOV-2001.
XX
PF 18-MAY-2001; 2001WO-US016353.
XX
PR 18-MAY-2000; 2000US-0205187P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Duda A, Kliem SE, Nandabalan K, Sausker EA;
XX
DR WPI; 2002-055683/07.
XX
PT New genetic variants of gonadotropin-releasing hormone 2 isogene, useful
PT in studying expression and function of protein and for screening drugs to
PT treat diseases e.g. reproduction disorders.
XX
PS Claim 18; Page 13; 64pp; English.
XX
CC The invention relates to genetic variants of human gonadotropin-
CC releasing hormone 2 (GNRH2) gene. The invention also relates to
CC compositions and methods for haplotyping and/or genotyping the GNRH2 gene
CC in an individual. Polynucleotides of the invention are useful for
CC studying the expression and function of GNRH2 and in expressing GNRH2
CC proteins for use in screening candidate drugs to treat diseases related
CC to GNRH2 activity. They are also used in gene therapy. The methods of the
CC invention are useful in determining whether an individual has a haplotype
CC or haplotype pairs. The haplotyping method is useful for improving the
CC efficiency and reliability of several steps in the discovery and
CC development of drugs for treating diseases associated with GNRH2
CC activity, e.g., reproductive disorders. The present sequence is a primer
CC used for detecting human GNRH2 gene polymorphisms
XX
SQ Sequence 10 BP; 1 A; 3 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 20.8%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1712 CTGCTGACTG 1721
||||||||||
Db 1 CTGCTGACTG 10

RESULT 79
AAD53533
ID AAD53533 standard; DNA; 10 BP.
XX
AC AAD53533;
XX
DT 28-MAY-2003 (first entry)
XX
DE Human GNRH2 gene polymorphism detecting primer #9.
XX
KW Human; gonadotropin-releasing hormone 2; GNRH2; reproductive disorder;
KW gynaecological; cytostatic; hormonal; target validation; gene therapy;
KW drug screening; lead compound; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200294850-A2.
XX

PD 28-NOV-2002.
XX
PF 01-NOV-2001; 2001WO-US050630.
XX
PR 18-MAY-2001; 2001WO-US016353.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Duda A, Kliem SE, Nandabalan K, Sausker EA;
XX
DR WPI; 2003-148454/14.
XX
PT New gonadotropin-releasing hormone 2 (GNRH2) polypeptide encoded by
PT genetic variants having polymorphisms in the GNRH2 gene, for studying the
PT function of, and treating disorders, such as, reproductive disorders.
XX
PS Claim 16; Col 14; 33pp; English.
XX
CC The invention relates to gonadotropin-releasing hormone 2 (GNRH2) and its
CC nucleic acid sequence. Polymorphic variants of the GNRH2 gene are useful
CC in studying the expression and function of GNRH2, and in expressing GNRH2
CC proteins for use in screening candidate drugs for treating diseases
CC associated with GNRH2 activity, such as reproductive disorders.
CC Polynucleotides comprising a polymorphic gene variant or fragment may be
CC used for therapeutic purposes, where a patient could benefit from
CC expression or increased expression of a particular GNRH2 protein isoform,
CC or an expression vector encoding the isoform may be administered to the
CC patient. Haplotype information is useful in improving the efficiency and
CC output of several steps in a drug discovery and development process,
CC including target validation, identifying lead compounds, and early phase
CC clinical trials. GNRH2 gene is used in gene therapy. The present sequence
CC is a primer used for detecting human GNRH2 gene polymorphisms
XX
SQ Sequence 10 BP; 1 A; 3 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 20.8%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1712 CTGCTGACTG 1721
||||||||||
Db 1 CTGCTGACTG 10

RESULT 80
ABV63381
ID ABV63381 standard; cDNA; 11 BP.
XX
AC ABV63381;
XX
DT 21-OCT-2002 (first entry)
XX
DE Human skin EST 1167.
XX
KW Human; skin; dermatological; vulnerary; antipsoriatic; antiseborrhaeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS Homo sapiens.
XX
PN WO200253774-A2.
XX
PD 11-JUL-2002.
XX
PF 20-DEC-2001; 2001WO-EP015179.
XX
PR 03-JAN-2001; 2001DE-01000127.
XX
PA (HENK) HENKEL KGAA.
XX
PI Petersohn D, Conradt M, Hofmann K;
XX
DR WPI; 2002-590638/63.
XX
PT In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX
PS Disclosure; Page 57; 1345pp; German.
XX
CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention
XX
SQ Sequence 11 BP; 2 A; 2 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 20.8%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 76;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1715 CTGACTGATG 1724
||||||||||
Db 1 CTGACTGATG 10

RESULT 81
ABV70802
ID ABV70802 standard; cDNA; 11 BP.
XX
AC ABV70802;
XX
DT 21-OCT-2002 (first entry)
XX
DE Human skin EST 8588.
XX
KW Human; skin; dermatological; vulnerary; antipsoriatic; antiseborrhaeic;
KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS Homo sapiens.
XX
PN WO200253774-A2.
XX
PD 11-JUL-2002.
XX
PF 20-DEC-2001; 2001WO-EP015179.
XX
PR 03-JAN-2001; 2001DE-01000127.
XX
PA (HENK) HENKEL KGAA.
XX
PI Petersohn D, Conradt M, Hofmann K;
XX
DR WPI; 2002-590638/63.
XX
PT In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.
XX
PS Claim 24; Page 275; 1345pp; German.
XX
CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or

```
CC   promotes skin homeostasis or that can be used for treating skin
CC   disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC   ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC   rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC   skin. The present sequence is that of a human expressed sequence tag
CC   (EST) of the invention
XX
SQ   Sequence 11 BP; 2 A; 2 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match            20.8%;  Score 10;  DB 1;  Length 11;
  Best Local Similarity  100.0%;  Pred. No. 76;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1715 CTGACTGATG 1724
              ||||||||||
Db          1 CTGACTGATG 10


RESULT 82
ABV67895/c
ID   ABV67895 standard; cDNA; 11 BP.
XX
AC   ABV67895;
XX
DT   21-OCT-2002  (first entry)
XX
DE   Human skin EST 5681.
XX
KW   Human; skin; dermatological; vulnerary; antipsoriatic; antiseborrhaeic;
KW   immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW   psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS   Homo sapiens.
XX
PN   WO200253774-A2.
XX
PD   11-JUL-2002.
XX
PF   20-DEC-2001; 2001WO-EP015179.
XX
PR   03-JAN-2001; 2001DE-01000127.
XX
PA   (HENK ) HENKEL KGAA.
XX
PI   Petersohn D,  Conradt M,  Hofmann K;
XX
DR   WPI; 2002-590638/63.
XX
PT   In vitro identification of skin-expressed genes, useful for determining
PT   homeostasis and identifying cosmetic or pharmaceutical agents against
PT   e.g. skin cancer.
XX
PS   Disclosure; Page 182; 1345pp; German.
XX
CC   The invention relates to in vitro identification (M1) of genes expressed
CC   in the skin of humans or animals by subjecting a mixture of genetically
CC   encoded factors from skin, to serial analysis of gene expression (SAGE)
CC   so as to identify skin-expressed genes and quantify their expression.
CC   (M1) is useful for identifying genes involved in skin homeostasis; to
CC   determine skin homeostasis and to test agent (A) that maintains or
CC   promotes skin homeostasis or that can be used for treating skin
CC   disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC   ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC   rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC   skin. The present sequence is that of a human expressed sequence tag
CC   (EST) of the invention
XX
SQ   Sequence 11 BP; 0 A; 3 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match            20.8%;  Score 10;  DB 1;  Length 11;
  Best Local Similarity  100.0%;  Pred. No. 76;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1731 GAACAGACAG 1740
              ||||||||||
Db         10 GAACAGACAG 1


RESULT 83
ABV64816/c
ID   ABV64816 standard; cDNA; 11 BP.
XX
AC   ABV64816;
XX
DT   21-OCT-2002  (first entry)
XX
DE   Human skin EST 2602.
XX
KW   Human; skin; dermatological; vulnerary; antipsoriatic; antiseborrhaeic;
KW   immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
KW   psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
OS   Homo sapiens.
XX
PN   WO200253774-A2.
XX
PD   11-JUL-2002.
XX
PF   20-DEC-2001; 2001WO-EP015179.
XX
PR   03-JAN-2001; 2001DE-01000127.
XX
PA   (HENK ) HENKEL KGAA.
XX
PI   Petersohn D,  Conradt M,  Hofmann K;
XX
DR   WPI; 2002-590638/63.
XX
PT   In vitro identification of skin-expressed genes, useful for determining
PT   homeostasis and identifying cosmetic or pharmaceutical agents against
PT   e.g. skin cancer.
XX
PS   Disclosure; Page 97; 1345pp; German.
XX
CC   The invention relates to in vitro identification (M1) of genes expressed
CC   in the skin of humans or animals by subjecting a mixture of genetically
CC   encoded factors from skin, to serial analysis of gene expression (SAGE)
CC   so as to identify skin-expressed genes and quantify their expression.
CC   (M1) is useful for identifying genes involved in skin homeostasis; to
CC   determine skin homeostasis and to test agent (A) that maintains or
CC   promotes skin homeostasis or that can be used for treating skin
CC   disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC   ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC   rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC   skin. The present sequence is that of a human expressed sequence tag
CC   (EST) of the invention
XX
SQ   Sequence 11 BP; 5 A; 1 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match            20.8%;  Score 10;  DB 1;  Length 11;
  Best Local Similarity  100.0%;  Pred. No. 76;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1747 TGCATCCATT 1756
              ||||||||||
Db         11 TGCATCCATT 2


RESULT 84
ABI79664
ID   ABI79664 standard; DNA; 12 BP.
XX
AC   ABI79664;
XX
DT   22-FEB-2002  (first entry)
XX
```

DE Oligonucleotide primer SEQ ID NO 379637 for detecting SNP TSC0063401.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 379637; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 0 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 20.8%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 80;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1739 AGGAGAAATG 1748
||||||||||
Db 3 AGGAGAAATG 12

RESULT 85
ABH71192
ID ABH71192 standard; DNA; 12 BP.
XX
AC ABH71192;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 271169 for detecting SNP TSC0002415.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 271169; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 20.8%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 80;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1722 ATGTTGAGGG 1731
||||||||||
Db 1 ATGTTGAGGG 10

RESULT 86
ABH80366/c
ID ABH80366 standard; DNA; 12 BP.
XX
AC ABH80366;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 280359 for detecting SNP TSC0008516.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

```
PS   Claim 1; SEQ ID NO 280359; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 2 A; 5 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 80;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1739 AGGAGAAATG 1748
             ||||||||||
Db         10 AGGAGAAATG 1


RESULT 87
ABH87503
ID   ABH87503 standard; DNA; 12 BP.
XX
AC   ABH87503;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 287496 for detecting SNP TSC0013116.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 287496; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 3 A; 0 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 80;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1720 TGATGTTGAG 1729
             ||||||||||
Db          3 TGATGTTGAG 12


RESULT 88
ABI01362
ID   ABI01362 standard; DNA; 12 BP.
XX
AC   ABI01362;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide primer SEQ ID NO 301335 for detecting SNP TSC0019456.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 301335; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 12 BP; 5 A; 0 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 80;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1739 AGGAGAAATG 1748
             ||||||||||
Db          2 AGGAGAAATG 11
```

```
RESULT 89
AAX14857/c
ID   AAX14857 standard; DNA; 13 BP.
XX
AC   AAX14857;
XX
DT   27-AUG-2003  (revised)
DT   24-MAR-1999  (first entry)
XX
DE   Triple helix third strand of 23S rRNA gene nucleotides 1758-1770.
XX
KW   Triplex formation; DNA detection; triple helix; identification; bacteria;
KW   oncogene; virus; ss.
XX
OS   Synthetic.
OS   Leptospira interrogans.
XX
PN   US5861244-A.
XX
PD   19-JAN-1999.
XX
PF   22-DEC-1993;   93US-00173489.
XX
PR   29-OCT-1992;   92US-00968436.
XX
PA   (PROF-) PROFILE DIAGNOSTIC SCI INC.
XX
PI   Hepburn AG,  Wang C;
XX
DR   WPI; 1999-130384/11.
XX
PT   Assay of genetic sequences based on triplex formation from double
PT   stranded analyte - and hybrid of anchor and reporter sequences, with
PT   reporter released if triplex formation occurs, used e.g. to identify
PT   bacteria.
XX
PS   Disclosure; Col 21-22; 168pp; English.
XX
CC   The present sequence represents a polynucleotide that is able to form a
CC   triple helix with a double stranded sequence. Cytosine bases in the
CC   present can be replaced with 5-methylcytosine for increased triplex
CC   stability. The present sequence is used in the assay of the invention,
CC   where it can be part of the anchor DNA or reporter DNA sequence. The
CC   assay comprises adding a sample containing double-stranded DNA test
CC   sequences to an aqueous medium containing at least one complex of anchor
CC   DNA, attached to a solid support, and reporter DNA, where either a part
CC   of the anchor DNA or reporter DNA is designed to form a triple-strand
CC   structure with part of the test sequence. Triplex formation results in
CC   displacement of the reporter DNA which is detected as an indication of
CC   the presence of the DNA test sequence. The method is used to detect DNA
CC   sequences, particularly for identification of bacteria (by detecting
CC   genes for ribosomal RNA) in clinical samples, but also detection of
CC   oncogenes and Hepatitis B virus. (Updated on 27-AUG-2003 to correct OS
CC   field.)
XX
SQ   Sequence 13 BP; 0 A; 7 C; 1 G; 5 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1727 GAGGGAACAG 1736
             ||||||||||
Db         12 GAGGGAACAG 3


RESULT 90
ABF28166
ID   ABF28166 standard; DNA; 13 BP.
XX
AC   ABF28166;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 128163 for detecting SNP TSC0032096.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 128163; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 1 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGG 1730
             ||||||||||
Db          2 GATGTTGAGG 11


RESULT 91
ABH24633/c
ID   ABH24633 standard; DNA; 13 BP.
XX
AC   ABH24633;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 224610 for detecting SNP TSC0054745.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
```

```
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 224610; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 1 A; 7 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1739 AGGAGAAATG 1748
             ||||||||||
Db         11 AGGAGAAATG 2


RESULT 92
ABF87825/c
ID   ABF87825 standard; DNA; 13 BP.
XX
AC   ABF87825;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 187822 for detecting SNP TSC0001439.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 187822; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1723 TGTTGAGGGA 1732
             ||||||||||
Db         11 TGTTGAGGGA 2


RESULT 93
ABC95357
ID   ABC95357 standard; DNA; 13 BP.
XX
AC   ABC95357;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 95374 for detecting SNP TSC0023742.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 95374; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
```

```
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 1 Other;

  Query Match             20.8%;  Score 10;  DB 1;  Length 13;
  Best Local Similarity   83.3%;  Pred. No. 84;
  Matches   10;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1743 GAAATGCATCCA 1754
              :|||| ||||||
Db          1 RAAATCCATCCA 12


RESULT 94
ABF87824
ID   ABF87824 standard; DNA; 13 BP.
XX
AC   ABF87824;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 187821 for detecting SNP TSC0001439.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 187821; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1723 TGTTGAGGGA 1732
              ||||||||||
Db          3 TGTTGAGGGA 12


RESULT 95
ABH06507/c
ID   ABH06507 standard; DNA; 13 BP.
XX
AC   ABH06507;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 206484 for detecting SNP TSC0050541.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 206484; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 5 C; 0 G; 5 T; 0 U; 1 Other;

  Query Match             20.8%;  Score 10;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1724 GTTGAGGGAA 1733
              ||||||||||
Db          12 GTTGAGGGAA 3


RESULT 96
ABH06506
ID   ABH06506 standard; DNA; 13 BP.
XX
AC   ABH06506;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 206483 for detecting SNP TSC0050541.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
```

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 206483; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 0 C; 5 G; 2 T; 0 U; 1 Other;

Query Match 20.8%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1724 GTTGAGGGAA 1733
||||||||||
Db 2 GTTGAGGGAA 11

RESULT 97
ABF97342
ID ABF97342 standard; DNA; 13 BP.
XX
AC ABF97342;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 197339 for detecting SNP TSC0048566.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 197339; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 20.8%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1721 GATGTTGAGG 1730
||||||||||
Db 3 GATGTTGAGG 12

RESULT 98
ABH54593/c
ID ABH54593 standard; DNA; 13 BP.
XX
AC ABH54593;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 254570 for detecting SNP TSC0062063.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 254570; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

```
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 5 C; 0 G; 4 T; 0 U; 1 Other;

  Query Match             20.8%;  Score 10;  DB 1;  Length 13;
  Best Local Similarity   83.3%;  Pred. No. 84;
  Matches   10;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1723 TGTTGAGGGAAC 1734
              ||| |||||||:
Db         12 TGTAGAGGGAAY 1


RESULT 99
ABF97343/c
ID   ABF97343 standard; DNA; 13 BP.
XX
AC   ABF97343;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 197340 for detecting SNP TSC0048566.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 197340; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 7 C; 0 G; 3 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGG 1730
              ||||||||||
Db         11 GATGTTGAGG 2


RESULT 100
ABH54592
ID   ABH54592 standard; DNA; 13 BP.
XX
AC   ABH54592;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 254569 for detecting SNP TSC0062063.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 254569; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 0 C; 5 G; 3 T; 0 U; 1 Other;

  Query Match             20.8%;  Score 10;  DB 1;  Length 13;
  Best Local Similarity   83.3%;  Pred. No. 84;
  Matches   10;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1723 TGTTGAGGGAAC 1734
              ||| |||||||:
Db          2 TGTAGAGGGAAY 13


RESULT 101
ABF28167/c
ID   ABF28167 standard; DNA; 13 BP.
XX
```

```
AC   ABF28167;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 128164 for detecting SNP TSC0032096.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 128164; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 5 C; 1 G; 2 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGG 1730
              ||||||||||
Db         12 GATGTTGAGG 3


RESULT 102
ABH24632
ID   ABH24632 standard; DNA; 13 BP.
XX
AC   ABH24632;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 224609 for detecting SNP TSC0054745.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 224609; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 0 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             20.8%;  Score 10;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 84;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1739 AGGAGAAATG 1748
              ||||||||||
Db          3 AGGAGAAATG 12


RESULT 103
ABC95356/c
ID   ABC95356 standard; DNA; 13 BP.
XX
AC   ABC95356;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 95373 for detecting SNP TSC0023742.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
```

```
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 95373; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 1 Other;

  Query Match             20.8%;  Score 10;  DB 1;  Length 13;
  Best Local Similarity   83.3%;  Pred. No. 84;
  Matches   10;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1743 GAAATGCATCCA 1754
              :|||| ||||||
Db         13 RAAATCCATCCA 2


RESULT 104
AAA92487
ID   AAA92487 standard; DNA; 13 BP.
XX
AC   AAA92487;
XX
DT   16-JAN-2001  (first entry)
XX
DE   DNA replication method related primer #3.
XX
KW   DNA replication; PCR; primer; cancerisation; ss.
XX
OS   Unidentified.
XX
PN   JP2000217599-A.
XX
PD   08-AUG-2000.
XX
PF   29-JAN-1999;   99JP-00021135.
XX
PR   29-JAN-1999;   99JP-00021135.
XX
PA   (FUIT ) FUJITSU LTD.
PA   (AGEN ) AGENCY OF IND SCI & TECHNOLOGY.
XX
DR   WPI; 2000-605052/58.
XX
PT   Replication method of DNA and apparatus for designing polymerase chain
PT   reactions for giving important information in the mechanism of
PT   cancerization of cells.
XX
PS   Disclosure; Page 5; 13pp; Japanese.
XX
CC   The present invention describes a method for the replication of a DNA in
CC   which only a specific DNA contained in a mixture of DNAs is replicated by
CC   using a polymerase chain reaction (PCR), comprising a primer acting as a
CC   replication point to the DNAs present in mixture and a sequence-specific
CC   substance which adheres only to the DNA. The method can be used for
CC   giving important informations in the mechanism of cancerisation of cells
CC   in which many similar genes interact complicatedly. The present sequence
CC   represents a primer which is used in the exemplification of the method of
CC   the present invention
XX
SQ   Sequence 13 BP; 4 A; 2 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1722 ATGTTGAGGGAAC 1734
              ||| ||| |||||
Db          1 ATGGTGACGGAAC 13


RESULT 105
ABC22259/c
ID   ABC22259 standard; DNA; 13 BP.
XX
AC   ABC22259;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 22276 for detecting SNP TSC0004415.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 22276; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 7 C; 0 G; 4 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1725 TTGAGGGAACAGA 1737
              ||||||||  |||
Db         13 TTGAGGGAGGAGA 1


RESULT 106
ABH34097/c
```

```
ID   ABH34097 standard; DNA; 13 BP.
XX
AC   ABH34097;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 234074 for detecting SNP TSC0057120.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 234074; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 8 C; 0 G; 3 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1724 GTTGAGGGAACAG 1736
              |||||||| | ||
Db         13 GTTGAGGGGAGAG 1


RESULT 107
ABC20825/c
ID   ABC20825 standard; DNA; 13 BP.
XX
AC   ABC20825;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 20842 for detecting SNP TSC0004233.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 20842; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 4 C; 0 G; 6 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1739 AGGAGAAATGCAT 1751
              ||| |||||| ||
Db         13 AGGTGAAATGAAT 1


RESULT 108
ABC07406
ID   ABC07406 standard; DNA; 13 BP.
XX
AC   ABC07406;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 7397 for detecting SNP TSC0002151.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
```

```
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 7397; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 0 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1720 TGATGTTGAGGGA 1732
                ||| | |||||||
Db          1 TGAGGATGAGGGA 13


RESULT 109
ABF07048
ID   ABF07048 standard; DNA; 13 BP.
XX
AC   ABF07048;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 107045 for detecting SNP TSC0026803.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 107045; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 0 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGAA 1733
                ||| ||||||| ||
Db          1 GAGGTTGAGGTAA 13


RESULT 110
ABC87934
ID   ABC87934 standard; DNA; 13 BP.
XX
AC   ABC87934;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 87951 for detecting SNP TSC0022105.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 87951; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       1720 TGATGTTGAGGGA 1732
              ||||| |||| ||
Db          1 TGATGGTGAGTGA 13


RESULT 111
ABF21698
ID   ABF21698 standard; DNA; 13 BP.
XX
AC   ABF21698;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 121695 for detecting SNP TSC0030400.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 121695; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGAA 1733
              | | |||||||||
Db          1 GGTTTTGAGGGAA 13


RESULT 112
ABH20206
ID   ABH20206 standard; DNA; 13 BP.
XX
AC   ABH20206;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 220183 for detecting SNP TSC0053581.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 220183; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1718 ACTGATGTTGAGG 1730
              | ||||||| |||
Db          1 ATTGATGTTTAGG 13


RESULT 113
ABH34096
ID   ABH34096 standard; DNA; 13 BP.
XX
AC   ABH34096;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 234073 for detecting SNP TSC0057120.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
```

```
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 234073; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 0 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1724 GTTGAGGGAACAG 1736
              |||||||| | ||
Db          1 GTTGAGGGGAGAG 13


RESULT 114
ABH42048
ID   ABH42048 standard; DNA; 13 BP.
XX
AC   ABH42048;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 242025 for detecting SNP TSC0059034.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 242025; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 0 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1725 TTGAGGGAACAGA 1737
              || |||||| |||
Db          1 TTTAGGGAAAAGA 13


RESULT 115
ABC48762
ID   ABC48762 standard; DNA; 13 BP.
XX
AC   ABC48762;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 48779 for detecting SNP TSC0013859.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 48779; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
```

```
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 0 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1739 AGGAGAAATGCAT 1751
              | ||||||||  ||
Db          1 ATGAGAAATGTAT 13


RESULT 116
ABC12427/c
ID   ABC12427 standard; DNA; 13 BP.
XX
AC   ABC12427;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 12434 for detecting SNP TSC0002943.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 12434; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 4 C; 0 G; 4 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGAA 1733
              |||||| | ||||
Db         13 GATGTTTATGGAA 1


RESULT 117
ABC87935/c
ID   ABC87935 standard; DNA; 13 BP.
XX
AC   ABC87935;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 87952 for detecting SNP TSC0022105.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 87952; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1720 TGATGTTGAGGGA 1732
              ||||| |||| ||
Db         13 TGATGGTGAGTGA 1


RESULT 118
ABC41627/c
ID   ABC41627 standard; DNA; 13 BP.
XX
AC   ABC41627;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 41644 for detecting SNP TSC0012495.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
```

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 41644; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 0 A; 7 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 20.4%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 89;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1730 GGAACAGACAGGA 1742
|||| ||| ||||
Db 13 GGAAGAGAGAGGA 1

RESULT 119
ABH24244/c
ID ABH24244 standard; DNA; 13 BP.
XX
AC ABH24244;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 224221 for detecting SNP TSC0054636.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 224221; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 20.4%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 89;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1744 AAATGCATCCATT 1756
|||| ||| ||||
Db 13 AAATACATACATT 1

RESULT 120
ABF86806
ID ABF86806 standard; DNA; 13 BP.
XX
AC ABF86806;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 186803 for detecting SNP TSC0046049.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 186803; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

```
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 0 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGAA 1733
                ||||||||| ||
Db          1 GATGTTGAGTTAA 13


RESULT 121
ABC83525/c
ID   ABC83525 standard; DNA; 13 BP.
XX
AC   ABC83525;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 83542 for detecting SNP TSC0021041.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 83542; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 5 C; 0 G; 6 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1735 AGACAGGAGAAAT 1747
                ||| ||||||| |
Db         13 AGAGAGGAGAATT 1


RESULT 122
ABH24245
ID   ABH24245 standard; DNA; 13 BP.
XX
AC   ABH24245;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 224222 for detecting SNP TSC0054636.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 224222; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1744 AAATGCATCCATT 1756
                |||| ||| ||||
Db          1 AAATACATACATT 13


RESULT 123
ABH42049/c
ID   ABH42049 standard; DNA; 13 BP.
XX
```

```
AC   ABH42049;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 242026 for detecting SNP TSC0059034.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 242026; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 4 C; 0 G; 6 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1725 TTGAGGGAACAGA 1737
              || |||||| |||
Db         13 TTTAGGGAAAAGA 1


RESULT 124
ABH50272
ID   ABH50272 standard; DNA; 13 BP.
XX
AC   ABH50272;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 250249 for detecting SNP TSC0061098.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 250249; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGAA 1733
              ||||||| | |||
Db          1 GATGTTGTGTGAA 13


RESULT 125
ABC74874
ID   ABC74874 standard; DNA; 13 BP.
XX
AC   ABC74874;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 74891 for detecting SNP TSC0019229.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
```

```
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 74891; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1718 ACTGATGTTGAGG 1730
              | || ||||||||
Db          1 ATTGTTGTTGAGG 13


RESULT 126
ABC10734
ID   ABC10734 standard; DNA; 13 BP.
XX
AC   ABC10734;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 10725 for detecting SNP TSC0002683.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 10725; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 8 A; 0 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1735 AGACAGGAGAAAT 1747
              | | |||||||||
Db          1 ATAAAGGAGAAAT 13


RESULT 127
ABH20207/c
ID   ABH20207 standard; DNA; 13 BP.
XX
AC   ABH20207;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 220184 for detecting SNP TSC0053581.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 220184; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1718 ACTGATGTTGAGG 1730
```

```
                  | ||||||| |||
Db          13 ATTGATGTTTAGG 1


RESULT 128
ABH10408
ID   ABH10408 standard; DNA; 13 BP.
XX
AC   ABH10408;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 210385 for detecting SNP TSC0005915.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 210385; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 0 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGAA 1733
                ||| |||||| ||
Db          1 GATATTGAGGAAA 13


RESULT 129
ABF86807/c
ID   ABF86807 standard; DNA; 13 BP.
XX
AC   ABF86807;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 186804 for detecting SNP TSC0046049.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 186804; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 4 C; 0 G; 4 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGAA 1733
                ||||||||| ||
Db         13 GATGTTGAGTTAA 1


RESULT 130
ABF88831/c
ID   ABF88831 standard; DNA; 13 BP.
XX
AC   ABF88831;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 188828 for detecting SNP TSC0046484.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
```

PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 188828; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 5 C; 0 G; 5 T; 0 U; 0 Other;

```
  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1720 TGATGTTGAGGGA 1732
              ||||||  |||||
Db         13 TGATGTAAAGGGA 1


RESULT 131
ABF88833/c
ID   ABF88833 standard; DNA; 13 BP.
XX
AC   ABF88833;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 188830 for detecting SNP TSC0046484.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 188830; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 6 C; 0 G; 4 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1720 TGATGTTGAGGGA 1732
              ||||||  |||||
Db         13 TGATGTGAAGGGA 1


RESULT 132
ABH64891/c
ID   ABH64891 standard; DNA; 13 BP.
XX
AC   ABH64891;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 264868 for detecting SNP TSC0064202.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 264868; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
```

```
XX
SQ   Sequence 13 BP; 2 A; 5 C; 0 G; 6 T; 0 U; 0 Other;

  Query Match           20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGAA 1733
              |||| ||| ||||
Db         13 GATGATGAAGGAA 1


RESULT 133
ABC20824
ID   ABC20824 standard; DNA; 13 BP.
XX
AC   ABC20824;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 20841 for detecting SNP TSC0004233.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 20841; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 0 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match           20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1739 AGGAGAAATGCAT 1751
              ||| |||||| ||
Db          1 AGGTGAAATGAAT 13


RESULT 134
ABC97855/c
ID   ABC97855 standard; DNA; 13 BP.
XX
AC   ABC97855;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 97872 for detecting SNP TSC0024301.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 97872; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 8 C; 0 G; 3 T; 0 U; 0 Other;

  Query Match           20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1724 GTTGAGGGAACAG 1736
              |||| ||||| ||
Db         13 GTTGGGGGAAGAG 1


RESULT 135
ABC48763/c
ID   ABC48763 standard; DNA; 13 BP.
XX
AC   ABC48763;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 48780 for detecting SNP TSC0013859.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
```

```
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 48780; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 3 C; 0 G; 6 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1739 AGGAGAAATGCAT 1751
              | ||||||||  ||
Db         13 ATGAGAAATGTAT 1


RESULT 136
ABC07407/c
ID   ABC07407 standard; DNA; 13 BP.
XX
AC   ABC07407;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 7398 for detecting SNP TSC0002151.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 7398; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 7 C; 0 G; 4 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1720 TGATGTTGAGGGA 1732
              ||| | |||||||
Db         13 TGAGGATGAGGGA 1


RESULT 137
ABF18398
ID   ABF18398 standard; DNA; 13 BP.
XX
AC   ABF18398;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 118395 for detecting SNP TSC0029588.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 118395; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
```

```
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1716 TGACTGATGTTGA 1728
                ||| ||||||| |
Db          1 TGATTGATGTTTA 13


RESULT 138
ABF21699/c
ID   ABF21699 standard; DNA; 13 BP.
XX
AC   ABF21699;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 121696 for detecting SNP TSC0030400.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 121696; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGAA 1733
                | | |||||||||
Db         13 GGTTTTGAGGGAA 1


RESULT 139
ABF46516
ID   ABF46516 standard; DNA; 13 BP.
XX
AC   ABF46516;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 146513 for detecting SNP TSC0036945.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 146513; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 0 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGAA 1733
                ||||||||  |||
Db          1 GATGTTGAAAGAA 13


RESULT 140
ABF51962
ID   ABF51962 standard; DNA; 13 BP.
XX
AC   ABF51962;
XX
```

```
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 151959 for detecting SNP TSC0038398.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 151959; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 0 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1720 TGATGTTGAGGGA 1732
              | || ||||||||
Db          1 TAATTTTGAGGGA 13


RESULT 141
ABF51963/c
ID   ABF51963 standard; DNA; 13 BP.
XX
AC   ABF51963;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 151960 for detecting SNP TSC0038398.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 151960; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 4 C; 0 G; 4 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1720 TGATGTTGAGGGA 1732
              | || ||||||||
Db          13 TAATTTTGAGGGA 1


RESULT 142
ABF02354
ID   ABF02354 standard; DNA; 13 BP.
XX
AC   ABF02354;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 102351 for detecting SNP TSC0025526.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
```

```
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 102351; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 0 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1723 TGTTGAGGGAACA 1735
              |||| |||||| |
Db          1 TGTTTAGGGAAAA 13


RESULT 143
ABC41626
ID   ABC41626 standard; DNA; 13 BP.
XX
AC   ABC41626;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 41643 for detecting SNP TSC0012495.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 41643; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 0 C; 7 G; 0 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1730 GGAACAGACAGGA 1742
              |||| ||| ||||
Db          1 GGAAGAGAGAGGA 13


RESULT 144
ABC97854
ID   ABC97854 standard; DNA; 13 BP.
XX
AC   ABC97854;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 97871 for detecting SNP TSC0024301.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 97871; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 0 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1724 GTTGAGGGAACAG 1736
              |||| ||||| ||
Db          1 GTTGGGGGAAGAG 13
```

```
RESULT 145
ABF14030/c
ID   ABF14030 standard; DNA; 13 BP.
XX
AC   ABF14030;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 114027 for detecting SNP TSC0028539.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 114027; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1744 AAATGCATCCATT 1756
              |||| |||||| |
Db         13 AAATACATCCACT 1


RESULT 146
ABF88830
ID   ABF88830 standard; DNA; 13 BP.
XX
AC   ABF88830;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 188827 for detecting SNP TSC0046484.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 188827; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 0 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1720 TGATGTTGAGGGA 1732
              |||||| |||||
Db          1 TGATGTAAAGGGA 13


RESULT 147
ABH44534
ID   ABH44534 standard; DNA; 13 BP.
XX
AC   ABH44534;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 244511 for detecting SNP TSC0059697.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
```

```
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 244511; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1723 TGTTGAGGGAACA 1735
              |||| |||||| |
Db          1 TGTTTAGGGAAGA 13


RESULT 148
ABC53910
ID   ABC53910 standard; DNA; 13 BP.
XX
AC   ABC53910;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 53927 for detecting SNP TSC0014835.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 53927; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 0 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1718 ACTGATGTTGAGG 1730
              | ||||||| |||
Db          1 ATTGATGTTAAGG 13


RESULT 149
ABF07049/c
ID   ABF07049 standard; DNA; 13 BP.
XX
AC   ABF07049;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 107046 for detecting SNP TSC0026803.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 107046; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 6 C; 0 G; 4 T; 0 U; 0 Other;
```

```
  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGAA 1733
              || ||||||| ||
Db         13 GAGGTTGAGGTAA 1


RESULT 150
ABF18399/c
ID   ABF18399 standard; DNA; 13 BP.
XX
AC   ABF18399;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 118396 for detecting SNP TSC0029588.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 118396; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1716 TGACTGATGTTGA 1728
              ||| ||||||| |
Db         13 TGATTGATGTTTA 1


RESULT 151
ABF88832
ID   ABF88832 standard; DNA; 13 BP.
XX
AC   ABF88832;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 188829 for detecting SNP TSC0046484.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 188829; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 0 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1720 TGATGTTGAGGGA 1732
              |||||| |||||
Db          1 TGATGTGAAGGGA 13


RESULT 152
ABH64890
ID   ABH64890 standard; DNA; 13 BP.
XX
AC   ABH64890;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 264867 for detecting SNP TSC0064202.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
```

PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 264867; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 0 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 20.4%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 89;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1721 GATGTTGAGGGAA 1733
|||| ||| ||||
Db 1 GATGATGAAGGAA 13

RESULT 153
ABC22258
ID ABC22258 standard; DNA; 13 BP.
XX
AC ABC22258;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 22275 for detecting SNP TSC0004415.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 22275; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 20.4%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 89;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1725 TTGAGGGAACAGA 1737
|||||||| |||
Db 1 TTGAGGGAGGAGA 13

RESULT 154
ABC53911/c
ID ABC53911 standard; DNA; 13 BP.
XX
AC ABC53911;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 53928 for detecting SNP TSC0014835.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 53928; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The

```
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 4 C; 0 G; 4 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1718 ACTGATGTTGAGG 1730
              | ||||||| |||
Db         13 ATTGATGTTAAGG 1


RESULT 155
ABC83524
ID   ABC83524 standard; DNA; 13 BP.
XX
AC   ABC83524;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 83541 for detecting SNP TSC0021041.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 83541; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 0 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1735 AGACAGGAGAAAT 1747
              ||| ||||||| |
Db          1 AGAGAGGAGAATT 13


RESULT 156
ABF11986/c
ID   ABF11986 standard; DNA; 13 BP.
XX
AC   ABF11986;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 111983 for detecting SNP TSC0027952.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 111983; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 0 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1744 AAATGCATCCATT 1756
              |||| ||| ||||
Db         13 AAATTCATTCATT 1


RESULT 157
ABF11987
ID   ABF11987 standard; DNA; 13 BP.
XX
AC   ABF11987;
XX
DT   21-FEB-2002  (first entry)
XX
```

```
DE   Oligonucleotide SEQ ID NO 111984 for detecting SNP TSC0027952.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 111984; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 2 C; 0 G; 6 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1744 AAATGCATCCATT 1756
              |||| ||| ||||
Db          1 AAATTCATTCATT 13


RESULT 158
ABH10409/c
ID   ABH10409 standard; DNA; 13 BP.
XX
AC   ABH10409;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 210386 for detecting SNP TSC0005915.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 210386; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 4 C; 0 G; 6 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGAA 1733
              ||| |||||| ||
Db         13 GATATTGAGGAAA 1


RESULT 159
ABH44535/c
ID   ABH44535 standard; DNA; 13 BP.
XX
AC   ABH44535;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 244512 for detecting SNP TSC0059697.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
```

```
PS   Claim 1; SEQ ID NO 244512; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1723 TGTTGAGGGAACA 1735
              |||| |||||| |
Db         13 TGTTTAGGGAAGA 1

RESULT 160
ABH50273/c
ID   ABH50273 standard; DNA; 13 BP.
XX
AC   ABH50273;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 250250 for detecting SNP TSC0061098.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 250250; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGAA 1733
              ||||||| | |||
Db         13 GATGTTGTGTGAA 1

RESULT 161
ABC72954
ID   ABC72954 standard; DNA; 13 BP.
XX
AC   ABC72954;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 72971 for detecting SNP TSC0018828.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 72971; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 0 C; 7 G; 0 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1736 GACAGGAGAAATG 1748
              || |||||||| |
Db          1 GAGAGGAGAAAGG 13
```

```
RESULT 162
ABC72955/c
ID   ABC72955 standard; DNA; 13 BP.
XX
AC   ABC72955;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 72972 for detecting SNP TSC0018828.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 72972; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 0 A; 7 C; 0 G; 6 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1736 GACAGGAGAAATG 1748
              || |||||||| |
Db         13 GAGAGGAGAAAGG 1


RESULT 163
ABC74875/c
ID   ABC74875 standard; DNA; 13 BP.
XX
AC   ABC74875;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 74892 for detecting SNP TSC0019229.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 74892; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1718 ACTGATGTTGAGG 1730
              | || ||||||||
Db         13 ATTGTTGTTGAGG 1


RESULT 164
ABC10735/c
ID   ABC10735 standard; DNA; 13 BP.
XX
AC   ABC10735;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 10726 for detecting SNP TSC0002683.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
```

```
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 10726; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 3 C; 0 G; 8 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1735 AGACAGGAGAAAT 1747
              | | |||||||||
Db         13 ATAAAGGAGAAAT 1


RESULT 165
ABC12426
ID   ABC12426 standard; DNA; 13 BP.
XX
AC   ABC12426;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 12433 for detecting SNP TSC0002943.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 12433; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 0 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGAA 1733
              |||||| | ||||
Db          1 GATGTTTATGGAA 13


RESULT 166
ABF02355/c
ID   ABF02355 standard; DNA; 13 BP.
XX
AC   ABF02355;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 102352 for detecting SNP TSC0025526.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 102352; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 4 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
```

```
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1723 TGTTGAGGGAACA 1735
              |||| |||||| |
Db         13 TGTTTAGGGAAAA 1


RESULT 167
ABF14031
ID   ABF14031 standard; DNA; 13 BP.
XX
AC   ABF14031;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 114028 for detecting SNP TSC0028539.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 114028; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1744 AAATGCATCCATT 1756
              |||| |||||| |
Db          1 AAATACATCCACT 13


RESULT 168
ABF46517/c
ID   ABF46517 standard; DNA; 13 BP.
XX
AC   ABF46517;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 146514 for detecting SNP TSC0036945.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 146514; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 4 C; 0 G; 6 T; 0 U; 0 Other;

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 89;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1721 GATGTTGAGGGAA 1733
              |||||||| |||
Db         13 GATGTTGAAAGAA 1


RESULT 169
ADD15389/c
ID   ADD15389 standard; DNA; 13 BP.
XX
AC   ADD15389;
XX
DT   15-JAN-2004  (first entry)
XX
DE   Plasmid pHIV-LTR EcoRI/HindIII restriction fragment 2 with target DNA.
XX
KW   ss; polyamide alkylator; conjugate; hairpin; regulator; gene therapy;
KW   knockout; pHIV-LTR EcoRI/HindIII.
XX
OS   Synthetic.
OS   Unidentified.
OS   Human immunodeficiency virus 1.
XX
PN   US6559125-B1.
```

XX
PD 06-MAY-2003.
XX
PF 26-JAN-2001; 2001US-00772315.
XX
PR 28-JAN-2000; 2000US-0178821P.
XX
PA (CALY) CALIFORNIA INST OF TECHNOLOGY.
XX
PI Dervan PB, Wurtz N, Chang A;
XX
DR WPI; 2003-775986/73.
XX
PT Polyimide-alkylator conjugate for therapeutic purposes, comprises
PT alkylator linked to polyamide having pyrrole and/or imidazole amino acid.
XX
PS Disclosure; SEQ ID NO 3; 52pp; English.
XX
CC This invention relates to a novel polyamide alkylator conjugate.
CC Specifically, it refers to a hairpin polyamide comprising a pyrrole and/
CC or imidazole amino acid linked to a gamma aminobutyric acid, which in
CC turn is linked to the alkylator that selectively alkylates only one
CC strand of a double-stranded DNA molecule. The present invention describes
CC a conjugate that can be used to target a predetermined DNA sequence and
CC thereby inhibit DNA-protein interactions, and hence provides a novel
CC regulator of gene expression. As such, in addition to competing with
CC transcription factors, the conjugates can be used in gene therapy to
CC target a gene's coding region for use as a knockout reagent. This
CC oligonucleotide sequence is restriction fragement 2 derived from the
CC plasmid pHIV-LTR EcoRI/HindIII that contains the target DNA sequence of
CC the polyamide alkylator conjugate of the invention.
XX
SQ Sequence 13 BP; 2 A; 4 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 20.4%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 89;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1741 GAGAAATGCATCC 1753
|||| |||||||
Db 13 GAGAGCTGCATCC 1

RESULT 170
ABT39656/c
ID ABT39656 standard; DNA; 17 BP.
XX
AC ABT39656;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 5293.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 652; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 8 A; 2 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 18.3%; Score 8.8; DB 1; Length 17;
Best Local Similarity 83.3%; Pred. No. 1.3e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1712 CTGCTGACTGAT 1723
|| ||| |||||
Db 13 CTCCTGCCTGAT 2

Search completed: July 13, 2004, 11:03:43
Job time : 1 secs

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: July 13, 2004, 11:05:04 ; Search time 0.001 Seconds
(without alignments)
52.032 Million cell updates/sec

Title: us-10-000-213-3
Perfect score: 48
Sequence: 1 ggctgctgactgatgttgag.....caggagaaatgcatccattc 48

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 41 seqs, 542 residues

Total number of hits satisfying chosen parameters: 82

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 50 summaries

Database : rnidb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.		Score	% Query Match	Length	DB	ID	Description
c	1	14.8	30.8	18	1	US-08-897-340-27	Sequence 27, Appl
c	2	14.8	30.8	18	1	US-09-252-329-27	Sequence 27, Appl
c	3	14.4	30.0	18	1	US-09-679-298A-23	Sequence 23, Appl
	4	13.4	27.9	16	1	US-09-371-772B-5840	Sequence 5840, Ap
c	5	13	27.1	17	1	US-09-866-108A-8341	Sequence 8341, Ap
c	6	13	27.1	17	1	US-09-866-108A-8342	Sequence 8342, Ap
c	7	13	27.1	17	1	US-09-866-108A-8343	Sequence 8343, Ap
c	8	13	27.1	17	1	US-09-866-108A-8344	Sequence 8344, Ap
c	9	13	27.1	17	1	US-09-866-108A-8345	Sequence 8345, Ap
c	10	12.8	26.7	16	1	US-08-666-341A-67	Sequence 67, Appl
	11	12.8	26.7	16	1	US-09-371-772B-5841	Sequence 5841, Ap
	12	11.8	24.6	15	1	US-08-533-472-5	Sequence 5, Appli
c	13	11.8	24.6	15	1	US-08-292-620A-78	Sequence 78, Appl
c	14	11.8	24.6	15	1	US-09-071-845-78	Sequence 78, Appl
c	15	11.4	23.7	15	1	US-09-081-646-601	Sequence 601, App
	16	10.4	21.7	12	1	US-08-368-071-8	Sequence 8, Appli
	17	10.4	21.7	12	1	US-08-458-181-8	Sequence 8, Appli
	18	10.4	21.7	12	1	PCT-US93-02172-8	Sequence 8, Appli
c	19	10	20.8	13	1	US-08-173-489C-244	Sequence 244, App
	20	9.8	20.4	13	1	US-08-284-746-10	Sequence 10, Appl
c	21	9.8	20.4	13	1	US-08-284-746-17	Sequence 17, Appl
c	22	9.8	20.4	13	1	US-09-772-315-3	Sequence 3, Appli
c	23	9.4	19.6	12	1	US-08-025-038-11	Sequence 11, Appl
c	24	9.4	19.6	12	1	US-08-545-785-2	Sequence 2, Appli
c	25	9	18.8	10	1	US-08-388-353-515	Sequence 515, App
c	26	9	18.8	10	1	US-08-388-353-516	Sequence 516, App
c	27	9	18.8	10	1	US-08-488-551B-515	Sequence 515, App
c	28	9	18.8	10	1	US-08-488-551B-516	Sequence 516, App
c	29	9	18.8	10	1	US-08-488-551B-833	Sequence 833, App
c	30	9	18.8	10	1	US-08-488-551B-834	Sequence 834, App
c	31	9	18.8	10	1	US-08-618-834C-17	Sequence 17, Appl
c	32	9	18.8	10	1	US-08-618-834C-54	Sequence 54, Appl
c	33	9	18.8	10	1	US-09-508-753B-21	Sequence 21, Appl
	34	9	18.8	11	1	US-08-192-942-8	Sequence 8, Appli
	35	9	18.8	11	1	US-08-646-695-15	Sequence 15, Appl
	36	9	18.8	11	1	PCT-US96-06053-15	Sequence 15, Appl
c	37	9	18.8	12	1	US-08-173-489C-256	Sequence 256, App
	38	9	18.8	12	1	US-08-507-032-14	Sequence 14, Appl
	39	9	18.8	12	1	US-08-862-431-22	Sequence 22, Appl
c	40	9	18.8	12	1	US-08-244-087-12	Sequence 12, Appl
c	41	9	18.8	12	1	PCT-US92-09955-12	Sequence 12, Appl
	42	7.4	15.4	15	1	US-09-081-646-601	Sequence 601, App
	43	7	14.6	17	1	US-09-866-108A-8341	Sequence 8341, Ap
	44	7	14.6	17	1	US-09-866-108A-8342	Sequence 8342, Ap
	45	7	14.6	17	1	US-09-866-108A-8343	Sequence 8343, Ap
	46	6.2	12.9	17	1	US-09-866-108A-8344	Sequence 8344, Ap
	47	6.2	12.9	17	1	US-09-866-108A-8345	Sequence 8345, Ap
	48	5.8	12.1	10	1	US-08-388-353-515	Sequence 515, App
	49	5.8	12.1	10	1	US-08-488-551B-515	Sequence 515, App
	50	5.8	12.1	10	1	US-08-488-551B-833	Sequence 833, App

ALIGNMENTS

RESULT 1
US-08-897-340-27/c
; Sequence 27, Application US/08897340
; Patent No. 5955306
; GENERAL INFORMATION:
; APPLICANT: Gimeno, Carlos J. and Errada, Patrick, R.
; TITLE OF INVENTION: Weight Control Pathway Genes and Uses
; TITLE OF INVENTION: Therefor
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/897,340
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/715,032
; FILING DATE: 17-SEP-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Silveri, Jean M.
; REGISTRATION NUMBER: 39,030
; REFERENCE/DOCKET NUMBER: MNI-005CP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)227-5941
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-897-340-27

Query Match 30.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.9;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1714 GCTGACTGATGTTGAGGG 1731
              ||||||||  | ||||||
Db         18 GCTGACTGACGCTGAGGG 1
```

```
RESULT 2
US-09-252-329-27/c
; Sequence 27, Application US/09252329
; Patent No. 6147192
;  GENERAL INFORMATION:
;    APPLICANT:  Gimeno, Carlos J. and Errada, Patrick, R.
;    TITLE OF INVENTION:  Weight Control Pathway Genes and Uses
;    TITLE OF INVENTION:  Therefor
;    NUMBER OF SEQUENCES:  36
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  LAHIVE & COCKFIELD, LLP
;      STREET:  28 State Street
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  USA
;      ZIP:  02109
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/252,329
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/897,340
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Silveri, Jean M.
;      REGISTRATION NUMBER:  39,030
;      REFERENCE/DOCKET NUMBER:  MNI-005CP
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617)227-7400
;      TELEFAX:  (617)227-5941
;  INFORMATION FOR SEQ ID NO:  27:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-09-252-329-27

  Query Match             30.8%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 2.9;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1714 GCTGACTGATGTTGAGGG 1731
              |||||||||  | ||||||
Db         18 GCTGACTGACGCTGAGGG 1


RESULT 3
US-09-679-298A-23/c
; Sequence 23, Application US/09679298A
; Patent No. 6566131
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF SMAD6 EXPRESSION
;  FILE REFERENCE: RTS-0045
;  CURRENT APPLICATION NUMBER: US/09/679,298A
;  CURRENT FILING DATE:  2001-03-05
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 23
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-679-298A-23

  Query Match             30.0%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 3.4;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1723 TGTTGAGGGAACAGAC 1738
              ||||||||||||  |||
Db         18 TGTTGAGGGAACGGAC 3


RESULT 4
US-09-371-772B-5840
; Sequence 5840, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5840
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-5840

  Query Match             27.9%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   60.0%;  Pred. No. 4.7;
  Matches    9;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1715 CTGACTGATGTTGAG 1729
              |:|| :||:|::|||
Db          2 CUGAGUGAUGUUGAG 16


RESULT 5
US-09-866-108A-8341/c
; Sequence 8341, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8341
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8341

  Query Match             27.1%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 5.8;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1713 TGCTGACTGATGT 1725
             |||||||||||||
Db         17 TGCTGACTGATGT 5


RESULT 6
US-09-866-108A-8342/c
; Sequence 8342, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8342
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8342

  Query Match             27.1%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 5.8;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1713 TGCTGACTGATGT 1725
             |||||||||||||
Db         16 TGCTGACTGATGT 4


RESULT 7
US-09-866-108A-8343/c
; Sequence 8343, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8343
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8343

  Query Match             27.1%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 5.8;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1713 TGCTGACTGATGT 1725
             |||||||||||||
Db         15 TGCTGACTGATGT 3


RESULT 8
US-09-866-108A-8344/c
; Sequence 8344, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
```

```
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8344
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8344

  Query Match             27.1%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 5.8;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1713 TGCTGACTGATGT 1725
             |||||||||||||
Db         14 TGCTGACTGATGT 2


RESULT 9
US-09-866-108A-8345/c
; Sequence 8345, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8345
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8345

  Query Match             27.1%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 5.8;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1713 TGCTGACTGATGT 1725
             |||||||||||||
Db         13 TGCTGACTGATGT 1


RESULT 10
US-08-666-341A-67/c
; Sequence 67, Application US/08666341A
; Patent No. 6365345
;  GENERAL INFORMATION:
;    APPLICANT:
;    TITLE OF INVENTION:  Antisense nucleic Acids for the
;    TITLE OF INVENTION:  prevention and treatment of disorders in which expression
;    TITLE OF INVENTION:  of c-erbB plays a role
;    NUMBER OF SEQUENCES:  106
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Jacobson, Price, Holman and Stern, PLLC
;      STREET:  400 Seventh street, N.W.
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  USA
;      ZIP:  20004
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disc
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25 (EPO)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/666,341A
;      FILING DATE:  15-AUG-1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  EP 93120710.4
;  INFORMATION FOR SEQ ID NO:  67:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
;    ANTI-SENSE:  YES
US-08-666-341A-67

  Query Match             26.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 6;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1723 TGTTGAGGGAACAGAC 1738
```

```
                    ||||||||||| | ||
Db          16 TGTTGAGGGAAAACAC 1


RESULT 11
US-09-371-772B-5841
; Sequence 5841, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5841
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-5841

  Query Match             26.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   62.5%;  Pred. No. 6;
  Matches   10;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1717 GACTGATGTTGAGGGA 1732
                || :||:|::|||| |
Db          1 GAGUGAUGUUGAGGAA 16


RESULT 12
US-08-533-472-5
; Sequence 5, Application US/08533472
; Patent No. 5756294
;  GENERAL INFORMATION:
;    APPLICANT:  White, Marga B.
;    APPLICANT:  Sadzewicz, Lisa K.
;    TITLE OF INVENTION:  Suceptibility Mutation for Breast and
;    TITLE OF INVENTION:  Ovarian Cancer
;    NUMBER OF SEQUENCES:  6
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  BURNS, DOANE, SWECKER & MATHIS
;      STREET:  699 Prince Street
;      CITY:  Alexandria
;      STATE:  VA
;      COUNTRY:  USA
;      ZIP:  22314-3187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/533,472
;      FILING DATE:  25-SEP-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Swecker, Robert S.
;      REGISTRATION NUMBER:  19,885
;      REFERENCE/DOCKET NUMBER:  020160-000
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  703-836-6620
;      TELEFAX:  703-836-2021
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  not relevant
;      TOPOLOGY:  not relevant
;    MOLECULE TYPE:  DNA (genomic)
US-08-533-472-5

  Query Match             24.6%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 8.5;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1731 GAACAGACAGGAGAA 1745
                ||||| | |||||||
Db          1 GAACACAGAGGAGAA 15


RESULT 13
US-08-292-620A-78/c
; Sequence 78, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  78:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
```

US-08-292-620A-78

Query Match 24.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 8.5;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1724 GTTGAGGGAACAGAC 1738
              ||  ||||||||||
Db         15 GTCCAGGGAACAGAC 1
```

RESULT 14
US-09-071-845-78/c
; Sequence 78, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 78:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-78

Query Match 24.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 8.5;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1724 GTTGAGGGAACAGAC 1738
              ||  ||||||||||
Db         15 GTCCAGGGAACAGAC 1
```

RESULT 15
US-09-081-646-601/c
; Sequence 601, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; TITLE OF INVENTION: Cancer Cells
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 601
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-601

Query Match 23.7%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 10;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1739 AGGAGAAATGCAT 1751
              ||||| |||||||
Db         14 AGGAGGAATGCAT 2
```

RESULT 16
US-08-368-071-8
; Sequence 8, Application US/08368071
; Patent No. 5707853
; GENERAL INFORMATION:
; APPLICANT: MILLAN, JOSE L.
; TITLE OF INVENTION: RECOMBINANT CALF INTESTINAL ALKALINE
; TITLE OF INVENTION: PHOSPHATASE
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CAMPBELL AND FLORES
; STREET: 4370 LA JOLLA VILLAGE DRIVE, SUITE 700
; CITY: SAN DIEGO
; STATE: CALIFORNIA
; COUNTRY: UNITED STATES
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/368,071
; FILING DATE: 03-JAN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: CAMPBELL, CATHRYN
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-LJ 1275
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-535-9001
; TELEFAX: 619-535-8949
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid

```
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-368-071-8

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 12;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1733 ACAGACAGGAGA 1744
              ||||| ||||||
Db          1 ACAGAGAGGAGA 12


RESULT 17
US-08-458-181-8
; Sequence 8, Application US/08458181
; Patent No. 5773226
;  GENERAL INFORMATION:
;    APPLICANT:  MILLAN, JOSE L.
;    TITLE OF INVENTION:  RECOMBINANT CALF INTESTINAL ALKALINE
;    TITLE OF INVENTION:  PHOSPHATASE
;    NUMBER OF SEQUENCES:  13
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  CAMPBELL AND FLORES
;      STREET:  4370 LA JOLLA VILLAGE DRIVE, SUITE 700
;      CITY:  SAN DIEGO
;      STATE:  CALIFORNIA
;      COUNTRY:  UNITED STATES
;      ZIP:  92122
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/458,181
;      FILING DATE:  30-DEC-1994
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  CAMPBELL, CATHRYN
;      REGISTRATION NUMBER:  31,815
;      REFERENCE/DOCKET NUMBER:  P-LJ 1275
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  619-535-9001
;      TELEFAX:  619-535-8949
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-458-181-8

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 12;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1733 ACAGACAGGAGA 1744
              ||||| ||||||
Db          1 ACAGAGAGGAGA 12


RESULT 18
PCT-US93-02172-8
; Sequence 8, Application PC/TUS9302172
;  GENERAL INFORMATION:
;    APPLICANT:  La Jolla Cancer Research Foundation
;    TITLE OF INVENTION:  RECOMBINANT CALF INTESTINAL ALKALINE
;    TITLE OF INVENTION:  PHOSPHATASE
;    NUMBER OF SEQUENCES:  13
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  La Jolla Cancer Research Foundation
;      STREET:  10901 North Torry Pines Road
;      CITY:  La Jolla
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  92037
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version 1.25 (EPO)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/02172
;      FILING DATE:  19930310
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/849,219
;      FILING DATE:  10-MAR-1992
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (619) 455-6480
;      TELEFAX:  (619) 455-0181
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
PCT-US93-02172-8

  Query Match             21.7%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 12;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1733 ACAGACAGGAGA 1744
              ||||| ||||||
Db          1 ACAGAGAGGAGA 12


RESULT 19
US-08-173-489C-244/c
; Sequence 244, Application US/08173489C
; Patent No. 5861244
;  GENERAL INFORMATION:
;    APPLICANT:  WANG, C. -G.
;    APPLICANT:  HEPBURN, A. G.
;    TITLE OF INVENTION:  GENETIC SEQUENCE ASSAY USING DNA
;    TITLE OF INVENTION:  TRIPLE-STRAND FORMATION.
;    NUMBER OF SEQUENCES:  365
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PROFILE DIAGNOSTIC SCIENCES, INC.,
;      STREET:  510 EAST 73RD STREET,
;      CITY:  NEW YORK
;      STATE:  NEW YORK
;      COUNTRY:  USA
;      ZIP:  10021.
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch, 1.44Mb storage
;      COMPUTER:  IBM PC/XT/AT
;      OPERATING SYSTEM:  MS-DOS version 6.2
;      SOFTWARE:  Wordperfect Version 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/173,489C
;      FILING DATE:  22 DEC 1993
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/968,436
;      FILING DATE:  29 OCT 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Handelman, Joseph H.
;      REGISTRATION NUMBER:  26,179
;      REFERENCE/DOCKET NUMBER:  U9518-6
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (attorney) (212) 708-1880
;      TELEFAX:  (attorney) (212) 246-8959
```

```
;  INFORMATION FOR SEQ ID NO:  244:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 bases
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  third strand derived from L.
;      DESCRIPTION:  interrogans 23s region in Seq ID No. 5861244243
;    HYPOTHETICAL:  yes
;    ANTI-SENSE:  no
;    PUBLICATION INFORMATION:
;      RELEVANT RESIDUES IN SEQ ID NO:  244 :FROM 1 TO 13
US-08-173-489C-244

  Query Match             20.8%;  Score 10;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   10;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1727 GAGGGAACAG 1736
             ||||||||||
Db         12 GAGGGAACAG 3


RESULT 20
US-08-284-746-10
; Sequence 10, Application US/08284746
; Patent No. 5525468
;  GENERAL INFORMATION:
;    APPLICANT:  James A. McSwiggen
;    TITLE OF INVENTION:  ASSAY FOR RIBOZYME TARGET SITE
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  611 West Sixth Street
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  90017
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  IBM P.C. DOS (Version 5.0)
;      SOFTWARE:  WordPerfect (Version 5.1)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/284,746
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/883,849
;      FILING DATE:  May 14, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  197/070
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  10:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-284-746-10

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 17;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1737 ACAGGAGAAATGC 1749
              || ||||||| ||
Db          1 ACTGGAGAAAGGC 13


RESULT 21
US-08-284-746-17/c
; Sequence 17, Application US/08284746
; Patent No. 5525468
;  GENERAL INFORMATION:
;    APPLICANT:  James A. McSwiggen
;    TITLE OF INVENTION:  ASSAY FOR RIBOZYME TARGET SITE
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  611 West Sixth Street
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  90017
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  IBM P.C. DOS (Version 5.0)
;      SOFTWARE:  WordPerfect (Version 5.1)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/284,746
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/883,849
;      FILING DATE:  May 14, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  197/070
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  17:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-284-746-17

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 17;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1737 ACAGGAGAAATGC 1749
              || ||||||| ||
Db         13 ACTGGAGAAAGGC 1


RESULT 22
US-09-772-315-3/c
; Sequence 3, Application US/09772315
; Patent No. 6559125
; GENERAL INFORMATION:
;  APPLICANT: DERVAN, Peter
;  APPLICANT:  WURTZ, Nicholas
;  APPLICANT:  CHANG, Aileen
;  TITLE OF INVENTION: POLYAMIDE-ALKYLATOR CONJUGATES & RELATED PRODUCTS & METHODS
;  FILE REFERENCE: GENESOFT09/772315
;  CURRENT APPLICATION NUMBER: US/09/772,315
;  CURRENT FILING DATE:  2001-01-26
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
```

```
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Description of Artificial Sequence: pHIV-LTR EcoRI/HindIII
;   OTHER INFORMATION: restriction fragment
US-09-772-315-3

  Query Match             20.4%;  Score 9.8;  DB 1;  Length 13;
  Best Local Similarity   84.6%;  Pred. No. 17;
  Matches   11;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1741 GAGAAATGCATCC 1753
              |||| |||||||
Db         13 GAGAGCTGCATCC 1


RESULT 23
US-08-025-038-11/c
; Sequence 11, Application US/08025038
; Patent No. 5545526
;  GENERAL INFORMATION:
;    APPLICANT:  BAXTER-LOWE, Lee-Ann
;    TITLE OF INVENTION:  Method For HLA Typing
;    NUMBER OF SEQUENCES:  46
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Foley & Lardner
;      STREET:  777 E. Wisconsin Avenue
;      CITY:  Milwaukee
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53202-5367
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/025,038
;      FILING DATE:  19930301
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/544,218
;      FILING DATE:  27-JUN-1990
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Meyers, Philip G.
;      REGISTRATION NUMBER:  30,478
;      REFERENCE/DOCKET NUMBER:  204 854
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (414)289-3761
;      TELEFAX:  (414)289-3791
;  INFORMATION FOR SEQ ID NO:  11:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-025-038-11

  Query Match             19.6%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   90.9%;  Pred. No. 18;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1730 GGAACAGACAG 1740
              ||||||| |||
Db         12 GGAACAGCCAG 2


RESULT 24
US-08-545-785-2/c
; Sequence 2, Application US/08545785
; Patent No. 5770713
;  GENERAL INFORMATION:
;    APPLICANT:  Imbach and Rayner
;    TITLE OF INVENTION:  Phosphorothioate Triester Oligonucleotides
;    TITLE OF INVENTION:  And Method Of Preparation
;    NUMBER OF SEQUENCES:  2
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz & No. 5770713ris LLP
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch disk, 1.44 Mb
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 6.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/545,785
;      FILING DATE:  17-JAN-1996
;      CLASSIFICATION:  536
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph Lucci
;      REGISTRATION NUMBER:  33,307
;      REFERENCE/DOCKET NUMBER:  ISIS-2114
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 bases
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-545-785-2

  Query Match             19.6%;  Score 9.4;  DB 1;  Length 12;
  Best Local Similarity   90.9%;  Pred. No. 18;
  Matches   10;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1727 GAGGGAACAGA 1737
              ||||||| |||
Db         11 GAGGGAAAAGA 1


RESULT 25
US-08-388-353-515/c
; Sequence 515, Application US/08388353
; Patent No. 6010895
;  GENERAL INFORMATION:
;    APPLICANT:  Deacon, Nicholas J.
;    APPLICANT:  Learmont, Jennifer C.
;    APPLICANT:  McPhee, Dale A.
;    APPLICANT:  Crowe, Suzanne
;    APPLICANT:  Cooper, David
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  800
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Scully, Scott, Murphy & Presser
;      STREET:  400 Garden City Plaza
;      CITY:  Garden City
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  11530
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/388,353
;      FILING DATE:  14-FEB-1995
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DiGiglio, Frank S.
;      REGISTRATION NUMBER:  31,346
```

```
;      REFERENCE/DOCKET NUMBER:  9606
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;      TELEX:  230 901 SANS UR
;  INFORMATION FOR SEQ ID NO:  515:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-388-353-515

  Query Match             18.8%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 18;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1749 CATCCATTC 1757
             |||||||||
Db         10 CATCCATTC 2


RESULT 26
US-08-388-353-516/c
; Sequence 516, Application US/08388353
; Patent No. 6010895
;  GENERAL INFORMATION:
;    APPLICANT:  Deacon, Nicholas J.
;    APPLICANT:  Learmont, Jennifer C.
;    APPLICANT:  McPhee, Dale A.
;    APPLICANT:  Crowe, Suzanne
;    APPLICANT:  Cooper, David
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  800
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Scully, Scott, Murphy & Presser
;      STREET:  400 Garden City Plaza
;      CITY:  Garden City
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  11530
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/388,353
;      FILING DATE:  14-FEB-1995
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DiGiglio, Frank S.
;      REGISTRATION NUMBER:  31,346
;      REFERENCE/DOCKET NUMBER:  9606
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;      TELEX:  230 901 SANS UR
;  INFORMATION FOR SEQ ID NO:  516:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-388-353-516

  Query Match             18.8%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 18;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1749 CATCCATTC 1757
             |||||||||
Db         10 CATCCATTC 2


RESULT 27
US-08-488-551B-515/c
; Sequence 515, Application US/08488551B
; Patent No. 6015661
;  GENERAL INFORMATION:
;    APPLICANT:  Nicholas J. Deacon
;    APPLICANT:  Dale A. McPhee
;    APPLICANT:  David Cooper
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  841
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SCULLY, SCOTT, MURPHY & PRESSER
;      STREET:  400 GARDEN CITY PLAZA
;      CITY:  GARDEN CITY
;      STATE:  NEW YORK
;      COUNTRY:  U.S.A.
;      ZIP:  11530-0299
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/488,551B
;      FILING DATE:  07-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PM3864 (AU)
;      FILING DATE:  14-FEB-1994
;      APPLICATION NUMBER:  PM4002 (AU)
;      FILING DATE:  21-FEB-1994
;      APPLICATION NUMBER:  PN0284 (AU)
;      FILING DATE:  23-DEC-1994
;      APPLICATION NUMBER:  US 08/388,353
;      FILING DATE:  14-FEB-1995
;      APPLICATION NUMBER:  PN3021/95
;      FILING DATE:  17-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FRANK S. DIGIGLIO
;      REFERENCE/DOCKET NUMBER:  9606Z
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;  INFORMATION FOR SEQ ID NO:  515:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-488-551B-515

  Query Match             18.8%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 18;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1749 CATCCATTC 1757
             |||||||||
Db         10 CATCCATTC 2


RESULT 28
US-08-488-551B-516/c
; Sequence 516, Application US/08488551B
; Patent No. 6015661
;  GENERAL INFORMATION:
;    APPLICANT:  Nicholas J. Deacon
;    APPLICANT:  Dale A. McPhee
;    APPLICANT:  David Cooper
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
```

```
;    NUMBER OF SEQUENCES:  841
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SCULLY, SCOTT, MURPHY & PRESSER
;      STREET:  400 GARDEN CITY PLAZA
;      CITY:  GARDEN CITY
;      STATE:  NEW YORK
;      COUNTRY:  U.S.A.
;      ZIP:  11530-0299
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/488,551B
;      FILING DATE:  07-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PM3864 (AU)
;      FILING DATE:  14-FEB-1994
;      APPLICATION NUMBER:  PM4002 (AU)
;      FILING DATE:  21-FEB-1994
;      APPLICATION NUMBER:  PN0284 (AU)
;      FILING DATE:  23-DEC-1994
;      APPLICATION NUMBER:  US 08/388,353
;      FILING DATE:  14-FEB-1995
;      APPLICATION NUMBER:  PN3021/95
;      FILING DATE:  17-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FRANK S. DIGIGLIO
;      REFERENCE/DOCKET NUMBER:  9606Z
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;  INFORMATION FOR SEQ ID NO:  516:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-488-551B-516

  Query Match           18.8%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity  100.0%;  Pred. No. 18;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1749 CATCCATTC 1757
              |||||||||
Db          9 CATCCATTC 1


RESULT 29
US-08-488-551B-833/c
; Sequence 833, Application US/08488551B
; Patent No. 6015661
;  GENERAL INFORMATION:
;    APPLICANT:  Nicholas J. Deacon
;    APPLICANT:  Dale A. McPhee
;    APPLICANT:  David Cooper
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  841
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SCULLY, SCOTT, MURPHY & PRESSER
;      STREET:  400 GARDEN CITY PLAZA
;      CITY:  GARDEN CITY
;      STATE:  NEW YORK
;      COUNTRY:  U.S.A.
;      ZIP:  11530-0299
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/488,551B
;      FILING DATE:  07-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PM3864 (AU)
;      FILING DATE:  14-FEB-1994
;      APPLICATION NUMBER:  PM4002 (AU)
;      FILING DATE:  21-FEB-1994
;      APPLICATION NUMBER:  PN0284 (AU)
;      FILING DATE:  23-DEC-1994
;      APPLICATION NUMBER:  US 08/388,353
;      FILING DATE:  14-FEB-1995
;      APPLICATION NUMBER:  PN3021/95
;      FILING DATE:  17-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FRANK S. DIGIGLIO
;      REFERENCE/DOCKET NUMBER:  9606Z
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;  INFORMATION FOR SEQ ID NO:  833:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-488-551B-833

  Query Match           18.8%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity  100.0%;  Pred. No. 18;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1749 CATCCATTC 1757
              |||||||||
Db         10 CATCCATTC 2


RESULT 30
US-08-488-551B-834/c
; Sequence 834, Application US/08488551B
; Patent No. 6015661
;  GENERAL INFORMATION:
;    APPLICANT:  Nicholas J. Deacon
;    APPLICANT:  Dale A. McPhee
;    APPLICANT:  David Cooper
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  841
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SCULLY, SCOTT, MURPHY & PRESSER
;      STREET:  400 GARDEN CITY PLAZA
;      CITY:  GARDEN CITY
;      STATE:  NEW YORK
;      COUNTRY:  U.S.A.
;      ZIP:  11530-0299
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/488,551B
;      FILING DATE:  07-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PM3864 (AU)
;      FILING DATE:  14-FEB-1994
;      APPLICATION NUMBER:  PM4002 (AU)
;      FILING DATE:  21-FEB-1994
;      APPLICATION NUMBER:  PN0284 (AU)
;      FILING DATE:  23-DEC-1994
;      APPLICATION NUMBER:  US 08/388,353
;      FILING DATE:  14-FEB-1995
;      APPLICATION NUMBER:  PN3021/95
```

```
;      FILING DATE:  17-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FRANK S. DIGIGLIO
;      REFERENCE/DOCKET NUMBER:  9606Z
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;  INFORMATION FOR SEQ ID NO:  834:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-488-551B-834

  Query Match             18.8%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 18;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1749 CATCCATTC 1757
             |||||||||
Db          9 CATCCATTC 1


RESULT 31
US-08-618-834C-17/c
; Sequence 17, Application US/08618834C
; Patent No. 6361937
;  GENERAL INFORMATION:
;    APPLICANT:  Stryer, Lubert
;    TITLE OF INVENTION:  Computer-Aided Nucleic Acid
;    TITLE OF INVENTION:  Sequencing
;    NUMBER OF SEQUENCES:  54
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Ritter, Van Pelt & Yi LLP
;      STREET:  4906 El Camino Real, Suite 205
;      CITY:  Los Altos
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94022
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/618,834C
;      FILING DATE:  19-MAR-1996
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Ritter, Michael J.
;      REGISTRATION NUMBER:  36,653
;      REFERENCE/DOCKET NUMBER:  AFFYP002
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  650-903-3500
;      TELEFAX:  650-903-3501
;  INFORMATION FOR SEQ ID NO:  17:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-618-834C-17

  Query Match             18.8%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 18;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1720 TGATGTTGA 1728
             |||||||||
Db          9 TGATGTTGA 1


RESULT 32
US-08-618-834C-54/c
; Sequence 54, Application US/08618834C
; Patent No. 6361937
;  GENERAL INFORMATION:
;    APPLICANT:  Stryer, Lubert
;    TITLE OF INVENTION:  Computer-Aided Nucleic Acid
;    TITLE OF INVENTION:  Sequencing
;    NUMBER OF SEQUENCES:  54
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Ritter, Van Pelt & Yi LLP
;      STREET:  4906 El Camino Real, Suite 205
;      CITY:  Los Altos
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94022
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/618,834C
;      FILING DATE:  19-MAR-1996
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Ritter, Michael J.
;      REGISTRATION NUMBER:  36,653
;      REFERENCE/DOCKET NUMBER:  AFFYP002
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  650-903-3500
;      TELEFAX:  650-903-3501
;  INFORMATION FOR SEQ ID NO:  54:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-618-834C-54

  Query Match             18.8%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 18;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1720 TGATGTTGA 1728
             |||||||||
Db         10 TGATGTTGA 2


RESULT 33
US-09-508-753B-21/c
; Sequence 21, Application US/09508753B
; Patent No. 6544736
; GENERAL INFORMATION:
;  APPLICANT: Akira SHIMAMOTO
;  APPLICANT:  Yasuhiro FURUICHI
;  APPLICANT:  Yuko SHIBATA
;  APPLICANT:  Hiroko FUNAKI
;  APPLICANT:  Eiji OHARA
;  APPLICANT:  Masanori WATAHIKI
;  TITLE OF INVENTION: Method for Synthesizing cDNA from mRNA sample
;  FILE REFERENCE: 00162/HG
;  CURRENT APPLICATION NUMBER: US/09/508,753B
;  CURRENT FILING DATE:  2000-06-16
;  PRIOR APPLICATION NUMBER: JP 9/270324
;  PRIOR FILING DATE: 1997-09-18
```

```
;  NUMBER OF SEQ ID NOS: 472
; SEQ ID NO 21
;   LENGTH: 10
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-508-753B-21

  Query Match             18.8%;  Score 9;  DB 1;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 18;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1738 CAGGAGAAA 1746
              |||||||||
Db             9 CAGGAGAAA 1


RESULT 34
US-08-192-942-8
; Sequence 8, Application US/08192942
; Patent No. 5989906
;  GENERAL INFORMATION:
;    APPLICANT:  JAMES D. THOMPSON
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING P-GLYCOPROTEIN mdr-
;    TITLE OF INVENTION:  1 GENE
;    NUMBER OF SEQUENCES:  9
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  611 West Sixth Street
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  90017
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb storage
;      COMPUTER:  IBM COMPATIBLE
;      OPERATING SYSTEM:  IBM P.C. DOS (Version 5.0)
;      SOFTWARE:  WordPerfect (Version 5.1)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/192,942
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/882,885
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  197/173
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  11
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-192-942-8

  Query Match             18.8%;  Score 9;  DB 1;  Length 11;
  Best Local Similarity   88.9%;  Pred. No. 20;
  Matches    8;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1740 GGAGAAATG 1748
              |||||||:|
Db             1 GGAGAAAUG 9


RESULT 35
US-08-646-695-15
; Sequence 15, Application US/08646695
; Patent No. 6168943
;  GENERAL INFORMATION:
;    APPLICANT:  Rose, John K.
;    TITLE OF INVENTION:  RECOMBINANT VESICULOVIRUSES AND THEIR
;    TITLE OF INVENTION:  USES
;    NUMBER OF SEQUENCES:  44
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PENNIE & EDMONDS
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  USA
;      ZIP:  10036-2711
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/646,695
;      FILING DATE:  On Even Date Herewith
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Misrock, S. Leslie
;      REGISTRATION NUMBER:  18,872
;      REFERENCE/DOCKET NUMBER:  6523-008
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 790-9090
;      TELEFAX:  (212) 869-9741/8864
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  11 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  RNA
US-08-646-695-15

  Query Match             18.8%;  Score 9;  DB 1;  Length 11;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1738 CAGGAGAAA 1746
              |||||||||
Db             2 CAGGAGAAA 10


RESULT 36
PCT-US96-06053-15
; Sequence 15, Application PC/TUS9606053
;  GENERAL INFORMATION:
;    APPLICANT:  Yale University
;    TITLE OF INVENTION:  RECOMBINANT VESICULOVIRUSES AND THEIR
;    TITLE OF INVENTION:  USES
;    NUMBER OF SEQUENCES:  41
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PENNIE & EDMONDS
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  USA
;      ZIP:  10036-2711
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US96/06053
;      FILING DATE:  01-MAY-1996
```

```
;       CLASSIFICATION:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Misrock, S. Leslie
;       REGISTRATION NUMBER:  18,872
;       REFERENCE/DOCKET NUMBER:  6523-009-228
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (212) 790-9090
;       TELEFAX:  (212) 869-9741/8864
;       TELEX:  66141 PENNIE
;   INFORMATION FOR SEQ ID NO:  15:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  11 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  unknown
;     MOLECULE TYPE:  RNA
PCT-US96-06053-15

  Query Match             18.8%;  Score 9;  DB 1;  Length 11;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1738 CAGGAGAAA 1746
              |||||||||
Db          2 CAGGAGAAA 10


RESULT 37
US-08-173-489C-256/c
; Sequence 256, Application US/08173489C
; Patent No. 5861244
;  GENERAL INFORMATION:
;    APPLICANT:  WANG, C. -G.
;    APPLICANT:  HEPBURN, A. G.
;    TITLE OF INVENTION:  GENETIC SEQUENCE ASSAY USING DNA
;    TITLE OF INVENTION:  TRIPLE-STRAND FORMATION.
;    NUMBER OF SEQUENCES:  365
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PROFILE DIAGNOSTIC SCIENCES, INC.,
;      STREET:  510 EAST 73RD STREET,
;      CITY:  NEW YORK
;      STATE:  NEW YORK
;      COUNTRY:  USA
;      ZIP:  10021.
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch, 1.44Mb storage
;      COMPUTER:  IBM PC/XT/AT
;      OPERATING SYSTEM:  MS-DOS version 6.2
;      SOFTWARE:  Wordperfect Version 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/173,489C
;      FILING DATE:  22 DEC 1993
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/968,436
;      FILING DATE:  29 OCT 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Handelman, Joseph H.
;      REGISTRATION NUMBER:  26,179
;      REFERENCE/DOCKET NUMBER:  U9518-6
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (attorney) (212) 708-1880
;      TELEFAX:  (attorney) (212) 246-8959
;  INFORMATION FOR SEQ ID NO:  256:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 bases
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  third strand derived from M. luteus
;      DESCRIPTION:  23s region in Seq ID No. 5861244255
;    HYPOTHETICAL:  yes
;    ANTI-SENSE:  no
;    PUBLICATION INFORMATION:
;      RELEVANT RESIDUES IN SEQ ID NO:  256 :FROM 1 TO 12
US-08-173-489C-256

  Query Match             18.8%;  Score 9;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 21;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1736 GACAGGAGA 1744
              |||||||||
Db          9 GACAGGAGA 1


RESULT 38
US-08-507-032-14
; Sequence 14, Application US/08507032
; Patent No. 5989810
;  GENERAL INFORMATION:
;    APPLICANT:  Flanagan, William A.
;    APPLICANT:  Crabtree, Gerald R.
;    TITLE OF INVENTION:  Screening Methods for Immunosuppressive
;    TITLE OF INVENTION:  Agents
;    NUMBER OF SEQUENCES:  19
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  William M. Smith
;      STREET:  One Market Plaza, Steuart Tower, Suite 2000
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94105
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/507,032
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/228,944
;      FILING DATE:
;      APPLICATION NUMBER:  US 07/749,385
;      FILING DATE:  22-AUG-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Smith, William M.
;      REGISTRATION NUMBER:  30,223
;      REFERENCE/DOCKET NUMBER:  5490A-89
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-326-2400
;      TELEFAX:  415-326-2422
;  INFORMATION FOR SEQ ID NO:  14:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-507-032-14

  Query Match             18.8%;  Score 9;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 21;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1738 CAGGAGAAA 1746
              |||||||||
Db          1 CAGGAGAAA 9


RESULT 39
US-08-862-431-22
; Sequence 22, Application US/08862431
```

```
; Patent No. 6120994
;  GENERAL INFORMATION:
;    APPLICANT:  TAM, SHUI-PANG
;    TITLE OF INVENTION:  ANTIOXIDANT RESPONSIVE ELEMENT
;    NUMBER OF SEQUENCES:  51
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
;      STREET:  1100 NEW YORK AVENUE, SUITE 600
;      CITY:  WASHINGTON
;      STATE:  DC
;      COUNTRY:  US
;      ZIP:  20005-3934
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/862,431
;      FILING DATE:  23-MAY-1997
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Kim, Judith U.
;      REGISTRATION NUMBER:  40,679
;      REFERENCE/DOCKET NUMBER:  1669.0020000
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202) 371-2600
;      TELEFAX:  (202) 371-2540
;  INFORMATION FOR SEQ ID NO:  22:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-862-431-22

  Query Match             18.8%;  Score 9;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 21;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1729 GGGAACAGA 1737
             |||||||||
Db          1 GGGAACAGA 9


RESULT 40
US-08-244-087-12/c
; Sequence 12, Application US/08244087
; Patent No. 6610294
;  GENERAL INFORMATION:
;    APPLICANT:  Lederman, Seth
;    APPLICANT:  Chess, Leonard
;    APPLICANT:  Yellin, Michael J.
;    TITLE OF INVENTION:  MURINE MONOCLONAL ANTIBODY (5c8)
;    TITLE OF INVENTION:  RECOGNIZES A HUMAN GLYCOPROTEIN ON THE SURFACE OF
;    TITLE OF INVENTION:  T-LYMPHOCYTES, COMPOSITIONS CONTAINING SAME AND METHODS
;    TITLE OF INVENTION:  OF USE
;    NUMBER OF SEQUENCES:  16
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooper & Dunham
;      STREET:  30 Rockefeller Plaza
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  United States of America
;      ZIP:  10112
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/244,087
;      FILING DATE:
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P.
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  0575/39757-A-PCT
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 977-9550
;      TELEFAX:  (212) 664-0525
;      TELEX:  422523 COOP UI
;  INFORMATION FOR SEQ ID NO:  12:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-08-244-087-12

  Query Match             18.8%;  Score 9;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 21;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1714 GCTGACTGA 1722
             |||||||||
Db         12 GCTGACTGA 4


RESULT 41
PCT-US92-09955-12/c
; Sequence 12, Application PC/TUS9209955
;  GENERAL INFORMATION:
;    APPLICANT:  Lederman, Seth
;    APPLICANT:  Chess, Leonard
;    APPLICANT:  Yellin, Michael J.
;    TITLE OF INVENTION:  MURINE MONOCLONAL ANTIBODY (5c8)
;    TITLE OF INVENTION:  RECOGNIZES A HUMAN GLYCOPROTEIN ON THE SURFACE OF
;    TITLE OF INVENTION:  T-LYMPHOCYTES, COMPOSITIONS CONTAINING SAME AND METHODS OF
;    TITLE OF INVENTION:  USE
;    NUMBER OF SEQUENCES:  16
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooper & Dunham
;      STREET:  30 Rockefeller Plaza
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  United States of America
;      ZIP:  10112
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US92/09955
;      FILING DATE:  19921116
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P.
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  0575/39757-A-PCT
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 977-9550
;      TELEFAX:  (212) 664-0525
;      TELEX:  422523 COOP UI
;  INFORMATION FOR SEQ ID NO:  12:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    HYPOTHETICAL:  NO
```

```
;    ANTI-SENSE:  NO
PCT-US92-09955-12

  Query Match             18.8%;  Score 9;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 21;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1714 GCTGACTGA 1722
                ||||||||| 
Db         12 GCTGACTGA 4


RESULT 42
US-09-081-646-601
; Sequence 601, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
;  APPLICANT: Kinzler, Kenneth
;  APPLICANT: Vogelstein, Bert
;  APPLICANT: Zhang, Lin
;  APPLICANT: Zhou, Wei
;  TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
;  TITLE OF INVENTION: Cancer Cells
;  FILE REFERENCE: 01107.74664
;  CURRENT APPLICATION NUMBER: US/09/081,646
;  CURRENT FILING DATE: 1998-05-20
;  EARLIER APPLICATION NUMBER: 60/047,352
;  EARLIER FILING DATE: 1997-05-21
;  NUMBER OF SEQ ID NOS: 871
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 601
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-081-646-601

  Query Match             15.4%;  Score 7.4;  DB 1;  Length 15;
  Best Local Similarity   88.9%;  Pred. No. 41;
  Matches    8;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1749 CATCCATTC 1757
                ||| ||||| 
Db          1 CATGCATTC 9


RESULT 43
US-09-866-108A-8341
; Sequence 8341, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8341
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8341

  Query Match             14.6%;  Score 7;  DB 1;  Length 17;
  Best Local Similarity   66.7%;  Pred. No. 46;
  Matches   10;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1728 AGGGAACAGACAGGA 1742
                ||  | ||| ||| |
Db          3 AGACATCAGTCAGCA 17


RESULT 44
US-09-866-108A-8342
; Sequence 8342, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8342
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8342
```

Query Match 14.6%; Score 7; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 46;
Matches 10; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

```
Qy       1728 AGGGAACAGACAGGA 1742
              ||  | ||| ||| |
Db          2 AGACATCAGTCAGCA 16
```

RESULT 45
US-09-866-108A-8343
; Sequence 8343, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8343
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8343

Query Match 14.6%; Score 7; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 46;
Matches 10; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

```
Qy       1728 AGGGAACAGACAGGA 1742
              ||  | ||| ||| |
Db          1 AGACATCAGTCAGCA 15
```

RESULT 46
US-09-866-108A-8344
; Sequence 8344, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8344
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8344

Query Match 12.9%; Score 6.2; DB 1; Length 17;
Best Local Similarity 72.7%; Pred. No. 54;
Matches 8; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1732 AACAGACAGGA 1742
              | ||| ||| |
Db          4 ATCAGTCAGCA 14
```

RESULT 47
US-09-866-108A-8345
; Sequence 8345, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8345
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8345

  Query Match             12.9%;  Score 6.2;  DB 1;  Length 17;
  Best Local Similarity   72.7%;  Pred. No. 54;
  Matches    8;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1732 AACAGACAGGA 1742
             | ||| ||| | |
Db          3 ATCAGTCAGCA 13


RESULT 48
US-08-388-353-515
; Sequence 515, Application US/08388353
; Patent No. 6010895
;  GENERAL INFORMATION:
;    APPLICANT:  Deacon, Nicholas J.
;    APPLICANT:  Learmont, Jennifer C.
;    APPLICANT:  McPhee, Dale A.
;    APPLICANT:  Crowe, Suzanne
;    APPLICANT:  Cooper, David
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  800
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Scully, Scott, Murphy & Presser
;      STREET:  400 Garden City Plaza
;      CITY:  Garden City
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  11530
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/388,353
;      FILING DATE:  14-FEB-1995
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DiGiglio, Frank S.
;      REGISTRATION NUMBER:  31,346
;      REFERENCE/DOCKET NUMBER:  9606
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;      TELEX:  230 901 SANS UR
;  INFORMATION FOR SEQ ID NO:  515:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-388-353-515

  Query Match             12.1%;  Score 5.8;  DB 1;  Length 10;
  Best Local Similarity   77.8%;  Pred. No. 56;
  Matches    7;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1743 GAAATGCAT 1751
             | |||| ||
Db          1 GGAATGGAT 9


RESULT 49
US-08-488-551B-515
; Sequence 515, Application US/08488551B
; Patent No. 6015661
;  GENERAL INFORMATION:
;    APPLICANT:  Nicholas J. Deacon
;    APPLICANT:  Dale A. McPhee
;    APPLICANT:  David Cooper
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  841
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SCULLY, SCOTT, MURPHY & PRESSER
;      STREET:  400 GARDEN CITY PLAZA
;      CITY:  GARDEN CITY
;      STATE:  NEW YORK
;      COUNTRY:  U.S.A.
;      ZIP:  11530-0299
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/488,551B
;      FILING DATE:  07-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PM3864 (AU)
;      FILING DATE:  14-FEB-1994
;      APPLICATION NUMBER:  PM4002 (AU)
;      FILING DATE:  21-FEB-1994
;      APPLICATION NUMBER:  PN0284 (AU)
;      FILING DATE:  23-DEC-1994
;      APPLICATION NUMBER:  US 08/388,353
;      FILING DATE:  14-FEB-1995
;      APPLICATION NUMBER:  PN3021/95
;      FILING DATE:  17-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FRANK S. DIGIGLIO
;      REFERENCE/DOCKET NUMBER:  9606Z
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;  INFORMATION FOR SEQ ID NO:  515:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-488-551B-515

  Query Match             12.1%;  Score 5.8;  DB 1;  Length 10;
  Best Local Similarity   77.8%;  Pred. No. 56;
  Matches    7;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1743 GAAATGCAT 1751
             | |||| ||
Db          1 GGAATGGAT 9


RESULT 50
US-08-488-551B-833
; Sequence 833, Application US/08488551B
; Patent No. 6015661
```

```
;  GENERAL INFORMATION:
;    APPLICANT:  Nicholas J. Deacon
;    APPLICANT:  Dale A. McPhee
;    APPLICANT:  David Cooper
;    TITLE OF INVENTION:  NON-PATHOGENIC STRAINS OF HIV-1
;    NUMBER OF SEQUENCES:  841
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SCULLY, SCOTT, MURPHY & PRESSER
;      STREET:  400 GARDEN CITY PLAZA
;      CITY:  GARDEN CITY
;      STATE:  NEW YORK
;      COUNTRY:  U.S.A.
;      ZIP:  11530-0299
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/488,551B
;      FILING DATE:  07-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PM3864 (AU)
;      FILING DATE:  14-FEB-1994
;      APPLICATION NUMBER:  PM4002 (AU)
;      FILING DATE:  21-FEB-1994
;      APPLICATION NUMBER:  PN0284 (AU)
;      FILING DATE:  23-DEC-1994
;      APPLICATION NUMBER:  US 08/388,353
;      FILING DATE:  14-FEB-1995
;      APPLICATION NUMBER:  PN3021/95
;      FILING DATE:  17-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FRANK S. DIGIGLIO
;      REFERENCE/DOCKET NUMBER:  9606Z
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (516) 742-4343
;      TELEFAX:  (516) 742-4366
;  INFORMATION FOR SEQ ID NO:  833:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  10 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-488-551B-833

  Query Match             12.1%;  Score 5.8;  DB 1;  Length 10;
  Best Local Similarity   77.8%;  Pred. No. 56;
  Matches    7;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1743 GAAATGCAT 1751
              | |||| ||
Db          1 GGAATGGAT 9


Search completed: July 13, 2004, 11:05:04
Job time : 0.001 secs
```

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: July 13, 2004, 11:06:28 ; Search time 0.001 Seconds
(without alignments)
43.488 Million cell updates/sec

Title: us-10-000-213-3
Perfect score: 48
Sequence: 1 ggctgctgactgatgttgag.....caggagaaatgcatccattc 48

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 27 seqs, 453 residues

Total number of hits satisfying chosen parameters: 54

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 20 summaries

Database : rnpbdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.		Score	% Query Match	Length	DB	ID	Description
c	1	20	41.7	20	1	US-10-000-213-53	Sequence 53, Appl
c	2	20	41.7	20	1	US-10-000-213-54	Sequence 54, Appl
c	3	20	41.7	20	1	US-10-000-213-55	Sequence 55, Appl
c	4	20	41.7	20	1	US-10-000-213-56	Sequence 56, Appl
	5	14.4	30.0	17	1	US-10-138-674-7673	Sequence 7673, Ap
	6	14.4	30.0	17	1	US-10-287-949A-7673	Sequence 7673, Ap
c	7	14.4	30.0	18	1	US-10-327-805-23	Sequence 23, Appl
	8	13.8	28.7	17	1	US-09-740-332-3026	Sequence 3026, Ap
	9	13.8	28.7	17	1	US-09-817-879-3026	Sequence 3026, Ap
	10	13.8	28.7	17	1	US-10-138-674-7674	Sequence 7674, Ap
	11	13.8	28.7	17	1	US-10-287-949A-7674	Sequence 7674, Ap
	12	13.4	27.9	16	1	US-10-138-674-5840	Sequence 5840, Ap
	13	13.4	27.9	16	1	US-10-287-949A-5840	Sequence 5840, Ap
c	14	13	27.1	17	1	US-09-866-108-8341	Sequence 8341, Ap
c	15	13	27.1	17	1	US-09-866-108-8342	Sequence 8342, Ap
c	16	13	27.1	17	1	US-09-866-108-8343	Sequence 8343, Ap
c	17	13	27.1	17	1	US-09-866-108-8344	Sequence 8344, Ap
c	18	13	27.1	17	1	US-09-866-108-8345	Sequence 8345, Ap
	19	12.8	26.7	16	1	US-10-138-674-5841	Sequence 5841, Ap
	20	12.8	26.7	16	1	US-10-287-949A-5841	Sequence 5841, Ap

ALIGNMENTS

RESULT 1
US-10-000-213-53/c
; Sequence 53, Application US/10000213
; Publication No. US20030125271A1
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker
; APPLICANT: Mark P. Roach
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF VITAMIN D NUCLEAR RECEPTOR EXPRESSION
; FILE REFERENCE: RTS-0327
; CURRENT APPLICATION NUMBER: US/10/000,213
; CURRENT FILING DATE: 2001-11-14
; NUMBER OF SEQ ID NOS: 94
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-000-213-53

Query Match 41.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.2;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1710 GGCTGCTGACTGATGTTGAG 1729
||||||||||||||||||||
Db 20 GGCTGCTGACTGATGTTGAG 1

RESULT 2
US-10-000-213-54/c
; Sequence 54, Application US/10000213
; Publication No. US20030125271A1
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker
; APPLICANT: Mark P. Roach
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF VITAMIN D NUCLEAR RECEPTOR EXPRESSION
; FILE REFERENCE: RTS-0327
; CURRENT APPLICATION NUMBER: US/10/000,213
; CURRENT FILING DATE: 2001-11-14
; NUMBER OF SEQ ID NOS: 94
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-000-213-54

Query Match 41.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.2;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1722 ATGTTGAGGGAACAGACAGG 1741
||||||||||||||||||||
Db 20 ATGTTGAGGGAACAGACAGG 1

RESULT 3
US-10-000-213-55/c
; Sequence 55, Application US/10000213
; Publication No. US20030125271A1
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker
; APPLICANT: Mark P. Roach
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF VITAMIN D NUCLEAR RECEPTOR EXPRESSION
; FILE REFERENCE: RTS-0327
; CURRENT APPLICATION NUMBER: US/10/000,213
; CURRENT FILING DATE: 2001-11-14
; NUMBER OF SEQ ID NOS: 94
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-000-213-55

```
  Query Match             41.7%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.2;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1730 GGAACAGACAGGAGAAATGC 1749
              ||||||||||||||||||||
Db         20 GGAACAGACAGGAGAAATGC 1


RESULT 4
US-10-000-213-56/c
; Sequence 56, Application US/10000213
; Publication No. US20030125271A1
; GENERAL INFORMATION:
;  APPLICANT: Brenda F. Baker
;  APPLICANT:  Mark P. Roach
;  APPLICANT:  Kenneth Dobie
;  TITLE OF INVENTION: ANTISENSE MODULATION OF VITAMIN D NUCLEAR RECEPTOR EXPRESSION
;  FILE REFERENCE: RTS-0327
;  CURRENT APPLICATION NUMBER: US/10/000,213
;  CURRENT FILING DATE:  2001-11-14
;  NUMBER OF SEQ ID NOS: 94
; SEQ ID NO 56
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-000-213-56

  Query Match             41.7%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.2;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1738 CAGGAGAAATGCATCCATTC 1757
              ||||||||||||||||||||
Db         20 CAGGAGAAATGCATCCATTC 1


RESULT 5
US-10-138-674-7673
; Sequence 7673, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7673
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-7673

  Query Match             30.0%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 9.1;
  Matches   10;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1715 CTGACTGATGTTGAGG 1730
              |:|| :||:|::||||
Db          2 CUGAGUGAUGUUGAGG 17


RESULT 6
US-10-287-949A-7673
; Sequence 7673, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7673
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-7673

  Query Match             30.0%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 9.1;
  Matches   10;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1715 CTGACTGATGTTGAGG 1730
              |:|| :||:|::||||
Db          2 CUGAGUGAUGUUGAGG 17


RESULT 7
US-10-327-805-23/c
; Sequence 23, Application US/10327805
; Publication No. US20030144241A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF SMAD6 EXPRESSION
;  FILE REFERENCE: RTS-0045
;  CURRENT APPLICATION NUMBER: US/10/327,805
;  CURRENT FILING DATE:  2002-12-20
;  PRIOR APPLICATION NUMBER: US/09/679,298
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 23
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-327-805-23

  Query Match             30.0%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 10;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1723 TGTTGAGGGAACAGAC 1738
              ||||||||||||  |||
Db         18 TGTTGAGGGAACGGAC 3


RESULT 8
US-09-740-332-3026
; Sequence 3026, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: RPI 400/003
;  CURRENT APPLICATION NUMBER: US/09/740,332
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9704
```

```
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3026
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3026

  Query Match             28.7%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 10;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1714 GCTGACTGATGTTGAGG 1730
              ||:|| :||:| :||||
Db          1 GCUGAGUGAUGGUGAGG 17


RESULT 9
US-09-817-879-3026
; Sequence 3026, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: MBHB00-801-F
;  CURRENT APPLICATION NUMBER: US/09/817,879
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9703
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3026
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3026

  Query Match             28.7%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 10;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1714 GCTGACTGATGTTGAGG 1730
              ||:|| :||:| :||||
Db          1 GCUGAGUGAUGGUGAGG 17


RESULT 10
US-10-138-674-7674
; Sequence 7674, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7674
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-7674

  Query Match             28.7%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 10;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1716 TGACTGATGTTGAGGGA 1732
              :|| :||:|::|||| |
Db          1 UGAGUGAUGUUGAGGAA 17


RESULT 11
US-10-287-949A-7674
; Sequence 7674, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7674
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-7674

  Query Match             28.7%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 10;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1716 TGACTGATGTTGAGGGA 1732
              :|| :||:|::|||| |
Db          1 UGAGUGAUGUUGAGGAA 17


RESULT 12
US-10-138-674-5840
; Sequence 5840, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5840
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-5840

  Query Match             27.9%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   60.0%;  Pred. No. 10;
  Matches    9;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1715 CTGACTGATGTTGAG 1729
              |:|| :||:|::|||
Db          2 CUGAGUGAUGUUGAG 16
```

```
RESULT 13
US-10-287-949A-5840
; Sequence 5840, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5840
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-5840

  Query Match             27.9%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   60.0%;  Pred. No. 10;
  Matches    9;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1715 CTGACTGATGTTGAG 1729
              |:|| :||:|::|||
Db          2 CUGAGUGAUGUUGAG 16


RESULT 14
US-09-866-108-8341/c
; Sequence 8341, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8341
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-8341

  Query Match             27.1%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 13;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1713 TGCTGACTGATGT 1725
              |||||||||||||
Db         17 TGCTGACTGATGT 5


RESULT 15
US-09-866-108-8342/c
; Sequence 8342, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8342
```

```
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-8342

  Query Match             27.1%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 13;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1713 TGCTGACTGATGT 1725
              |||||||||||||
Db         16 TGCTGACTGATGT 4


RESULT 16
US-09-866-108-8343/c
; Sequence 8343, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8343
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-8343

  Query Match             27.1%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 13;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1713 TGCTGACTGATGT 1725
              |||||||||||||
Db         15 TGCTGACTGATGT 3


RESULT 17
US-09-866-108-8344/c
; Sequence 8344, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8344
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-8344

  Query Match             27.1%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 13;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1713 TGCTGACTGATGT 1725
              |||||||||||||
Db         14 TGCTGACTGATGT 2


RESULT 18
US-09-866-108-8345/c
; Sequence 8345, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
```

```
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8345
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-8345

  Query Match             27.1%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 13;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1713 TGCTGACTGATGT 1725
              |||||||||||||
Db         13 TGCTGACTGATGT 1


RESULT 19
US-10-138-674-5841
; Sequence 5841, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5841
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-5841

  Query Match             26.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   62.5%;  Pred. No. 12;
  Matches   10;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1717 GACTGATGTTGAGGGA 1732
              || :||:|::|||| |
Db          1 GAGUGAUGUUGAGGAA 16


RESULT 20
US-10-287-949A-5841
; Sequence 5841, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5841
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-5841

  Query Match             26.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   62.5%;  Pred. No. 12;
  Matches   10;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1717 GACTGATGTTGAGGGA 1732
              || :||:|::|||| |
Db          1 GAGUGAUGUUGAGGAA 16


Search completed: July 13, 2004, 11:06:29
Job time : 1 secs
```